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Abstract 
Essential hypertension is defined as a chronic elevation of blood pressure of 
unknown cause.  Though a definitive trigger for this change in blood pressure has not 
been established, there is a strong association with an upregulation of sympathetic 
output from the central nervous system.  There are a number of central autonomic 
nuclei involved in the maintenance of blood pressure, including the brainstem regions 
of the nucleus tractus solitarii (NTS), caudal ventrolateral medulla (CVLM), rostral 
ventrolateral medulla (RVLM), the sympathetic preganglionic neurons (SPNs) within 
the  intermediolateral  cell  column  (IML)  of  the  spinal  cord,  as  well  as  forebrain 
regions  such  as  the  paraventricular  nucleus  (PVN)  of  the  hypothalamus.    Within 
these centers, a vast number of neurotransmitters have been identified that contribute 
to  the  control  of  blood  pressure,  including  glutamate,  angiotensin  II,  serotonin, 
neurotensin, neuropeptide Y, opioids and catecholamines.  Recognition of the role of 
nitric oxide (NO) and its multiple influences over the neural control of blood pressure 
is gaining increasing significance. 
Nitric oxide is a unique modulatory molecule that acts as a non-conventional 
neurotransmitter.    As  NO  is  a  gas  with  a  short  half-life  of  4  –  6  seconds,  its’ 
synthesising  enzyme,  nitric  oxide  synthase  (NOS)  is  often  used  as  a  marker  of 
location of production.  Once activated, the best-known “receptor” for NO is soluble 
guanylate  cyclase  (sGC),  which  drives  the  production  of  cyclic  guanosine 
monophosphate (cGMP).  Identifying the presence of cGMP can therefore be used to 
determine sites receptive to NO.  Previous studies examining the role of NO in the 
central  autonomic  control  of  blood  pressure  have  focused  predominantly  upon 
application of either excitatory or inhibitory drugs into the key central autonomic 
regions and assessing pressor or depressor effects.  This thesis aims instead to study   iv 
the  neuroanatomical  relationship  and  functional  significance  of  NO  and  cGMP 
expression in the brain and spinal cord of a hypertensive and normotensive rat model.  
In the first experimental chapter (Chapter 3), a comparative neuroanatomical 
analysis of neuronal NOS expression and its relationship with cGMP in the SPN of 
mature  Spontaneously  Hypertensive  Rats  (SHR)  and  their  controls,  Wistar  Kyoto 
(WKY)  was  undertaken.    Fluorescence  immunohistochemistry  confirmed  the 
expression of nNOS in the majority of SPN located within the IML region of both 
strains.  However, a strain specific anatomical arrangement of SPN cell clusters was 
evident and while there was no significant difference between the total number of 
SPN in each strain, there were significantly fewer nNOS positive SPN in the SHR 
animals.    All  nNOS  positive  SPN  were  found  to  express  cGMP,  and  a  novel 
subpopulation of nNOS negative, cGMP-positive SPN was identified. These cells 
were located in the medial edge of the IML SPN cell group.  These results suggest 
that cGMP is a key signalling molecule in SPN, and that a reduced number of nNOS 
positive SPN in the SHR may be associated with the increase in sympathetic tone 
seen in essential hypertension. 
The second experimental chapter (Chapter 4) aimed to determine if reduced 
numbers of nNOS containing SPN translated into reduced detectable cGMP.  The 
functional significance of cGMP signalling in the two strains was then examined. 
Based on previous work by our group, it was predicted that reduced nNOS in the 
SHR  would  translate  into  reduced  cGMP  and  that  intrathecal  administration  of 
exogenous cGMP in the spinal cord would drive a differential pressor response in the 
two  animal  strains.    Immunohistochemical  techniques  confirmed  that  within  each 
SPN, the relative level of cGMP expression was significantly reduced in the SHR 
when  compared  to  the  WKY.    Intrathecal  application  of  8-bromo-cGMP,  a  drug   v 
analogous to cGMP, increased blood pressure in both strains and had a differential 
and  dose  dependent  effect,  causing  only  a  small  increase  in  blood  pressure  in 
anaesthetised WKY animals, while driving a significant pressor response in the SHR.  
This finding raised the novel hypothesis that in the SHR, reduced nNOS expression is 
not a driver of hypertension, but is instead a protective mechanism limiting the potent 
pressor effects of cGMP within SPN. 
The  third  experimental  chapter  (Chapter  5)  examines  the  expression  of 
neuronal and inducible isoforms of NOS (nNOS, iNOS) within the RVLM of SHR 
and WKY rats.  Reverse transcription-polymerase chain reaction (RT-PCR) was used 
to analyse the level of mRNA expression and immunohistochemistry was then used 
to further analyse protein levels of nNOS.  Total RNA was extracted and reverse 
transcribed from the RVLM of mature male WKY and SHR.  Quantitative real-time 
PCR  indicated  that  relative  to  WKY,  mRNA  levels  for  nNOS  was  significantly 
higher in RVLM of the SHR.  This was confirmed immunohistochemically.  When 
compared  to  iNOS,  nNOS  was  expressed  at  significantly  higher  levels  overall, 
however there was no difference in iNOS mRNA expression between the two strains.  
This demonstration of differential expression levels of nNOS and iNOS in the RVLM 
raises the possibilities that (i) NO production is up-regulated in the RVLM in SHR in 
response  to  increased  sympathetic  activity  in  order  to  re-establish  homeostatic 
balance or alternatively that (ii) an alteration in the balance between nNOS and iNOS 
activity may underlie the genesis of augmented sympathetic vasomotor tone during 
hypertension. 
The  fourth  experimental  chapter  (Chapter  6)  extends  the  observations  in 
Chapter  5  through  examination  of  the  expression  of  cGMP  and  sGC  within  the 
RVLM.  There is strong functional evidence to suggest that NO signalling in the   vi 
RVLM relies on cGMP as an intracellular signalling molecule and that this pathway 
is  impaired  in  hypertension.    Immunohistochemistry  was  used  to  assess  cGMP 
expression as a marker of active NO signalling in the C1 region of the RVLM, again 
comparing  SHR  and  WKY  animals.    Fluorescence  immunohistochemistry  on 
sections  of  the  RVLM,  double  labelled  for  cGMP  and  either  nNOS  or 
phenylethylamine  methyl-transferase  (PNMT)  failed  to  reveal  cGMP  positive 
neurons in the RVLM from aged animals of either strain, despite consistent detection 
of  cGMP  immunoreactivity  neurons  in  the  nucleus  ambiguus  from  the  same  or 
adjacent sections.  This was demonstrated both in the presence and absence of the 
phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) and in young vs. aged 
animals.  In-vitro incubation of RVLM slices in the NO donor DETA-NO or NMDA 
did  not  reveal  any  additional  cGMP  neuronal  staining  within  the  RVLM.    In  all 
studies,  cGMP  was  prominent  within  the  vasculature.    Soluble  guanylate  cyclase 
immunoreactivity was found throughout the RVLM, although it did not co-localise 
with the PNMT or nNOS neuronal populations.  Overall, results suggest that within 
the RVLM, cGMP is not detectable in the resting state and cannot be elicited by 
phosphodiesterase inhibition, NMDA receptor stimulation or NO donor application. 
A  short  time  course  of  cGMP  signalling  or  degradation  not  inhibited  by  the 
phosphodiesterase inhibitor utilised (IBMX) in the RVLM cannot be excluded. 
The  final  experimental  chapter  (Chapter  7)  examines  cGMP  expression  in 
magnocellular  and  preautonomic  parvocellular  neurons  of  the  PVN.    Retrograde 
tracing  techniques  and  immunohistochemistry  were  used  to  visualise  cGMP 
immunoreactivity within functionally, neurochemically and topographically defined 
PVN neuronal populations in Wistar rats.  Basal cGMP immunoreactivity was readily 
observed  in  the  PVN,  both  in  neuronal  and  vascular  profiles.    Cyclic  GMP   vii 
immunoreactivity  was  significantly  higher  in  magnocellular  compared  to 
preautonomic neuronal populations.  In preautonomic neurons, the level of cGMP 
expression  was  independent  on  their  subnuclei  location,  innervated  target  or 
neurochemical  phenotype.    The  data  presented  in  this  chapter  indicates  a  highly 
heterogeneous distribution of basal cGMP levels within the PVN, and supports work 
by others indicating that constitutive NO inhibitory actions on preautonomic PVN 
neurons are likely mediated indirectly through activation of interneurons. 
Summary 
Together, these studies comprise a detailed analysis of the neuroanatomical 
expression of NO and its signalling molecule cGMP in key central autonomic regions 
involved in the regulation of blood pressure.  Under resting or basal conditions, the 
studies  demonstrate  notable  differences  in  the  expression  of  NO  synthesising 
enzymes between normotensive and hypertensive animals, and correlating changes in 
the  downstream  signalling  molecule  cGMP.    In  the  spinal  cord,  novel  functional 
differences  in  cGMP  activity  were  also  demonstrated.    In  the  RVLM,  although 
differences  in  nNOS  were  demonstrated,  cGMP  expression  could  not  be  readily 
detected in either the WKY or SHR, while in contrast within the PVN, cGMP was 
detected in both magnocellular and parvocellular neuronal populations.  
Conclusion 
This  thesis  gives  insight  into  the  physiological  role  of  NO  and  cGMP  as 
mediators of central blood pressure control.  The results presented indicate that the 
NO-cGMP dependent signalling pathway may not be the dominant driver responsible 
for maintaining high blood pressure in the SHR model of essential hypertension, and 
that there is no globally consistent pattern of expression, and indeed the role of NO as 
a  mediator  of  pressor  and  depressor  function  may  vary  between  the  autonomic   viii 
regions examined.  Further, it is possible that this pathway is only recruited during 
activation of reflex homeostatic pathways or during times of marked physiological 
stress, and that the differences we see in basal expression between the normotensive 
and SHR animals are instead a result of compensatory mechanisms.   ix
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1. Literature review 
1.1.  Regulation of blood pressure 
1.1.1.  Hypertension 
Homeostasis,  the  regulation  of  the  internal  environment,  is  dependent  on 
efficient  and  appropriate  blood  flow  to  all  regions  of  the  body.    This  flow  is 
determined by pressure gradients within the cardiovascular system which we routinely 
gauge through assessment of mean arterial pressure (MAP) (Bernard, 1865; Dampney 
et al., 2002).  Various stressors in a daily routine can cause blood pressure (BP) to 
fluctuate dramatically, but ultimately, over a 24-hour period it is a tightly controlled 
variable (Guyenet, 2006).  However, in response to ongoing stressors that challenge 
the maintenance of BP, individuals may lose the ability to maintain MAP within the 
normal physiological range (Monahan, 2007).  Hypertension is diagnosed when there 
is chronic elevation of the 24-hour average BP, and can be classified as one of either 
two  broad  categories  of  hypertension  essential  (or  primary)  hypertension,  and 
secondary hypertension (Guyenet, 2006).  
Essential  hypertension  is  defined  as  a  rise  in  BP  of  unknown  cause  that 
increases risk for cerebral, cardiac, and renal events (Messerli et al., 2007).   It is 
generally agreed that essential hypertension arises from a combination of genetic and 
environmental influences (Folkow, 1982).   Human population studies  have shown 
that the development of hypertension has some genetic basis (Staessen et al., 2003) 
with  at  least  17  human  genes  having  been  identified  with  either  hypertension  or       2 
hypotension  (Lifton  et  al.,  2001).    However,  interventional  studies  show  that 
environmental changes, such as diet, exercise and salt intake can affect BP, regardless 
of genetic disposition, indicating that environmental factors are powerful contributors 
to essential hypertension (Fagard, 2001; Graudal et al., 1998; Sacks et al., 2001). 
Secondary hypertension is diagnosed in patients whose increase in BP has an 
identifiable cause (Messerli et al., 2007).  The most common cause is chronic renal 
disease,  which  can  be  brought  on  by  diabetes,  glomerulonephritis,  or  polycystic 
kidney  disease  (Fesler  et  al.,  2005;  Phillips,  2005;  Textor,  2004).    Other  known 
factors include phaeochromocytoma, Cushing’s syndrome and primary aldosteronism 
(Barzon et al., 2002; Sawka et al., 2003). 
Present  statistics  indicate  that  20  –  30%  of  the  worldwide  population  is 
afflicted with hypertension (Mackay and Mensah, 2004; Staessen et al., 2003), and 
given that its’ prevalence rises with age, between 60 – 70% of those over 60 are 
afflicted (Staessen et al., 2003).  While hypertension itself has no physical symptoms, 
the secondary effects of hypertension can be devastating.  For example, one of the 
most consistent and powerful predictors of stroke is elevated BP (Zhang et al., 2006).  
Estimates published by the World Health Organisation indicate that up to 15 million 
people each year suffer from stroke, of whom ~5 million die and another ~5 million 
are left permanently disabled (Mackay and Mensah, 2004).  Furthermore, population 
mortality trends show that those who have suffered a stroke have symptoms similar to 
those who suffer from hypertension (Luepker et al., 2006; Wolf-Maier et al., 2003) 
with elevated systolic BP >115mmHg and above explaining 60% of the population-
attributable risk of stroke (Lawes et al., 2006).  Hypertension also aggregates with 
other  disorders,  such  as  abdominal  obesity,  dyslipidaemia,  glucose  intolerance,       3 
hyperinsulinaemia  and  hyperuricaemia,  indicating  that  these  are  likely  to  have 
hypertension as a contributing factor (Staessen et al., 2003). 
A  number  of  early  studies  have  shown  that  the  onset  and  early  stages  of 
human hypertension is characterised by augmented sympathetic activity at both rest 
and  during  physical  and  psychological  stressors  (Egan  et  al.,  1987;  Julius,  1986; 
Nestel, 1969).  Plasma adrenaline (Goldstein, 1983) and noradrenaline (Esler et al., 
1986) levels are higher in younger persons with hypertension (under the age of 40), 
and muscle sympathetic nervous activity is elevated in individuals in the early stages 
of  hypertension  (Anderson  et  al.,  1989b).    Together,  these  data  suggest  that 
augmented sympathetic output may contribute to the development of hypertension 
(Anderson et al., 1989b).   
1.1.2.  The baroreceptor reflex 
Blood pressure is a function of vascular resistance and cardiac output, two 
variables that are tightly controlled by the autonomic nervous system (ANS).  It is in a 
constant state of flux, and is regulated over short and long-term time frames, through 
changes  in  vasomotor  tone  and  sodium  fluid  balance  (Staessen  et  al.,  2003).  
Vasomotor tone refers to the degree of vascular contractility and reflects sympathetic 
drive,  with  increased  peripheral  resistance  being  another  key  factor  driving 
hypertensive states (Staessen et al., 2003).  These mechanisms are affected to various 
degrees by  genetic  and  environmental factors, and are controlled by local factors, 
circulating hormones, and the central nervous system (Staessen et al., 2003).  The 
kidneys play a key role in regulating sodium and fluid balance, which is central in 
long-term BP control through the control of blood volume.  Abnormalities in kidney 
function  can  therefore  contribute  significantly  to  the  pathophysiology  of  renal       4 
hypertension via this and other mechanisms including effects on sympathetic drive 
(Guyton, 1990; Phillips, 2005). 
Within  the  central  nervous  system,  a  number  of  centres  act  as  a  unit  to 
maintain  BP,  within  the  actions  of  the  baroreceptor  reflex.    The  stimulus  for  the 
baroreflex originates at the level of the baroreceptors (Fig 1.1).  These receptors are 
highly specialised stretch sensitive nerve endings, and are located in various regions 
of  the  cardiovascular  system,  such  as  the  carotid  artery,  aorta,  and  the 
cardiopulmonary region (Aicher et al., 2000; Averill and Diz, 2000; Dampney, 1994).  
An increase in BP within the arterial wall, for example by the arterial pulse wave, 
causes  the  wall  to  distort  activating  the  receptors  (Aicher  et  al.,  2000;  Dampney, 
1994; Spyer, 1994). 
Once activated the baroreceptors send afferent impulses to the central nervous 
system, via the vagus and carotid sinus nerves (Averill, 2000).  The primary response 
to stimulation of these stretch receptors (by an increase in BP) is a resultant fall in BP, 
mediated by inhibition of the tonic activity of sympathetic vascular innervation and 
therefore reduction of total peripheral resistance, and excitation of the cardiovagal 
motor neurons, driving bradycardia and reducing cardiac output (Aicher et al., 2000).  
The work presented in this thesis has focused on the sympathetic control of vasomotor 
tone, as a key regulator of BP.        5 
 
Figure 1.1: Location of baroreceptors 
Baroreceptors  (seen  in  yellow  in  the  aortic  arch 
and  left  and  right  carotid  sinuses)  are  located 
within the aortic arch and the carotid sinus.  These 
specialised receptors detect the pressure of blood 
flowing past them, and send inputs to the central 
nervous system to alter vascular tone and cardiac 
output.    Image  taken  from 
http://www.cvphysiology.com/Blood%20Pressure/
bp012%20baroreceptor%20anat.gif.       6 
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The primary central sympathetic components of the baroreceptor reflex are 
located within the medulla oblongata and thoracic spinal cord, though there are many 
supramedullary  premotor  centres  that  can  modulate  the  final  output  of  the 
baroreceptor reflex (Aicher et al., 2000).  For example, the hypothalamus has been 
shown  to  elicit  sympathoexcitation  via  both  the  medulla  and  spinal  cord,  which 
increases BP and HR (Coote et al., 1998).  For the purposes of this review, I shall 
focus on three key regions in the medulla, then the sympathetic preganglionic neurons 
(SPNs) of the spinal cord and the paraventricular nucleus of the hypothalamus (PVN), 
discussing  their  roles  in  the  homeostatic  control  of  blood  pressure,  perturbations 
associated  with  hypertension  and  specific  neuromodulators  involved  in  regulating 
their activity.  The review will follow the path of the baroreceptor reflex, beginning 
with the point where the baroreceptors terminate in the nucleus tractus solitarii (NTS), 
progressing  to  the  caudal  ventrolateral  medulla  (CVLM),  the  rostral  ventrolateral 
medulla (RVLM), and then the SPNs (Fig 1.2) being final integration point of the 
baroreceptor reflex.  I will then discuss the specific issues relation to the PVN. 
1.1.3.  Transmitters in hypertension 
Many neurotransmitters and neuropeptides have been shown to signal within 
the  baroreceptor  reflex.    These  include  classical  neurotransmitters,  such  as  g-
aminobutyric acid (GABA), and L-glutamate (Averill, 2000), as well as angiotensin II 
(Boscan et al., 2001; Campagnole-Santos et al., 1988; Paton and Kasparov, 1999; 
Schreihofer  and  Guyenet,  2002),  serotonin  (N'Diaye  et  al.,  2001),  neurotensin 
(Seagard et al., 2000), neuropeptide Y (Kubo and Kihara, 1990), opioids (Li et al., 
1996) and catecholamines (Sved et al., 1992).  In recent years, studies have shown       8 
that nitric oxide (NO) is an important factor in the maintenance of cardiovascular 
autonomic  control  (Chowdhary  and  Townend,  1999),  and  is  critical  to  the 
maintenance of normal BP (Huang et al., 1995).  In experimental animals, it has been 
shown that NO regulates vasomotor tone and arterial pressure, at least in part, by 
modulating sympathetic neural outflow (Sartori et al., 2005).  Furthermore, it has been 
shown now in a number of experimental models of hypertension that NO signalling 
appears to be impaired (Sartori et al., 2005). 
In this thesis, the central tenant of many of the studies presented is that altered 
NO  signalling  in  central  autonomic  nuclei  is  linked  to  hypertension,  as  either  an 
initiating or secondary response mechanism.   
In this chapter, I will present the mechanisms underlying NO signalling and 
then  introduce  the  afore  mentioned  central  autonomic  regions  involved  in  the 
baroreceptor  reflex,  and  discuss  how  these  areas  are  affected  by  NO  both  in  the 
normal physiological condition and during altered states of BP.       9 
 
Figure 1.2: Centres involved in the baroreceptor reflex 
Pathway of the baroreceptor reflex.  Input from the 
baroreceptors (not shown) are first relayed to the 
NTS, progressing to the CVLM, then the RVLM 
of  the  medulla,  before  terminating  at  the  SPNs 
before relaying signals to the peripheral nervous 
system,  via  the  sympathetic  post  ganglionic 
neurons.        10 
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1.2.  Nitric oxide 
1.2.1.  Definition  
Nitric  oxide  is  a  ubiquitous  modulatory  molecule  that  acts  as  a  non-
conventional  neurotransmitter  in  the  central  nervous  system  (CNS)  (Schuman  and 
Madison, 1994).  It is a colourless, odourless gas (Bruckdorfer, 2005), with a short 
half life of about 4 - 6 seconds (Cannon, 1998; Furchgott, 1983; Thomas et al., 2001) 
and is a diatomic free radical (Bruckdorfer, 2005; McDonald and Murad, 1995) which 
can be a potent toxin to the body (Cary et al., 2006).  Nitric oxide has a low molecular 
weight, is reasonably hydrophobic and is membrane permeable, so it can not be stored 
for long periods of time, but theoretically is able to reach anywhere within cells and 
tissues (Baranano and Snyder, 2001).  Nitric oxide is formed only after activation of 
its  synthesising  enzyme  NO  synthase  (NOS)  and  is  therefore  highly  regulated 
(Baranano and Snyder, 2001). 
1.2.2.  Location and production of NO 
Being a gas, NO is difficult to visualise, so NOS is often used as a marker to 
indicate the capacity of a cell to produce NO.  There are three NOS enzymes which 
use L-arginine as a substrate (Nathan and Xie, 1994).  All isoforms require co-factors 
for  synthesis,  including  reduced  nicotinamide-adenine-dinucleotide  phosphate 
(NADPH),  flavin  adenine  dinucleotide,  flavin  mononucleotide  and  (6R)-6,5,7,8-
tetrahydrobiopterin (BH4) (Hevel and Marletta, 1992; Mayer et al., 1991; Pollock et 
al., 1991; Stuehr et al., 1991).  Once these elements are combined with oxygen, the 
subsequent reaction is the production of citrulline, NADP and the free radical NO 
(Alderton  et  al.,  2001).    Many  cells  are  capable  of  synthesising  NO  (Li  and       12 
Forstermann, 2000) and this include central nervous system (CNS) regions involved 
in cardiovascular control (Bhat et al., 1995; Chang et al., 2003; Kantzides and Badoer, 
2005).   
1.2.3.  General function 
Since  it’s  discovery,  studies  have  shown  that  NO  is  involved  in  many 
physiological  processes  throughout  the  body.    In  peripheral  organs,  such  as  the 
digestive,  respiratory  and  urogenital  organs,  NO  acts  in  a  neurotransmitter-like 
manner,  in  that  it  is  released  from  nitrergic  nerves  to  mediate  smooth  muscle 
relaxation (Rand and Li, 1995; Toda et al., 2005; Toda and Okamura, 2003).  Within 
the  CNS,  NO  is  associated  with  many  functions,  including  learning  and  memory 
formation, feeding, sleeping, reproductive behaviour as well as sensory and motor 
function (Garthwaite, 2008).  Nitric oxide most often acts as a local paracrine factor 
influencing physiological functions of cells in the immediate locale of its production 
(Horn et al., 1994).  Dysregulation of NO is known to contribute to  a myriad of 
diseases including heart disease, hypertension, stroke, gastrointestinal distress, erectile 
dysfunction  and  neurodegeneration  (Bredt,  1999;  Dawson  and  Dawson,  1998; 
Takahashi, 2003). 
An  important  function  of  NO  is  in  the  regulation  of  sympathetic  outflow 
within the CNS (Krukoff, 1999).  This includes general inhibition of sympathetic 
activity  (Kantzides  and  Badoer,  2005;  Sakuma  et  al.,  1992)  and  reduction  of  BP 
(Togashi et al., 1992) and conversely it has been shown to stimulate pressor responses 
(Hirooka et al., 1996; Malik et al., 2007).  This is covered in more detail in later 
sections discussing NO and the specific autonomic regions.         13 
1.2.4.  Nitric oxide synthase isoforms 
Overview 
There  are  three  isoforms  of  NOS  that  catalyse  the  formation  of  NO 
(McDonald and Murad, 1995).  The three isoforms are generated from separate genes 
on different loci (Griffith and Stuehr, 1995), but each of the genes have a similar 
genomic structure, suggesting a common ancestral NOS gene (Alderton et al., 2001).  
All 3 isoforms are self sufficient enzymes with two major functional domains fused 
into a single polypeptide.  Each isoform has a different physiological function, despite 
the fact that they all produce NO (Bruckdorfer, 2005). 
The biosynthesis of NO by NOS involves the conversion of L-arginine (L-arg) 
to L-citrulline (Masters et al., 1996).  Nitric oxide synthase functions as a dimer made 
of  two  identical  monomers  that  are  functionally  and  structurally  divided  into  2 
domains,  the  C-terminal  reductase  domain,  and  an  N-terminal  oxygenase  domain 
(Hemmens and Mayer, 1998).  The C-terminal reductase domain contains binding 
sites for NADPH, which carries electrons from one reaction to another, flavin adenine 
dinucleotide, involved in changing redox states, and flavin mononucleotide, involved 
in oxidoreductases (Alderton et al., 2001).  The N-terminal contains binding sites for 
haem, which detects oxygen and BH4, which is essential for the synthesis of NO by 
NOS  (Andrew  and  Mayer,  1999).    Between  the  two  regions  lies  the  calmodulin 
binding domain, which  plays  a key  role in both the structure and  function of the 
enzyme.  The reductase and oxygenase domains of NOS are distinct catalytic unis, 
which together provide the complete machinery required for NO production (Andrew 
and Mayer, 1999).         14 
Biosynthesis of NO involves a two-step oxidation of L-arg to L-citrulline, with 
concomitant production of NO.  L-arginine is hydroxylated to form N
G- hydroxy-L-
arginine, which is then further oxidated with NADPH to form  L-citrulline and NO 
(Andrew and Mayer, 1999).  The manner in which this reaction is initiated differs 
between the isoforms and is discussed below.   
Endothelial nitric oxide synthase 
As the name suggests, endothelial NO synthase (eNOS) was first discovered 
within the endothelial layer of blood vessels (Furchgott and Zawadzki, 1980).  The 
gene for eNOS is located on chromosome 7, and the protein encodes for a 1203 amino 
acid  sequence  (Alderton  et  al.,  2001).    In  their  seminal  experiment,  Furgott  and 
Zawadzki found that strips of rabbit aorta with intact endothelium relaxed in response 
to  acetylcholine,  but  constricted  in  response  to  this  same  agonist  when  the 
endothelium had been rubbed off (Cannon, 1998; Furchgott and Zawadzki, 1980).  
The  substance  responsible  for  this  relaxation,  initially  called  endothelium-derived 
relaxing factor, was subsequently found to be NO.  Endothelial NOS is found within 
the caveolae of the endothelial cell plasma membrane (Garcia-Cardena et al., 1996; 
Shaul  et  al.,  1996),  which  is  where  receptors  for  agents  that  regulate  endothelial 
activity  accumulate.    Though  it  was  originally  purified  and  cloned  from  vascular 
endothelium, its expression has been reported in cardiomyocytes, blood platelets, and 
hippocampal neurons (Arnal et al., 1999).   
Endothelial  NOS  attaches  to  the  membrane  with  hydrophobic  anchors, 
(Bruckdorfer, 2005), and only minute amounts of eNOS are required for a reaction to 
occur.    Regulated  by  influx  of  calcium  into  the  cell,  the  production  of  eNOS  is 
stimulated  by  blood  flow  through  the  arteries  (Bruckdorfer,  2005).    Shear  stress, 
which  is  exerted  by  the  blood  stream  on  the  endothelial  cell  surface,  regulates       15 
endothelial autacoid production and gene transcription (Davies, 1995; Takahashi et 
al., 1997), and it has been demonstrated in numerous vascular preparations that shear 
stress  leads  to  vasodilation  through  the  release  of  endothelial  NO  and/or 
prostaglandins (de Wit et al., 1997; Koller and Kaley, 1990; Koller et al., 1993; Pohl 
et al., 1991).  The main role of eNOS within the vasculature is to therefore regulate 
changes in blood flow and pressure in response to local stimuli (Bruckdorfer, 2005).  
Neuronal nitric oxide synthase 
Located on chromosome 12; the neuronal NOS (nNOS) gene encodes for an 
144 amino acid protein (Alderton et al., 2001) and is the largest of the 3 isoforms.  
Neuronal NOS is located primarily within neurons of both the central and peripheral 
nervous system (Alderton et al., 2001; Patel et al., 2001), though its expression has 
been  demonstrated  in  other  cell  types,  including  smooth  muscle  and  cardiac  cells 
(Casadei, 2006; Webb et al., 2006).  Neuronal NOS is located within the cytoplasm, 
and unlike eNOS has no anchors (Bruckdorfer, 2005).   Instead, nNOS has a post 
synaptic  density  protein  (PSD95),  Drosophila  disc  large  tumour  suppressor,  and 
zonula occludens-1 protein (zo-1) (PDZ domain), that targets nNOS to synaptic sites 
in the brain (Alderton et al., 2001).   
Functionally,  NO  released  from  nerves  is  involved  in  a  wide  range  of 
neurotransmitter  functions  throughout  the  body  including  regulation  of  gastro-
intestinal  function,  penile  erection,  neuronal  control  of  blood  flow  and  central 
neuronal signalling.  Within the CNS, there is strong support for it having a role in 
plasticity, as it plays a key role as a modulator of responses to glutamate.   
Both  nNOS  and  eNOS  are  expressed  constitutively  in  mammals  and 
collectively are called constitutive NOS (cNOS) (Li and Poulos, 2005).       16 
Inducible nitric oxide synthase 
The gene for iNOS is located on chromosome 17, and encodes for a 133 kDA 
1203 amino acid protein (Alderton et al., 2001).  Unlike endothelial and nNOS, iNOS 
is activated by  external stimuli, such as bacterial lipopolysaccharide  (Bruckdorfer, 
2005), produces a large amount of NO, and has long lasting activity of 24 hours or 
more (Bruckdorfer, 2005).  Though there is evidence that iNOS can produce NO in all 
tissues,  it  is  mainly  localised  to  macrophages,  hepatocytes  and  smooth  muscle 
(McDonald  and  Murad,  1995).    Functionally,  iNOS  contributes  a  non-specific 
immune component as part of the inflammatory response.   
Constitutive NOS activity is controlled by calmodulin binding in a calcium 
concentration dependent manner (Li and Poulos, 2005).  In sharp contrast, iNOS has 
calmodulin bound permanently as an additional subunit, and hence is not regulated by 
calmodulin binding, but instead is under transcriptional control (Li and Poulos, 2005).   
In  addition  to  regulation  by  Ca2+/calmodulin,  nNOS  possesses  several 
phosphorylation sites.  Phosphorylation sites for cGMP-dependent protein kinases, 
protein kinase C or Ca2+/calmodulin-dependent protein kinase (CaMK)II have been 
found on purified nNOS enzymes, but their effects on the activity of nNOS have been 
found to be modest and sometimes contradictory (Nakane et al., 1991; Bredt et al., 
1992;  Dinerman  et  al.,  1994b).    Ca2+/calmodulin-dependent  protein  kinase,  a  co-
resident with NMDA receptors and nNOS at synapses (Kennedy, 2000), has been 
found  to  inhibit  NO  formation  by  ~50%,  probably  by  affecting  Ca2+/calmodulin 
binding  (Hayashi  et  al.,  1999;  Komeima  et  al.,  2000).    In  the  cultured  neurones, 
phosphorylated nNOS was concentrated in dendritic spines but the phosphorylation 
process was slow, taking 15 min to be detectable (Rameau et al., 2004), suggesting       17 
that CaMKII is likely to be not a dynamic regulator of nNOS activity but more a 
longer-term gain controller. 
1.2.5.  Nitric oxide signalling mechanisms  
As a membrane permeable neuronal messenger, NO produces its biological 
actions through distinct signal transduction pathways (Ahern et al., 2002; Stamler et 
al., 1997).  Its most well known role is the activation of the second messenger cyclic 
guanosine monophosphate (cGMP) (Chowdhary and Townend, 1999).   
The soluble guanylate cyclase - cyclic GMP cascade 
As NO diffuses across membranes (Dawson and Dawson, 1998), it binds with 
a family of enzymes referred to as the guanylyl cyclases (GCs), which synthesise 
cGMP from intracellular guanosine triphosphate (Krumenacker et al., 2004).  There 
are two main classes of GCs, one that is located in the membranous compartment or 
organelles, and one in the cytosolic compartment (Murad, 1994; Schmidt, 1992; Vles 
et al., 2000; Wedel and Garbers, 1997).  The membrane bound GCs, otherwise known 
as particulate GC are large transmembrane molecules that have a receptor domain at 
the outside of the cell and an intracellular catalytic site (Vles et al., 2000).  Particulate 
GC is activated through interaction with peptide hormones such as atrial, brain and C-
type natriuretic peptides, with the receptor domain (Vles et al., 2000).  In contrast, 
soluble  guanylate  cyclase  (sGC)  is  only  activated  by  NO.    It  can  respond  to 
nanomolar concentrations of NO and catalyse the conversion of GTP to 3’5’ cGMP 
and pyrophosphate (Bredt, 1999; Cary et al., 2006; Dawson and Dawson, 1998).  The 
sGC receptors are composed of two subunits, an alpha (a) and beta (b) heterodimer, 
of which there are 2 known isoforms a1b1 and a2b1 (Garthwaite, 2008).       18 
The production of cGMP by sGC is the mechanism by which NO exerts most 
of its physiological effects as a cell signalling molecule (Krumenacker et al., 2004).  
Cyclic GMP binds to target proteins such as cGMP dependant protein kinases such as 
protein kinase G (PKG) (Jaffrey and Snyder, 1995), cGMP regulated ion channels 
(Zagotta and Siegelbaum, 1996) and several families of phosphodiesterases (Ahern et 
al., 2002; Pineda et al., 1996), resulting in specific down stream outputs (Bredt, 1999; 
Cary et al., 2006; Dawson and Dawson, 1998).  Within brain cells, NO activates the 
associated guanylyl cyclase activity with no observable delay (with a 20-ms sampling 
time) and, on removal of NO, the activity decays with a half-time of 200 ms (Bellamy 
and Garthwaite, 2001). 
The  actions  of  cGMP  have  been  predominantly  studied  by  binding  cGMP 
agonists to its regulatory sites on either cyclic nucleotide-gated (CNG) ion channels 
(Kaupp  and  Seifert,  2002)  or  hyperpolarization-activated,  cyclic  nucleotide-
modulated  (HCN)  channels  (Craven  and  Zagotta,  2006).    Cyclic  GMP  also  binds 
directly to a number of the phosphodiesterase enzymes (PDE), particularly PDE2, 5 
and in retinal photoreceptor cells, PDE6.  This results in heightened catalytic activity 
and  cGMP  breakdown.    Probably  the  most  widespread  mechanism  employed  by 
cGMP is activation of PKG, which exists in three forms, PKG1α and PKG1β (splice 
variants), and PKGII, which is anchored to the plasma membrane by nitrosylation 
(Garthwaite, 2008).  The three forms are found in different locations of the brains 
with PKG1α is concentrated in cerebellum and dorsal root ganglia, and PKG1β the 
hippocampus  and  olfactory  bulb.    Conversely,  PKGII  has  a  more  widespread 
distribution in the brain with a particular abundance in the thalamus (Feil et al., 2005; 
Hofmann et al., 2006; Vaandrager et al., 2005).  Several substrates for PKG have been 
identified (Schlossmann and Hofmann, 2005) and many of its actions are exerted at       19 
the  level  of  phosphatases,  leading  indirectly  to  increased  or  decreased  levels  of 
phosphorylation of effector proteins (Garthwaite, 2008). 
Nitrosylation of protein thiols 
In addition to the well-described cGMP pathway, there are many biological 
functions that can be attributed to the actions of NO (Broillet, 1999).  This includes 
the  modification  of  proteins  through  direct  chemical  reactions  such  as  the 
nitrosylation of protein thiols (Davis et al., 2001).   
The transfer of NO group to cysteine sulfhydryls on proteins is known as S-
nitrosylation (Broillet, 1999), where by NO forms stable covalent interactions with 
free thiol groups of proteins (Foster et al., 2003).  Direct action of NO on proteins has 
been shown to involve cysteine or tyrosine residues (Broillet, 1999; Stamler, 1994) 
and metals such as the haem-Fe
++ interaction (Butler et al., 1995).  The nitrosylation 
of  thiols  involves  joining  NO  with  oxygen,  which  causes  changes  in  enzymatic 
activity (Bruckdorfer, 2005). 
S-Nitrosylation requires higher concentrations of NO than does activation of 
sGC and tends to proceed with slower kinetics than cGMP-mediated actions (Ahern et 
al., 2002).  Physiological studies show that the range of ion channels and receptors 
that are affected by S-Nitrosylation is as many as the ones affected by cGMP (Ahern 
et al., 2002).  These include Ca
2+, Na
+, cyclic-nucleotide-gated channels, glutamate 
receptors and N-methyl-D-aspartate (NMDA) receptors.  S-Nitrosylation is known to 
affect exocytosis, synaptic transmission and synaptic plasticity (Bruckdorfer, 2005).   
Activation of NMDA receptors  
The major excitatory neurotransmitter within the central nervous system is L-
Glutamate (Collingridge and Lester, 1989).  L-Glutamate functions via activation of       20 
excitatory amino acid ionotropic and metabotropic receptors (Collingridge and Lester, 
1989; Nakanishi, 1992).  There are 3 main types of amino acid ionotropic receptors; 
(i)  NMDA  receptors,  (ii)  a-amino-3-hydroxy-5-methyl-4-isoxazole  propionic  acid 
(AMPA) receptors, and (iii) kainate receptors (Collingridge and Lester, 1989).  In 
addition to the capacity for NO to nitrosylate the NMDA receptor, NOS activation has 
been linked to excitatory input via NMDA receptors. 
The  NMDA  receptor  is  a  ligand-gated  ion  channel,  permeable  to  sodium, 
calcium,  and  potassium  (Nakanishi,  1992).    To  date,  one  N-methyl-D-aspartate 
receptor 1 (NR1) subunit, and four N-methyl-D-aspartate receptor 2 (NR2) subunits 
(NR2A–D) have been identified and cloned (Kimura et al., 2000).  Functional NMDA 
receptor  complexes  are  formed  by  different  combinations  of  the  subunits 
(Contestabile, 2000; Kimura et al., 2000).  The NR1 unit is the obligatory subunit and 
contains all the fundamental properties necessary for a functional receptor-channel 
complex, including a binding site (Hollmann and Heinemann, 1994; Kaczmarek et al., 
1997; Nakanishi, 1992), however homomeric combinations of NR1 lead to a receptor 
with low affinity for binding (Contestabile, 2000).  Instead, functional receptors are 
combinations  of  the  NR1  with  at  least  one  of  the  NR2  subunits.    Different 
combinations of the NR1 with the NR2 subunits can alter the functional properties of 
the  NMDA  receptor  (Monyer  et  al.,  1994),  modify  the  characteristics  of  currents 
elicited,  calcium  conductance  and  regulation  by  other  modulators  (Contestabile, 
2000).   
NMDA receptors occur selectively at the post synaptic density of excitatory 
synapses  (Moriyoshi  et  al.,  1991)  and  although  there  are  several  distinct  calcium 
stores at the synapse, only influx through the NMDA receptor efficiently activates 
nNOS (Kiedrowski et al., 1992).  Neuronal NOS does not directly bind to the NMDA       21 
receptor,  instead  interact  via  the  post  synaptic  protein  PSD-95/SAP90  (PSD-95) 
(Brenman et al., 1996), which is a membrane-associated guanylate kinase (Cho et al., 
1992; Kistner et al., 1993).  PSD-95 has 3 PDZ domains, small modular protein-
protein  interaction  interfaces  that  mediate  assembly  of  protein  complexes  at  cell 
junctions.  Neuronal NOS is unique in that it has it’s own PDZ domain, which is 
critical in allowing nNOS to target specific cellular membranes (Brenman and Bredt, 
1997).  The tail end of the NMDA receptor binds to one of the PDZ domain of the 
PSD-95, while nNOS PDZ domain binds to another of the PSD-95 PDZ domains 
(Christopherson  et  al.,  1999),  forming  a  ternary  signalling  complex,  critical  to 
efficient coupling of calcium influx through the NMDA receptor (Christopherson et 
al., 1999).  
Linkage  of  NMDA  neurotransmission  and  NO  production  occurs  when  a 
presynaptic neuron is depolarised and glutamate crosses the synapse, binding to the 
NMDA receptor (Nelson et al., 2003).  This causes displacement of a magnesium ion 
from the receptor, allowing an influx of extra cellular calcium into the cell through the 
NMDA receptor (Lodish et al., 1997), which instigates NOS to produce NO.  Studies 
have  shown  that  the  activation  of  the  NMDA  receptor  by  glutamate  stimulates 
constitutive  forms  of  NOS  (Crane  et  al.,  1997;  Crane  et  al.,  1998;  Dawson  and 
Snyder,  1994),  i.e.  nNOS  (in  the  brain)  and  eNOS  (in  the  vasculature).    NMDA 
stimulation with glutamate and the associated increase in NO in turn has been shown 
to  increase  cGMP  (Garthwaite  et  al.,  1988;  Garthwaite  and  Garthwaite,  1987; 
Garthwaite  et  al.,  1989).    Nitric  oxide  can  subsequently  influence  the  release  of 
glutamate from surrounding presynaptic terminals (Matsuo et al., 2001) and it can 
interact in an autocrine fashion with thiol groups on the NMDA receptor, causing a       22 
conformational  change  (S-nitrosylation)  that  serves  to  inactivate  receptor  function 
(Gbadegesin et al., 1999; Gow et al., 2000). 
Within the CNS, NMDA receptor modulation by NO in key central autonomic 
nuclei  can  influence  sympathetic  outflow  and  BP  responses.    For  example, 
microinjection of NMDA into the NTS causes a dose dependent increase in NO levels 
within the NTS, and a decrease in BP that is the same as that seen when NO agonists 
are  applied to the NTS (Matsuo et al., 2001).   Furthermore, both the  response to 
microinjection  of  NMDA  and  NO  is  attenuated  when  NOS  inhibitors  are  applied 
(Matsuo et al., 2001).   
1.3.  Nitric Oxide and autonomic areas 
There is a considerable amount of evidence supporting a role for NO as a key 
central autonomic regulator of cardiovascular function, with substantial data showing 
modulation  of  sympathetic  activity  and  corresponding  changes  in  BP  in  several 
species (del Carmen Garcia et al., 1997), including the rat  (Minami et al., 1995; 
Mollace et al., 1992; Sakuma et al., 1992), cat (Hegde et al., 1994; Shapoval et al., 
1991) and dog (Nakahara et al., 1995; Nakahara et al., 2000).  This review will now 
focus on the role of NO in the key central autonomic regions that are the focus of this 
thesis. 
1.4.  Nucleus tractus solitarii  
Stimulation of the NTS, the first relay station in the baroreflex arc, elicits a 
decrease in renal sympathetic nerve activity (RSNA), BP and heart rate (HR) (del 
Carmen Garcia et al., 1997).  Analysis of nNOS messenger RNA (mRNA) expression 
during  the  development  and  maintenance  of  hypertension  in  the  NTS  of  the       23 
hypertensive Spontaneously Hypertensive Rat (SHR) model and their normotensive 
genetic control, the Wistar Kyoto (WKY) showed that SHRs had significantly higher 
nNOS mRNA expression, compared to the WKY, although nNOS mRNA expression 
decreased as in both strains with aging (Ferrari and Fior-Chadi, 2005).  Interestingly, 
both nNOS protein  and mRNA levels increased in the SHR prior to the onset of 
hypertension.  Whether this is causal is unclear, however previous studies showing 
that NOS activity increases with age indicates that nNOS may be a compensatory 
response to elevated levels of BP, as the central nervous system may be trying to 
offset the increased sympathetic output (Qadri et al., 2003).   
1.4.1.  Location 
The NTS is located within the brain stem, dorsal to the RVLM and in the rat, 
it consists of a column of cells on each side of the fourth ventricle (Sapru, 1994).  At 
the rostral edge of the area postrema, the bilateral columns of the NTS cells merge in 
the midline to form the commissural subnucleus (CSN) (Sapru, 1994).  The CSN of 
the NTS is approximately 0.5mm rostral to 1mm caudal to the calamus scriptorius 
(Sapru,  1994).    The  most  critical  region  pertaining  to  cardiovascular  control  are 
concentrated in the most caudal  regions of the  NTS (Loewy, 1990), for example, 
aortic  baroreceptors  send  their  central  processes  to  make  synaptic  contacts  with 
second  order  cells  that  are  contained  within  the  dorsal  caudal  NTS  (Dean  and 
Seagard, 1995).  These neurons then may make contact with either third order neurons 
in the NTS, or may send axons out of the NTS to other brain areas,  such as the 
hypothalamus, RVLM or CVLM (Andresen et al., 2004).       24 
1.4.2.  Function 
The  NTS  is  pivotal  in  assimilating  and  integrating  a  multitude  of 
viscerosensory processes, including cardiovascular, respiratory, gustatory, hepatic and 
renal control mechanisms (Lawrence and Jarrott, 1996).  It is the first central relay for 
baroreceptor  control  (Lawrence  and  Jarrott,  1996),  as  afferent  baroreceptor  fibres 
from the carotid sinus and aortic arch terminate primarily in the intermediate portion 
of the NTS (Andresen and Kunze, 1994; Ciriello, 1983) and form excitatory synaptic 
contacts with second-order neurons (Aicher et al., 1999; Velley et al., 1991).  The 
carotid  chemoreceptors  (chemoreflex)  and  the  cardiopulmonary  afferent  C-fibres 
(Bezold-Jarisch  reflex),  both  of  which  have  involved  in  the  regulation  arterial 
pressure, also have their first synapse in the NTS (Machado et al., 1997).  Activation 
of the baroreflex or Bezold-Jarisch reflex increases parasympathetic drive to the heart 
and decreases sympathetic drive to the heart and vessels to normalise BP (Machado et 
al.,  1997),  whereas  activation  of  the  chemoreflex  increases  both  sympathetic  and 
parasympathetic drive which results in an increase in arterial pressure and intensifies 
the bradycardic response (Haibara et al., 1995; Marshall, 1994).  The activation of 
these cardiovascular afferents release excitatory amino acids within the NTS, which 
prompts  excitation  of  different  postsynaptic  neurons  that  the  NTS  projects  to, 
including the CVLM and RVLM (Machado et al., 1997). 
1.4.3.  Nitric oxide in the NTS 
Moderately stained small and medium sized nNOS immunoreactive cells are 
found in low density throughout the NTS at both caudal and rostral levels (Simonian 
and  Herbison,  1996).    When  NO  donors  are  injected  into  the  NTS,  sympathetic 
responses  such  as  hypotension  and  bradycardia  are  elicited,  indicating  that  NO  is       25 
involved in the regulation of sympathetic output (Ferrari and Fior-Chadi, 2005).  The 
microdialysis  of  nitrosothiol,  an  important  component  of  NO  mediated  biological 
events, increases the release of glutamate, which is the most utilised neurotransmitter 
at  barosensitive  terminals  within  the  NTS  (Lawrence  and  Jarrott,  1993;  1996).  
Together, these data indicate that NO is an important modulator of autonomic output 
within the NTS. 
1.5.  Caudal ventrolateral medulla   
The NTS influences the output of the RVLM by stimulating the bulbospinal 
vasomotor neurons that mediate tonic and reflex adjustments of sympathetic outflow 
(Haselton  and Guyenet, 1989; Morrison  et al.,  1988).  Although there  are studies 
showing  direct  connections  between  the  RVLM  and  NTS  (Ross  et  al.,  1985), 
electrophysiological  (Agarwal  and  Calaresu,  1991;  Jeske  et  al.,  1993)  and 
pharmacological  (Blessing,  1988;  Willette  et  al.,  1984c)  experiments  show  that 
baroreceptor information is modulated by the CVLM (Aicher et al., 1995; Jeske et al., 
1995;  McKitrick  et  al.,  1992).    Furthermore,  anatomical  studies  indicate  that 
GABAergic  neurons  in  the  CVLM  receive  numerous  inputs  from  NTS  areas  that 
receive  primary  baroreceptor  afferent  fibers  (Dampney,  1994;  Hirooka,  2006; 
McKitrick  et  al.,  1992).    Coupled  with  the  evidence  showing  that  this  is  a 
vasodepressor  area,  the  CVLM  constitutes  the  necessary  inhibitory  link  in  the 
baroreceptor reflex mediating the control of sympathetic vasomotor outflow.  
1.5.1.  Location 
Located  caudal  to  the  RVLM,  the  CVLM  has  been  defined  to  the  region 
ventral and overlapping the nucleus ambiguus (NA), mainly dorsal to, but extending 
ventrally into the medial aspect of the lateral reticular nucleus (Bonham and Jeske,       26 
1989; Gordon and McCann, 1988; Willette et al., 1983).  Rostrally, it terminates at the 
RVLM,  though  there  is  evidence  for  some  overlap  (Sved  et  al.,  2000).    In  other 
species this may differ.  For example, in the rabbit, there is the inter ventrolateral 
medulla,  which  lies  between  the  RVLM  and  CVLM  (Dampney  et  al.,  2003b).  
Furthermore, not only is the area spread over a large region, but there is evidence that 
shows that there are at least 2 distinct populations of cells, the rostral CVLM and 
caudal CVLM, otherwise known as the caudal pressor area (Sved et al., 2000), the 
two areas appearing to have distinct functional differences (Pilowsky and Goodchild, 
2002).   
1.5.2.  Function 
In  1973,  Guertzenstein  reported  that  the  application  of  neuroactive  drugs 
thought to excite neurons on the ventral surface of the most caudal regions of the cat 
brainstem elicited dramatic decreases in arterial pressure (Guertzenstein, 1973; Sved 
et  al.,  2000).    When  the  CVLM  is  stimulated  chemically,  such  as  through 
microinjection of L-glutamate, there is a significant reduction in sympathetic nerve 
activity  (Blessing  and  Reis,  1982;  1983;  Cravo  et  al.,  1991)  and  vasodilation  of 
vessels in the renal mesenteric and hind limb vascular beds vasodilate (Willette et al., 
1987) resulting in a decrease in BP.  This result is consistent in a number of species, 
such as the cat, rabbit and rat (Blessing and Reis, 1982; Gatti et al., 1986; Willette et 
al., 1983).  Conversely, lesions to the CVLM neurons result in an increase in BP 
(Willette et al., 1984b), associated  with significant increases in sympathetic nerve 
activity (Blessing and Reis, 1982).  Indeed, this acute hypertension can be of such 
impact that is leads to  ventricular failure and pulmonary  oedema (Blessing  et al., 
1982;  Cravo  et  al.,  1991;  Willette  et  al.,  1987).    Stimulation  of  CVLM  neurons 
appears to also decrease HR, independent of the actions of nearby pre-cardiac neurons       27 
in the nucleus ambiguus (McKitrick and Calaresu, 1997).  As part of the baroreflex 
pathway therefore, the CVLM receives prominent projections from the region of the 
NTS and then projects to RVLM bulbospinal neurons that project to the SPNs (Aicher 
et al., 1995; Jeske et al., 1995), and functions to provide the necessary inhibitory 
inputs needed to regulate the baroreceptor reflex. 
There are however some discrepancies associated with lesion studies of the 
CVLM.  While the majority of studies show that lesioning the CVLM results in an 
increase in BP (Sved et al., 2000), some studies show that despite the increase in BP 
after lesioning, the baroreceptor reflex remains intact  (Granata et al., 1985; Imaizumi 
et al., 1985).  Studies by Cravo and colleagues (Cravo et al., 1991) found that the site 
of chemical lesioning affected the outcome, in that injections into the rostral portion 
of  the  CVLM  destroyed  the  baroreceptor  response,  but  injections  into  the  caudal 
region, though increasing BP, did not affect the baroreceptor response.  Furthermore, 
local injections of glutamate into the caudal pressor area do not appear to decrease 
MAP, and in fact increase BP (Seyedabadi et al., 2006), providing support that the 
rostral and caudal regions of the CVLM appear to have distinct functions (Sved et al., 
2000). 
1.5.3.  Nitric oxide in CVLM 
Neurons positively labeled for nNOS can be found scattered throughout the 
CVLM (Simonian and Herbison, 1996), of which, 8% of these neurons project to the 
CVLM  (Kantzides  and  Badoer,  2005).    The  majority  of  nNOS  positive,  RVLM 
projecting neurons are located at the caudal end of the CVLM (Kantzides and Badoer, 
2005).  Microinjections studies have shown that NO influences the blood pressure 
responses elicited from the CVLM, as microinjections of L-arginine (L-Arg) a NO 
promoter produces a hypertensive effect, where as N(G)-nitro-L-arginine methyl ester       28 
L-NAME, an nNOS inhibitor produces a significant hypotensive effect (Lage et al., 
1999).   
1.6.  Rostral ventrolateral medulla  
The CVLM sends GABAergic (inhibitory) monosynaptic projections to the 
RVLM.  The importance of the RVLM as a critical region in the maintenance of BP 
was  discovered  over  a  century  ago  (Owsjannikow,  1871,  cited  in  Madden,  2003 
#193),  though  this  discovery  was  largely  ignored  till  over  a  century  later,  when 
Guertzenstein and Feldberg examined the effects of drug application to the ventral 
surface  of  the  brain  stem  on  BP  (Feldberg  and  Guertzenstein,  1972;  1976; 
Guertzenstein, 1973; Guertzenstein and Silver, 1974).  This region was further refined 
to the area ventral of the retrofacial nucleus, at the level of the rostral portion of the 
inferior olive, where it was found that microinjection of glutamate (Goodchild and 
Dampney, 1985) or other neuroexcitatory amino acids (Dampney et al., 1987) caused 
a significant increase in BP, and that bilateral destruction led to a profound fall in BP 
(Dampney et al., 1987). 
The RVLM is the final site within the brainstem that integrates the various 
influences  on  BP  from  higher  centres  such  as  the  paraventricular  hypothalamus, 
lateral hypothalamus, midbrain periaqueductal gray (Dampney, 1994), and it has been 
shown that inhibition of this region causes BP to drop by as much as the total removal 
of supraspinal influences (Madden and Sved, 2003).  Given that this region is so 
influential on BP, it is of high significance.   
1.6.1.  Location 
The  RVLM  is  located  in  the  ventral  portion  of  the  brainstem,  beginning 
immediately caudal to the facial nucleus, lateral to the inferior olives, and ventral to       29 
the nucleus ambiguus (Phillips et al., 2001),  This relatively small area is anatomically 
heterogeneous,  containing  many  cell  groups  such  as  nucleus  reticularis 
rostroventrolateralis,  gigantocellular  nucleus  paragigantocellularis  lateralis  and  the 
external and semi compact formations of the nucleus ambiguus (Andrezik et al., 1981; 
Guyenet, 1990; Newman, 1985; Ruggiero et al., 1989).  One of the most common 
ways to differentiate this heterogenous population of cells is by the identification of 
the neurochemical phenotype of neurons with the region. 
1.6.2.  Receptors and transmitters 
The RVLM neuronal cell population can be divided into two main categories, 
the  C1  neurons  and  non-C1  neurons.    The  C1  neurons  are  adrenergic  neurons, 
identified on the basis of their expression of phenylethanolamine-n-methyltransferase 
(PNMT) (Hokfelt et al., 1984b; Jeske and McKenna, 1992; Ross et al., 1981; Ross et 
al., 1984a), which is the enzyme that is responsible for converting noradrenaline to 
adrenaline  (Brownstein  and  Palkovits,  1984).    The  remainder  of  the  baroreceptor 
neurons are broadly categorised as the non-C1 population.  
Throughout  the  brainstem,  the  catecholamine  groups,  first  described  by 
Dahlstroem and Fuxe (Dahlstroem and Fuxe, 1964) are grouped into the A1 – A12 
groups  (noradrenergic),  and  the  C1  –  C3  (adrenergic)  and  can  be  collectively 
visualised  with  tyrosine  hydroxylase  (TH),  the  enzyme  that  converts  tyrosine  into 
dopa  (Hokfelt  et  al.,  1984a).    Within  the  ventrolateral  medulla,  PNMT  positive 
neurons extend from the caudal pole of the facial nucleus to the level of the calamus 
scriptorius (Ruggiero et al., 1985).  The traditionally defined C1 cell group can be 
subdivided into two distinct divisions (1) a cell column originating in the CVLM and 
extending rostrally and ventrally towards the ventral surface of the RVLM and (2) a       30 
cell cluster developing rostral and medial to the column and expanding close to the 
surface of the RVLM (Ruggiero et al., 1985).   
The noradrenergic neurons are confined mainly to two groups: the A1 cell 
groups,  in  the  ventromedial  medulla  oblongata,  and  the  A2  group,  located  in  the 
dorsal vagal complex (Hokfelt et al., 1984b).  Both cell groups start caudally in the 
upper cervical spinal cord (Hokfelt et al., 1984b).  The main group of A1 cell bodies 
are located in the ventrolateral medulla oblongata, at caudal levels ventrolateral to the 
most rostral part of the ventral horn  cells.   At the rostral end, they  are primarily 
located  dorsolateral  to  the  lateral  reticular  nucleus,  with  only  a  few  cells  in  this 
nucleus.  The A2 group extends rostrally to the area postrema, where they intermingle 
somewhat, with the most caudal cells of the magnocellular C2 group (Hokfelt et al., 
1984b).  A third group of neurons, the A5 cell group has also been implicated in 
cardiovascular control (Hokfelt et al., 1984a).  The A5 noradrenaline group form a 
continuous  column,  starting  at  the  level  of  the  ventrolateral  pons  medial  to  the 
trigeminal and facial nerves and extending in a caudal direction approximately to the 
level where the C1 neurons begin, and slightly overlap them (Hokfelt et al., 1984c). 
C1 cells 
The C1 group is composed of rostral and caudal subdivisions.  The rostral C1 
region  contains  barosensitive  neurons  with  axons  that  project  to  the  spinal  cord 
(Kanjhan et al., 1995; Lipski et al., 1995; Schreihofer and Guyenet, 1997), providing 
tonic, excitatory drive to SPNs (Sun, 1995; Guyenet et al., 1996), while caudal C1 
neurons project to the hypothalamus and  forebrain regions (Stornetta et al., 1999; 
Tucker et al., 1987; Verberne et al., 1999). 
In  addition  to  their  adrenergic  phenotype,  many  C1  cells  express  other 
peptides as well such as enkephalin and neuropeptide Y, whose roles in regards to       31 
cardiovascular control has yet to be defined (Pilowsky and Goodchild, 2002).  While 
C1 neurons show the ability to produce catecholamines, specifically adrenaline, their 
use of adrenaline needs to be questioned, as high performance liquid chromatography 
was unable to reveal the presence of adrenaline in the IML of the spinal cord, where 
PNMT containing bulbospinal neurons terminate (Sved, 1989).  Furthermore, some 
species, such as the rabbit, guinea pig and sheep do not express PNMT, indicating that 
perhaps  adrenaline  is  not  contributing  to  sympathetic  output  in  the  RVLM 
(McLachlan et al., 1989; Tillet, 1988).  Also, it has been shown that some of the most 
rostral  C1  neurons  do  not  express  aromatic  L-amino  acid  decarboxylase,  which 
converts dopa to dopamine, also critical in adrenaline synthesis (Phillips et al., 2001), 
which implies that a percentage of C1 neurons may not synthesise catecholamines 
(Phillips et al., 2001). 
C1 and non C1 receptors and transmitters 
There  have  been  many  studies  into  the  receptors  and  transmitters  present 
within the RVLM including adrenergic receptors and transmitters, neuropeptides such 
as  angiotensin  II,  amino  acids  such  as  GABA,  and  opioid  signalling  mechanisms 
(Dampney et al., 2003a; Guyenet et al., 2002). 
Immunohistochemically, it has been shown that bulbospinal neurons express 
alpha-2  receptors,  and  this  has  been  substantiated  functionally  as  a  significant 
population  of  barosensitive  neurons  as  they  are  inhibited  by  clonidine  (Allen  and 
Guyenet, 1993), a powerful agonist for the alpha-2 adrenoreceptor.  Reja et al. have 
shown that the level of alpha-2 adrenoreceptor cDNA is significantly less in SHRs 
compared to WKY controls (Reja et al., 2002b), and it has also been shown that 
alpha-2 adrenoreceptor knock-out mice express elevated levels of catecholamines, HR 
and BP (Gavras and Gavras, 2001).         32 
Within the RVLM, both angiotensin II (Ang II) and Ang II receptors have 
been demonstrated in a number of species (Allen et al., 1988a; Allen et al., 1987; 
Allen et al., 1988b; Lind et al., 1985; Mendelsohn et al., 1988), and microinjection of 
Ang II into the RVLM causes an increase in sympathetic nerve activity and arterial 
pressure,  which  can  be  blocked  by  Ang  II  antagonists  (Muratani  et  al.,  1991).  
Overall, the renin-angiotensin system has been shown to play an important role in the 
development of hypertension, as blockade of this system results in resetting of the 
baroreflex  function,  and  improves  the  sensitivity  for  control  of  heart  rate  and 
sympathetic nerve activity (Averill and Diz, 2000). 
During  resting  conditions,  bulbospinal  neurons  in  the  RVLM  are  strongly 
inhibited  by  GABA  (Schreihofer  and  Guyenet,  2002).    Iontophoretic  experiments 
reveal that application of the GABAA receptor antagonist bicuculline increases the 
firing rate of bulbospinal neurons (Sun and Guyenet, 1985), and microinjection of 
bicuculline  causes  an  increase  in  sympathetic  nerve  activity  and  BP  (Kubo  and 
Kihara,  1987;  Willette  et  al.,  1984a).    This  indicates  that  GABA  is  involved  in 
tonically  inhibiting  the  activity  of  RVLM  neurons,  which  ultimately  lowers 
sympathetic nerve activity and BP (Schreihofer and Guyenet, 2002).   
A  small  subset  of  RVLM  neurons  also  express  preproenkephalin  (PPE) 
mRNA,  (Guyenet  et  al.,  2002),  and  in  situ  hybridisation  studies,  coupled  with 
retrograde labelling indicates that most of these neurons project to the SPNs (Guyenet 
et al., 2002).  Hypotension induced by hydralazine (a vasodilator) causes the PPE 
neurons to express c-fos suggesting opioids are utilised during hypotension (Guyenet 
et al., 2002).         33 
1.6.3.  Projections 
The RVLM is critical as a cardiovascular control centre where inputs from 
higher centres are modified.  The RVLM has also been identified as an area that 
heavily  innervates  the  spinal  cord  region  containing  SPNs  and  which,  when 
stimulated  either  electrically  or  chemically,  caused  a  marked  increase  in  blood 
pressure (Ross et al., 1983; 1984a; Ross et al., 1984b). 
Projections to the RVLM 
There are a number of centres that project to the RVLM that are involved in 
BP  control.    These  include  the  central  nucleus  of  the  amygdala,  important  in  the 
control of BP during or in response to stressful or fearful stimuli (Saha, 2005), the 
NTS  and  CVLM  (Colombari  et  al.,  2001),  covered  in  previous  sections,  the 
paratrigeminal  nucleus,  which  has  been  implicated  in  BP  control  as  it  causes  a 
pressure response when stimulated by bradykinin (de Sousa Buck et al., 2001) and of 
specific relevance to this project, from the PVN (Badoer, 2001).   
The PVN, which is later discussed in detail further on (section 1.8), is a major 
integrative  site  for  autonomic  function  (Badoer,  2001).    It  has  2  distinct  cell 
populations, of which the parvocellular neurons project to the RVLM.  It has been 
shown that electrical or chemical stimulation of the PVN leads to a pressor response 
and the activation of c-fos in the RVLM, suggesting that the stimulation of PVN 
neurons  leads  to  the  activation  of  RVLM  neurons  (Krukoff  et  al.,  1994).  
Furthermore,  the  pressor  response  from  electrical  stimulation  of  the  PVN  can  be 
inhibited by microinjection into the RVLM of choline inhibitors, indicating that it is 
working through the RVLM via a cholinergic pathway (Kubo et al., 2000).  Also, 
during  experimental  haemorrhage  it  has  been  shown  that  a  specific  population  of       34 
RVLM projecting PVN neurons are activated, however these cells are not activated 
by  the  administration  of  hypotension  inducing  drugs,  indicating  that  RVLM 
projecting PVN neurons are important in detecting specific functional responses, in 
this case, changes in blood volume (Badoer, 1998).   
Projections from the RVLM 
C1 cells 
The majority of C1 neurons project to the spinal cord, where they provide a 
dense plexus of terminals in the thoracic IML (Kantzides and Badoer, 2005; Madden 
and Sved, 2003; Ross et al., 1984a) and synapse on SPNs (Milner et al., 1988).  Along 
the length of the RVLM, more rostral C1 cells project to the spinal cord than caudal 
C1 cells (Kanjhan et al., 1995; Lipski et al., 1995; Phillips et al., 2001; Schreihofer 
and Guyenet, 1997) which have an increased proportion of neurons that project to the 
hypothalamus  and  forebrain  areas  (Stornetta  et  al.,  1999;  Tucker  et  al.,  1987; 
Verberne et al., 1999).  Terminal projections from C1 neurons have been identified in 
the dorsal motor vagal complex, A1 area, raphe pallidus and obscurus of the caudal 
RVLM, and also within the locus coeruleus and nucleus subcoeruleus of the rostral 
RVLM (Card et al., 2006).  In the midbrain, projections from the RVLM can be found 
in  the  periaquaductal  gray,  while  forebrain  projections  from  C1  neurons  project 
predominantly to the hypothalamus (Card et al., 2006).    
Non-C1 cells 
Only a subset of neurons that project to the SPNs contain PNMT- i.e. only 50 
– 70% of spinally projecting RVLM neurons are actually C1 cells, - the rest are non 
C1 cells (Madden and Sved, 2003).  Non-C1 neurons from the mid RVLM region 
project to the medullary respiratory neurons, and innervate phrenic motor neurons       35 
(Dobbins  and  Feldman,  1994;  Ellenberger  and  Feldman,  1990;  Ellenberger  et  al., 
1992),  as  well  as  to  various  regions  in  the  brainstem,  midbrain  and  diencephalon 
(Card et al., 2006).  Like C1 cells, there are also a percentage of non-C1 cells that 
have reciprocal projection to the spinal cord (Burman et al., 2004; Stornetta et al., 
2001) and hypothalamus (Verberne et al., 1999), showing that these cells are capable 
of influencing autonomic output.  Many of the non-C1 cells are highly active at rest 
and are barosensitive (Guyenet et al., 2001).  They have lightly myelinated axons and 
could be a source of supraspinal glutamatergic drive from the RVLM to vasomotor 
SPNs.    It  has  not  been  identified  as  yet  whether  non-C1  cells  release  glutamate 
(Madden et al., 1999). 
1.6.4.  Function 
As described, the RVLM is an essential brain region involved in the tonic 
generation of sympathetic nerve activity (Sun et al., 1988), and the integration of a 
number  of  autonomic  and  somatic  functions,  including  the  control  of  BP  and 
respiration.  Activation of specific RVLM neurons has been shown to increase arterial 
pressure,  by  increasing  peripheral  resistance,  the  secretion  of  catecholamines  and 
cardiac output (Campos Junior and Guertzenstein, 1989; Feldberg and Guertzenstein, 
1972).  Bulbospinal neurons in the RVLM respond to a variety of visceral, somatic 
and  supramedullary  inputs  (Guyenet  et  al.,  1996).    Stimulation  of  this  region  via 
electrical  or  chemical  stimulation  elicits  marked  increases  in  BP  and  sympathetic 
nerve activity (Ross et al., 1983; 1984a; Ross et al., 1984b) whilst destruction of the 
RVLM  region  as  a  whole  results  in  a  reduction  in  sympathetic  nerve  discharge 
(Kantzides and Badoer, 2005). 
Indeed, inhibition of the RVLM causes BP to decrease by as much as is seen 
with total removal of supraspinal influences, for example with cervical spinal cord       36 
transection (Madden and Sved, 2003).  The region is also essential for many neurally 
mediated  cardiovascular  reflexes,  including  those  stimulated  by  aortic  and  carotid 
baroreceptors,  carotid  chemoreceptors,  muscle  afferents,  and  cardiopulmonary 
receptors (Granata et al., 1985; Guyenet, 1990; Kiely and Gordon, 1993; Koshiya et 
al., 1993; Stornetta et al., 1989; Verberne and Guyenet, 1992). 
In addition to cardiovascular control, subpopulations of neurons in the RVLM 
are  involved  in  nociception  and  are  activated  by  peripheral  noxious  stimuli,  with 
stimulation of the medial RVLM able to alter nociceptive transmission (Babic and 
Ciriello, 2004).  Neurons in the medial RVLM are also involved in the regulation of 
breathing (Dobbins and Feldman, 1994; Ellenberger and Feldman, 1990; Ellenberger 
et al., 1992).    
Functional subpopulations C1 cells vs. non-C1 cells 
C1  cells  are  tonically  active  and  powerfully  inhibited  by  elevations  of  BP 
(Ross et al., 1984a).  As the majority of rostral C1 cells project to the SPNs in the 
spinal  cord,  it  would  suggest  that  they  are  critical  for  the  maintenance  of  tonic 
sympathetic outflow (Madden and Sved, 2003).  However, destruction of C1 neurons 
reduces the pressor response elicited by glutamate stimulation by only 40% (Madden 
and  Sved,  2003)  and  while  it  reduces  reflex  sympathoexcitation  in  response  to 
decreased BP it does not abolish it (Madden and Sved, 2003).  This suggests that the 
C1 neurons are involved in the sympathoexcitation evoked from the RVLM, although 
not essential for the process.  It is possible that because unilateral lesions have only 
destroyed a percentage of C1 cells, remaining C1 neurons are sufficient to attenuate 
the responses described.  However, experiments involving bilateral lesioning of the 
C1  neurons,  as  well  as  experiments  where  spinally  projecting  C1  neurons  are 
destroyed  have  yielded  similar  results;  C1  neurons  are  not  essential  for  RVLM-      37 
mediated  maintenance  of  resting  sympathetic  vasomotor  tone  (Madden  and  Sved, 
2003),  but  do  contribute  to  baroreceptor-evoked  sympathoexcitation  and  other 
sympathoexcitatory reflexes (Madden and Sved, 2003). 
However, C1 cells are not the only cells involved in the regulation of BP. 
Electrophysiological studies using indirect criteria, such as juxtacellular labelling to 
distinguish between putative C1 neurons and non-C1 neurons, show that both C1 and 
non C1 cells respond to changes in arterial pressure (Haselton and Guyenet, 1989; 
Schreihofer and Guyenet, 1997).  Furthermore, studies using hypotension-evoked Fos 
expression as a means of identifying barosensitive neurons conclusively demonstrated 
that spinally  projecting  C1 neurons  and non-C1 neurons in the RVLM were both 
responsive to decreases in BP (Chan and Sawchenko, 1994; Sved et al., 1994). 
1.6.5.  Changes in the RVLM during hypertension 
The RVLM has been studied in a number of different hypertensive models, 
showing  major  changes  between  the  normotensive  and  hypertensive  state.    An 
enhanced pressor response to microinjections of glutamate into the RVLM has been 
demonstrated in rats with Goldblatt 2 Kidney 1 Clip (2K1C) hypertension (induced by 
partial obstruction of one renal artery) (Bergamaschi et al., 1995).  Further, 2K1C rats 
respond  to  blockade  of  RVLM  glutamatergic  synapses  with  a  decrease  in  blood 
pressure, while normotensive rats do not, indicating a change of sensitivity of the 
glutamate receptors in the RVLM of this model (Colombari et al., 2001).  In the SHR, 
electrical stimulation of the RVLM produces greater pressor responses than in control 
WKY  (Lin  et  al.,  1995)  and  it  has  also  been  demonstrated  that  SHR  rats  have 
approximately 2.5 times more TH mRNA expression in the C1 and A1 regions of the 
RVLM, compared to their normotensive controls (Reja et al., 2002a).  These data       38 
indicate  both  functional  and  neurochemical  alterations  in  the  RVLM  in  the 
hypertensive state.   
1.6.6.  Nitric Oxide in the RVLM 
Location 
The  expression  of  NO  in  the  RVLM  has  been  examined  through  its 
synthesising enzyme NOS in a number of immunohistochemical and cytochemical 
studies.  Neuronal  NOS  positive  neurons  can  been  found  scattered  throughout  the 
gigantocellular  reticular  and  lateral  paragigantocellular  nucleus  (Nazu  and 
Thippeswamy, 2002), with their dendrites producing a lattice-like appearance in the 
region (Simonian and Herbison, 1996).  More clustered groups of nNOS neurons can 
be  seen  in  the  medial,  lateral  and  ventrolateral  portions  of  the  RVLM  (Nazu  and 
Thippeswamy, 2002).  Interesting, NOS expressing neurons appear to be distinct from 
other neurochemically defined cell populations within the RVLM, and do not appear 
to  co-localise  with  any  of  the  known  classical  transmitter  systems  (Nazu  and 
Thippeswamy,  2002).    Studies  have  shown  that  although  NOS  and  TH/PNMT 
immunoreactive neurons are widely distributed in the RVLM, the two do not coexist 
in any neurons.  Furthermore, only a small number of cells retrogradely labeled from 
the  spinal  cord  showed  co-localisation  with  NOS  producing  cells  (Nazu  and 
Thippeswamy, 2002).  This suggests that the RVLM contains a well-defined group of 
neurons that express NO that are distinct from the adrenergic C1 group and have only 
limited monosynaptic projections to the spinal cord (Iadecola et al., 1993; Ohta et al., 
1993).       39 
Function 
There is significant evidence showing that NO can influence the output of the 
RVLM  (Chan  et  al.,  2003a;  Chan  et  al.,  2001a),  although,  the  actual  response  is 
controversial.  It has been shown that microinjections of sodium nitroprusside, a NO 
donor and L -Arg, into the RVLM of cats reduced arterial pressure and sympathetic 
nerve  activity,  while  microinjection  of  N
G-  methyl-L-Arg,  a  non  selective  NOS 
inhibitor, increased them (Shapoval et al., 1991).  Hirooka et al. (Hirooka et al., 1996) 
however, reported conflicting results showing that in rabbits a decrease in BP and 
sympathetic nerve activity in response to NO donors.  This may be species related, but 
in the rat, both pressor (Martins-Pinge et al., 1997) and depressor (Kagiyama et al., 
1997) responses have been reported in response to NO donors.  Regardless, NO does 
effect the RVLM, and its control over BP and one of the aims of this thesis is to 
further define the significance of NO production in the region.   
With  regards  to  NO  signalling  in  the  RVLM,  there  is  strong  functional 
evidence to show cGMP dependent and independent mechanism of action (Chan et 
al., 2003b), however, expression of cGMP or changes in cGMP levels in this region, 
has not been documented and is one of the goals of this thesis. 
1.7.  Sympathetic preganglionic neurons 
Sympathetic preganglionic neurons are the last point in the central nervous 
system where autonomic output can be modulated (Minson et al., 1997).  Sympathetic 
preganglionic  neurons  are  located  within  the  spinal  cord,  predominantly  between 
cervical  segments  C8  and  lumbar  segment  L2,  and  project  to  sympathetic 
postganglionic neurons, whose axons in turn innervate autonomic targets including       40 
vascular smooth muscle, penile tissue and the heart (Anderson, 1998; Giuliano and 
Rampin, 2004; Janig and McLachlan, 1987). 
1.7.1.  Topographic organisation 
The SPNs are topographically organised into four distinct nuclei, the nucleus 
intermediolateral lateral cell column (IML), the nucleus intermediolateralis thoraco-
lumbalis pars funicularis, the nucleus intercalatus spinalis and the nucleus intercalatus 
pars paraependymalis (Petras and Cummings, 1972).  Approximately 85% of SPNs 
can be found within the IML, which occupies the lateral dorsal horn of the spinal grey 
matter (Lee et al., 1996).  The SPNs are arranged in a ladder like pattern, with “the 
uprights formed by neurons of the IML and central CA area, and their rostrocaudal 
oriented  dendrites.    The  rungs  of  the  ladder  are  primarily  formed  by  the 
mediolaterally-oriented dendrites of the SPNs” (Ezerman and Forehand, 1996) which 
are clustered approximately 200 microns apart.   
1.7.2.  Receptors, transmitters, and function  
As the major excitatory input to post ganglionic neurons supplying a variety of 
target organs, SPNs play host to a large number of receptors, and have a large source 
of neurotransmitters, with multiple functional outcomes.  This next section will cover 
3  of  the  main  categories  of  neurotransmitter  synaptic  input  to  the  SPNs,  the 
monoamines, amino acids and other neurotransmitters including peptides, and discuss 
their sources and functional significance. 
Monoamines 
Anatomical  studies  indicate  that  the  IML  receives  a  dense  noradrenergic 
innervation (Dahlstrom and Fuxe, 1965), with many noradrenergic terminals localised       41 
in  clusters  around  SPN  cell  bodies  (McCall,  1988).    Furthermore,  autoradiograph 
studies indicate there are high concentrations of alpha2-adrenergic receptors within 
SPNs (McCall, 1988).  The main source of adrenergic input appears to come from the 
A5 cell group, which is rostral of the RVLM (Blessing et al., 1981; Dahlstrom and 
Fuxe,  1965)  both  of  which  have  direct  connections  to  SPNs  in  the  IML.  
Microiontophoretic studies indicate that these inputs inhibit the activity of SPNs, as 
stimulation of the A5 area inhibits the firing rates of SPNs (Coote et al., 1981; De 
Groat and Ryall, 1967),  
Interestingly, microiontophoretic administration of adrenaline has been shown 
to inhibit the activity of SPN (McCall, 1988), as does the application of alpha 1-AR 
agonists (Aghajanian and Rogowski, 1983).  This is in conflict to the purportedly 
excitatory role of the C1- bulbospinal adrenergic cell  group, and indicates that in 
regards to monoamines, SPN are a complex population of neurons and that other co-
transmitter inputs may assume greater functional significance. 
Amino acids 
Amino  acid  neurotransmitters  are  crucial  in  the  control  of  most  central 
neurons,  including  SPNs  (Llewellyn-Smith,  2002).    Sympathetic  preganglionic 
neurons  are  densely  innervated  by  axon  terminals  containing  glutamate 
immunoreactivity (Llewellyn-Smith et al., 1998; Llewellyn-Smith et al., 1992).  This 
innervation arises from supraspinal sources, such as the RVLM (Morrison, 2003), as 
well as from intraspinal sources, as glutamate immunoreactive input to SPN remains 
after  complete  spinal  cord  transection  (Llewellyn-Smith  et  al.,  1997a;  Llewellyn-
Smith et al., 2007).  Sympathetic preganglionic neurons respond to glutamate with 
fast  excitatory  post-synaptic  potentials  mediated  by  NMDA  and/or  non-NMDA 
receptors (Deuchars et al., 1995; Inokuchi et al., 1992b; Sah and McLachlan, 1995),       42 
while glutamate antagonists profoundly affect SPNs autonomic responses (Llewellyn-
Smith et al., 2007).  For example, intrathecal administration of kynurenate, a broad-
spectrum antagonist for glutamate receptors, reduces BP and HR (Verberne et al., 
1990), and direct application of kynurenate, using iontophoretic or pneumatic pressure 
injection, decreases the activity of SPNs (Morrison, 2003).  
Studies  have  also  shown  that  there  is  a  dense  network  of  GABA-like 
immunoreactive processes that surrounds the soma and dendrites of SPNs (Llewellyn-
Smith, 2002; McCall, 1988).  These GABAergic inputs come from supraspinal sites, 
such  as  the  ventral  medulla,  (Llewellyn-Smith,  2002),  as  well  as  from  intraspinal 
sources (Llewellyn-Smith, 2002), and cause fast inhibitory post synaptic potentials 
(Backman and Henry, 1983; Inokuchi et al., 1992a; Yoshimura and Nishi, 1982).  
Alternative transmitters 
There  are  a  wide  variety  of  other  neurotransmitters  concentrated  in  SPNs, 
including acetylcholine, which is found in all SPN including those which innervate 
the chromaffin cells and ganglionic cells of the adrenal medulla (Murphy et al., 2003) 
and enkephalin, which is found specifically in those SPN that innervate adrenergic 
chromaffin cells (Pelto-Huikko et al., 1985) and function to regulate the release of 
catecholamines into the circulation (Llewellyn-Smith, 2002; Llewellyn-Smith et al., 
2007).  Furthermore, there is a subset of SPN innervating the adrenal medulla that 
express phosphorylated extracellular signal–regulated kinase (Springell et al., 2005).  
The  secretion  of  adrenaline  and  noradrenaline  from  adrenal  medullary  chromaffin 
cells  is  an  important  contributor  to  the  homeostatic  responses  to  a  variety  of 
challenges including cold exposure, haemorrhage, myocardial ischemia, shock and 
hypoglycaemia (Brown and Fisher, 1984; Maddens and Sowers, 1987; Vollmer, 1996; 
Vollmer et al., 1997; Yamaguchi, 1992; Young et al., 1984).       43 
A subpopulation of SPNs express neuropeptide Y (Gibbins, 1992).  They can 
be further divided into neurons that synapse directly onto vasodilator neurons, which 
express  substance  P,  or  that  synapse  directly  on  vasoconstrictor  neurons,  which 
express  calcitonin  gene-related  peptide  (CGRP)  (Gibbins,  1992).    Intrathecal 
administration of substance P, or its analogues increases the firing rate of SPNs, and 
subsequently  increases  BP  (McCall,  1988),  while  intrathecal  administration  of 
substance P antagonists drops BP to spinally transected animal levels.   
There  is  a  vast  amount  of  evidence  showing  that  there  are  monosynaptic 
connections between the PVN and SPNs (Ranson et al., 1998).  As discussed in the 
next section, the PVN expresses oxytocin (OT) and arginine vasopressin (AVP), and 
SPNs contain receptors for both these transmitters (McCall, 1988).  Superfusion of 
AVP over spinal slices causes SPN to depolarise, while intrathecal administration of 
AVP increases BP (McCall, 1988).  Functionally, it has been shown that neurons 
from the PVN projecting to the SPNs are activated when there is a decrease in blood 
volume (Badoer, 2001), indicating that PVN neurons are likely able to influence the 
autonomic output of the SPNs.  
1.7.3.  Changes in SPNs during hypertension 
Whilst  there  have  been  many  studies  demonstrating  the  neuroanatomical 
functional differences in the NTS, CVLM and RVLM between hypertensive models 
and their genetic normotensive counterparts, there has been very little information 
regarding changes at the level of the SPN in association with hypertension. Minson et 
al  has  shown  that  SHRs  have  increased  c-Fos  expression  compared  to  its 
normotensive control, the Wistar Kyoto (Minson et al., 1996).  Furthermore, Tang et 
al  have  demonstrated  a  decreased  proportion  of  NOS  containing  SPN  from  the 
intermediolateralis pars funicularis that project to the superior cervical ganglion (Tang       44 
et  al.,  1995a).    One  of  the  goals  of  this  thesis  is  to  extend  this  knowledge,  by 
examining the nNOS expression in SPN of the IML within the thoracic spinal cord. 
1.7.4.  Nitric Oxide in the SPNs 
Within  the  IML,  NOS  containing  SPNs  have  been  identified  as  an 
anatomically distinct population of cells, and in the Sprague-Dawley rat, up to 70% of 
the  SPNs  in  the  IML  (between  T2  and  T13)  contain  nNOS  (Anderson,  1992).  
Functional responses to NO driven by SPN are controversial, with both pressor or 
depressor responses documented (del Carmen Garcia et al., 1997; Koga et al., 1999; 
Lee et al., 1996). 
Intrathecal  administration  of  endogenous  NOS  attenuates  pressor  responses 
induced  by  NMDA  (Arnolda,  2002)  suggesting  a  role  for  NO  as  a  modulator  of 
descending excitatory cardiovascular signals.  Evidence for spinal NO as a functional 
regulator  of  BP  is  evidenced  by  its  role  in  mediating  hypotensive  reactions  to 
haemorrhage.  In a study by Lu et al. (Lu et al., 1999) intrathecal administration of 
NOS  inhibitors  significantly  attenuated  the  precipitous  decrease  in  BP  seen  with 
severe haemorrhage. 
1.8.  Paraventricular hypothalamus 
In addition to the reflex BP control pathways modulated by the brainstem and 
spinal cord regions, superimposed upon this is input from higher regions that serve to 
maintain homeostasis in response to both acute and chronic stressors.  One of these 
regions involved in control vascular sympathetic responses is the PVN (Stern et al., 
2003).       45 
1.8.1.  Location 
The PVN is located within the hypothalamus and is a complex, heterogenous 
region containing both large magnocellular neurons and small parvocellular neurons 
(Shafton  et  al.,  1998),  which  are  associated  with  neuroendocrine  and  autonomic 
outflow respectively.  The neurons of the PVN can be divided in a variety of ways, 
including on the basis of cytoarchitecture, cellular characteristics, (i.e. magnocellular 
and  parvocellular)  (Swanson  and  Kuypers,  1980),  or  chemically  coded 
neurotransmitter  subpopulation  (Swanson  and  Sawchenko,  1983),  or  by  projection 
target (Swanson and Sawchenko, 1983).  The regions of the PVN involved in BP 
control are located either side along the entire length of the third ventricle of the 
hypothalamus over a distance of ~4.25mm in the rat (de Wardener, 2001).  In addition 
to the PVN, other hypothalamic regions involved in BP control in this region are the 
medial  preoptic  nucleus,  which  arches  upward  and  posteriorly  over  the  ventricle 
(Lind, 1988), and the supraoptic nucleus (Sawchenko and Swanson, 1982).  
Subpopulations 
Magnocellular neurons 
The magnocellular subdivisions of the PVN contain large cells that synthesise 
AVP  (otherwise  known  as  antidiuretic  hormone,  ADH)  or  OT  (Benarroch,  2005).  
These cells give rise to the hypothalamus-neurohypophyseal system and project to the 
posterior pituitary where they release AVP or OT into the blood stream (Engelmann 
et al., 2004; Renaud and Bourque, 1991).  The majority of magnocellular neurons lie 
in the magnocellular balls within the lateral and medial magnocellular region of the 
PVN (Paxinos and Watson, 1998), with the oxytocinergic cells lying in a ring around 
the vasopressinergic neuron mass.         46 
Parvocellular neurons 
The  smaller  neurons  of  the  PVN  make  up  the  parvocellular  neuronal 
population.    The  medial  parvocellular  subdivision  of  the  PVN  synthesises 
corticotropic releasing hormone (CRH) and somatostatin and cells from this region 
project to the neurohemal zone of the median eminence, where they regulate secretion 
from the anterior pituitary (Sawchenko et al., 1996).  Neurons of the anterior, ventral 
and posterior parvocellular subdivisions of the rat PVN project to autonomic nuclei of 
the  brain  stem  and  spinal  cord.    These  autonomic  PVN  neurons  may  be 
immunoreactive  to  contain  AVP,  OT,  CRH,  TH,  angiotensin,  somatostatin, 
enkephalin or neurotensin in different combinations (Hallbeck et al., 2001; Jansen et 
al., 1995).  
1.8.2.  Receptors and transmitters 
Synaptic control of the PVN is extremely complex.  Excitatory inputs, which 
are mediated by glutamate (Herman et al., 2004) act on the PVN via both AMPA and 
NMDA receptors (Benarroch, 2005; Herman et al., 2004).  
The PVN also receives inhibitory inputs that are mediated by GABA (Herman 
et al., 2004) primarily by GABAA receptors, although presynaptic GABAB receptors 
may also regulate both glutamatergic and GABAergic neurotransmission in the PVN 
(Benarroch, 2005). GABAergic inhibition of the PVN comes from several different 
sources;  GABA  provides  the  tonic  inhibitory  effect  of  baroreceptors  and  atrial 
receptors  over  magnocellular  AVP  secretion  (Benarroch,  2005;  Yang  and  Coote, 
2003).  Furthermore, GABAergic inputs from the nucleus of the stria terminals and 
dorsomedial nucleus of the hypothalamus relay inhibitory limbic influences on CRH 
PVN neurons in response to external stressors (Herman et al., 2004).       47 
The catecholaminergic A1/C1 groups are critical for activation of the PVN in 
response to stressors such as hypoxia, hypovolemia, or cytokines (Sawchenko et al., 
2000).  Noradrenaline, acting via postsynaptic a1 receptors, activates magnocellular 
AVP neurons (Boudaba et al., 2003), parvocellular CRH neurons (Chen et al., 2004b) 
and sympathoexcitatory neurons in the PVN.  Activation of presynaptic a2 receptors 
reduces  release  of  GABA  from  inhibitory  synapses  on  sympathoexcitatory  PVN 
neurons (Li et al., 2005).  Activation of NMDA receptors leads to an increase in 
intracellular  Ca
2+  and  NO  production  in  the  PVN  (Herman  et  al.,  2003).    Other 
excitatory  neurotransmitter  inputs  to  PVN  to  the  RVLM  may  be  mediated  by 
glutamate, AVP (acting via V1 receptors), or AngII (via AT1 receptors) (Dampney et 
al., 2003a).  
1.8.3.  Projections  
Two major areas that project to the PVN are the subfornical organ (SFO), and 
organum vascularis lamina terminalis (OVLT) (Bains and Ferguson, 1995).  These 
circumventricular organs contain neurons with secreting granules and vacuoles and 
fenestrated capillaries, an arrangement which allows the neurons to monitor levels of 
substances unable to penetrate the blood brain barrier (de Wardener, 2001), thereby 
providing  a  route  of  communication  from  the  periphery  to  the  central  autonomic 
control regions such as the PVN. 
The PVN has reciprocal connections to various centres of the brain including 
the supraoptic nucleus, NTS, RVLM and spinal cord (Luiten et al., 1985; Swanson 
and Kuypers, 1980; Swanson and Sawchenko, 1983; Zhang et al., 1997), which have 
been  demonstrated  using  various  techniques  including  classical  electrophysiology 
experiments and neuroanatomical studies with tracer (Magoun, 1940).  For example,       48 
using anterograde tracing, it was shown that projections to the autonomic centres in 
the  spinal  cord  came  from  the  dorsal  portion  of  the  hypothalamus  (Kuypers  and 
Maisky, 1975).  This was further refined in 1976, with retrograde tracing methods, 
revealing  that  the  majority  of  the  hypothalamic  innervation  of  SPNs  comes  from 
within the PVN (Saper et al., 1976).  Experiments using electrical stimulation of the 
various  cholinergic  and  adrenergic  groups  (A1)  of  the  medulla,  combined  with 
electrophysiological  identified  PVN  neurons,  confirmed  reciprocal  connections 
between the PVN neurons and RVLM neurons (Saphier, 1993).    
Projections from the PVN can be broken down into two main domains.  The 
first  is  the  posterior  pituitary  gland,  which  is  involved  in  endocrine  homeostasis 
within the body (Swanson and Kuypers, 1980), the second is to key CNS regions are 
involved  in  autonomic  control,  such  as  the  cardiovascular  centres  in  the  medulla 
(RVLM and NTS) as well as SPN within the IML (Hardy, 2001; Li et al., 2003a; 
Pyner and Coote, 1999; Ranson et al., 1998; Swanson and Kuypers, 1980).  The PVN-
IML pathway is especially important in regulation of the haemodynamic responses to 
stress and osmolarity changes in the blood (Coote, 1995). 
1.8.4.  Function 
Integrative function 
The PVN is involved in integrating inputs from interoceptors, humoral centres 
and limbic centres (Sawchenko et al., 2000).  Interoceptive inputs have both direct 
and indirect pathways into the PVN.  These inputs arise from the visceral receptors, 
nociceptors and thermoreceptors and reach all subdivisions of the PVN (Sawchenko 
et  al.,  2000).    Humoral  signals  such  as  steroid  levels,  glucose  levels,  and  blood 
osmolality  reach  the  PVN  by  different  mechanisms,  having  effects  on  the       49 
circumventricular organs, which then relay this information to the PVN (Benarroch, 
2005).  Limbic inputs from the orbitomedial prefrontal cortex and amygdala, related 
to emotional responses to external stressors, are relayed primarily via the bed nucleus 
of the hypothalamus (Sawchenko et al., 2000). 
The  PVN  also  receives  abundant  intrahypothalamic  projections.    These 
include inputs from the dorsomedial nucleus in response to stress, the suprachiasmatic 
nucleus, which is critical for circadian control of autonomic and endocrine function, 
and from the arcuate nucleus and perifornical area, which are involved in control of 
food intake and energy metabolism (Ferguson and Samson, 2003). 
Finally, the PVN plays an important role in the integration of autonomic and 
endocrine  homeostatic  responses  (Swanson  and  Sawchenko,  1980).    Through 
reciprocal interconnections with autonomic centres in the brain, the PVN integrates 
and moderates cardiovascular centres (Horn et al., 1994), sexual behaviour (Mani et 
al., 1994), control of autonomic outflow (Martin and Haywood, 1992) and vasomotor 
tone and BP (Porter and Brody, 1985; Zhang and Ciriello, 1985a; b). 
Autonomic regulation 
The PVN has been implicated in several aspects of cardiovascular control, 
such  as  sympathoexcitatory  responses  to  stress  (Badoer,  2001;  Blair  et  al.,  1996; 
Coote et al., 1998) and renal vasoconstriction (Cham and Badoer, 2008).  There have 
been several neurochemically distinct groups of PVN neurons identified that project, 
both ipsilaterally and contralaterally, via the hypothalamic decussation (Toth et al., 
1999) to autonomic nuclei of the brain stem and spinal cord.  The autonomic PVN 
neurons  constitute  a  heterogeneous  population  consisting  of  cells  with  unique 
morphological and physiological properties (Stern, 2001).  Separate populations of 
pre-autonomic PVN neurons selectively control functionally distinct subpopulations       50 
of preganglionic sympathetic or parasympathetic neurons (Coote et al., 1998; Portillo 
et al., 1998).  For example, the PVN sends direct projections to cardiac (Coote, 1995; 
Ranson  et  al.,  1998)  and  renal  (Coote  et  al.,  1998)  sympathoexcitatory  neurons.  
Stimulation of the PVN leads to an increase in BP, HR, and renal sympathetic nerve 
activity (Coote et al., 1998) and while spinally projecting PVN neurons are inhibited 
by  baroreceptor  and  atrial  afferents,  they  are  activated  by  systemic  hypotension 
(Coote et al., 1998).  The PVN elicits sympathoexcitation both via direct projections 
to SPNs in the IML and via collateral projections to neurons of the RVLM that in turn 
send excitatory inputs to the IML (Coote et al., 1998; Shafton et al., 1998).  Overall, it 
is apparent that the PVN is critical in both influencing and integrating various inputs 
that control autonomic outflow. 
1.8.5.  Changes in PVN during hypertension 
The  functional  cerebral  changes  that  have  been  detected  in  the  brains  of 
hypertensive animals occur predominantly in the hypothalamus and the medulla (de 
Wardener, 2001).  Furthermore, it has been shown that when the PVN of SHR, Dahl 
salt sensitive and rats with renal hypertension is lesioned, there are decreases in blood 
pressure (Ciriello et al., 1984; Goto et al., 1981; Herzig et al., 1991; Takeda et al., 
1991), and it has been proposed that hypertension is due to an increase in medullary 
pressor  activity  due  to  suppression  from  superior  medullary  inhibitory  activity 
(Chalmers, 1998; Chalmers and Pilowsky, 1991).   
A  number  of  differences  within  the  PVN  have  been  identified  between 
hypertensive and normotensive animal models.  At the age of 4 weeks, the mRNA 
levels of AVP within the PVN are 3 fold higher within the SHR, compared to the 
WKY, while their mRNA expression of OT is 35% lower (van Tol et al., 1988).  
Also,  it  has  been  shown  that  blockade  of  glutamate  receptors  within  the  PVN       51 
decreases the spontaneous firing activity of spinally PVN neurons within SHR rats, 
but has no effect in WKY (Li et al., 2008).  When examined with radioimmunoassay, 
Dahl  salt  sensitive  rats  show  a  higher  expression  of  NOS  activity,  compared  to 
controls (Serino et al., 2001).  Together, these data indicate augmented activity within 
the PVN during hypertension. 
1.8.6.  Nitric oxide in the PVN 
Nitric oxide has a major role in regulating the activity of PVN neurons and has 
been  shown  to  inhibit  both  magnocellular  AVP  producing  (Kadekaro,  2004)  and 
sympathoexcitatory PVN neurons (Li et al., 2003a; Qadri et al., 2003).  
Location 
Neuronal  NOS  is  densely  found  throughout  the  PVN  (Bredt  et  al.,  1990; 
Miyagawa et al., 1994; Vincent and Kimura, 1992).  It is produced by magnocellular 
neurons expressing OT but not by vasopressinergic neurons (Miyagawa et al., 1994; 
Vacher et al., 2003).  Nitric oxide produced in the PVN can induce cGMP synthesis in 
astrocytes,  as  well  as  in  GABAergic,  catecholaminergic,  glutamatergic  and 
serotenergic  fibres  (Vacher  et  al.,  2003).    However,  only  30%  of  preautonomic 
neurons in the PVN express NO under basal conditions – the majority of expression is 
otherwise found in magnocellular neurons.  This indicates that NO may be a bridging 
molecule between the two subpopulations (Stern et al., 2003), and functionally could 
be  important,  as  it  may  be  the  mechanism  through  with  magnocellular  and  pre-
autonomic cells are communicating (Stern et al., 2003).   
Interestingly, despite a number of studies looking at NO in the PVN, very little 
work has looked a down stream NO signalling and whether similar subpopulations of 
PVN neurons can be identified.  While Vacher et al have looked at cGMP expression       52 
in PVN neurons in the mouse, their findings show that nNOS expression is limited to 
OT expressing magnocellular neurons (Vacher et al., 2003) where as studies in rats 
have  shown  nNOS  in  expression  in  both  AVP  and  OT  magnocellular  neurons 
(Arevalo et al., 1992; Bredt et al., 1991; Hatakeyama et al., 1996), indicating that 
down stream signalling may also differ between species.  Of particular relevance to 
this thesis is the expression of cGMP and on of the aims of this thesis is to examine 
cGMP defined by PVN target innervations in the rat. 
Function 
Microinjection studies are often utilised to gain information about the effects 
of various neurotransmitters in the PVN, and the irrespective effects on sympathetic 
nervous discharge (SND) (Kenney et al., 2003).   
Paraventricular  hypothalamus  neurons  appear  to  be  under  a  strong,  NO-
mediated tonic inhibitory influence (Stern, 2004).  In particular, NO appears to have a 
strong influence over cells within the PVN that project to the RVLM.  When the 
relatively selective nNOS inhibitor 7-NI is applied to these neurons, the firing activity 
of RVLM-projecting PVN neurons is increased (Stern et al., 2003).  Conversely, the 
ongoing activity of RVLM projecting neurons is strongly inhibited by NO (Stern, 
2004).    Perfusion  of  the  PVN  with  NO  containing  CSF  or  microinjection  of  NO 
donor, sodium nitroprusside into the PVN elicits a significant reduction in arterial BP 
(Horn et al., 1994).  This supports a role for NO as an important inhibitory molecule 
controlling the electrical activity of pre-autonomic PVN neurons, and indicates that 
these neurons are tonically inhibited by an endogenous NO source (Stern et al., 2003).  
Mechanistically, it has been shown that NO suppresses the firing activity of spinally 
projecting PVN neurons through the potentiation of GABAergic synaptic inputs (Li et 
al., 2003a).       53 
As hyperactivity of PVN neurons plays an important part in the maintenance 
of increased sympathetic vasomotor tone in certain types of hypertension, decreased 
GABAergic inhibition of presympathetic neurons in PVN may be responsible for the 
elevated level of sympathetic outflow in hypertension.  Nitric oxide may therefore 
work  as  a  “brake’  preventing  excessive  excitation  of  PVN  neurons  and  sustained 
increases in sympathetic outflow.         54 
1.9.  This Thesis 
The demonstrated importance of neuronal NO in many of the key sites that 
participate in central autonomic regulation leads to the prediction that disease states 
associated  with  altered  autonomic  outflow  may  also  exhibit  altered  central  NO 
mechanisms.  
This project was undertaken to further understand NO signalling mechanisms 
within brain regions known to contribute to the maintenance of autonomic outflow.  
Specifically, we aimed to characterise the differences in basal NO expression between 
the SHR and its control strain, the WKY, in regions known to influence sympathetic 
activity, focussing on the SPNs RVLM, and PVN.  Given that previous work shows 
that the addition or subtraction of NO to these regions affects MAP, we hypothesised 
that basal expression of NO and cGMP would differ between the two animal strains.  
To  test  this  theory,  we  used  different  combinations  of  mRNA  analysis, 
histochemistry, immunohistochemistry and retrograde labelling, to assess difference 
in gene and protein levels between the two strains.  In the spinal cord, we went further 
and examined functional differences through assessment of blood pressure responses 
to intrathecal administration of cGMP donors.       55 
2. General materials and methods 
Materials and methods  general to the thesis are described in the following 
chapter.    Specific  details  pertinent  to  the  individual  experimental  chapters  are 
provided with the relevant chapter.  All animal experimentation was undertaken with 
full ethics approval  from Animal Ethics Committees of the following institutions; 
Murdoch  University,  (Murdoch),  Western  Australia;  The  University  of  Western 
Australia, (Crawley), Western Australia; and University of Cincinnati, (Cincinnati) 
OH, USA. 
2.1.  Animals 
Animals were obtained from the Animal Resources Centre (WA) or Harlan 
(Wisconsin, USA).  Animals were housed on a 12 hour light-dark cycle with access to 
standard rat chow and water ad libitum.  Environmental enrichment was provided 
through chewing blocks and peanuts, and animals were group housed where possible.  
Male rats were used in all experiments (aged 7 weeks through to 12 months, total 
n=118).  The strains Wistar, Wistar Kyoto (WKY) and Spontaneously Hypertensive 
Rat (SHR) were used as detailed in each chapter.  The Wistar rat is an outbred strain 
of albino rat developed at the Wistar  Institute  (Philadelphia, PA).   Spontaneously 
hypertensive rats were derived from a Wistar colony at Kyoto University, selected on 
the basis of increased blood pressure (Louis and Howes, 1990; Okamoto and Aoki, 
1963).  The Wistar Kyoto strain were derived from the same Wistar strain as the SHR, 
but were selected instead as normotensive genetic controls (Johnson et al., 1992).       56 
2.2.  Assessment of blood pressure 
2.2.1.  Systolic pressure readings via tail cuff recording 
Systolic  blood  pressure  was  measured  in  conscious  rats  with  the  tail-cuff 
method (NIBP controller, AD Instruments, Castle Hill, Australia).  One to two weeks 
prior to blood pressure testing, rats were trained for handling, restraint and inflation of 
the tail cuff.  For recordings, rats were placed inside a restrainer with a heat lamp used 
to ensure an ambient temperature of ~28°C. An inflatable cuff (AD Instruments, Bella 
Vista, NSW, Australia) and microphone (AD Instruments,) were placed around the 
rat’s tail.  The animal was allowed to settle for a period of 2 - 3 minutes.  The cuff 
was inflated to above systolic pressure (>250 mmHg), preventing blood flow into the 
tail  and  then  slowly  deflated.    Systolic  pressure  was  recorded  as  that  point  when 
pulsatile measurements of blood flow were first detected (Fig 2.1). The process was 
recorded with Chart (AD Instruments).  A minimum of 4 recordings were made for 
each rat and the average taken as systolic blood pressure.  Average systolic blood 
pressures for the three strains of rats used in this study were: Wistar: 106.5 ± 8.3, n = 
30, WKY: 126 ± 9.2, n = 37 and SHR: 180 ± 26.4, n = 31.       57 
 
Figure 2.1: Blood pressure trace of a SHR and WKY 
Illustration  of  blood  pressure  trace  recording 
results.  Figure depicts the blood pressure reading 
from an SHR (A) and WKY (B) respectively.  The 
SHR blood pressure reading is 188.1 (cross), while 
the WKY is significantly lower, at 126.2 (cross).  
An  average  of  a  minimum  of  4  recordings  was 
used  to  determine  each  animal’s  systolic  blood 
pressure.       58 
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2.3.  Surgical procedures 
All  surgical  and  perfusion  procedures  were  performed  under  general 
anaesthesia.  One hour prior to anaesthesia, food was withheld from animals to reduce 
gastrointestinal contents.  Depth of anaesthesia was assessed using responses to both 
noxious stimuli (tail pinching/toe pinching) and the blink reflex.  
2.3.1.  Retrograde labelling of IML sympathetic preganglionic neurons 
Fluorogold
® (FG
®) is a retrograde tracer used commonly in neuronal studies 
(Ju  et  al.,  1989),  and  has  been  shown  to  be  effective  in  labelling  all  sympathetic 
preganglionic neurons (SPNs) of the spinal cord when injected into the intraperitoneal 
(IP) space (Anderson, 1992; Anderson and Edwards, 1994; Anderson et al., 1989a; 
Hamilton et al., 1995).  It was used in these studies to confirm the identity of SPNs in 
the  intermediolateral  cell  column  (IML)  of  the  spinal  cord.    Fluorogold  powder 
(Fluorochrome, Denver Colorado) was diluted in sterile saline (0.9 % NaCl) to create 
a  2%  (w/v)  solution.    The  2  %  FG
®  solution  was  aliquoted  (100  ml)  into  sterile 
microtubes and stored at -80°C.  On the day of use, the 2% FG
® solution was thawed 
at room temperature and diluted in 1ml of sterile saline to provide a 0.2% solution for 
injection.  Animals were physically restrained and bilateral IP) injections of FG
® were 
made (0.5ml each side).  Animals were euthanased 14 days post injection as detailed 
in section 2.4. 
2.4.  Perfusion and fixation 
Fixation was achieved by cardiac perfusion through the left ventricle and aorta 
to enable rapid and complete fixation of body tissues.  Prior to perfusion, rats were       60 
anaesthetised  with  O2/CO2  (oxygen  20%  carbon  dioxide  80%)  and  sodium 
pentobarbitone (Thiobarb, Jurox, Rutherford, Australia; 100mg/kg) administered IP. 
2.4.1.  Immunohistochemical experiments 
Once  anaesthetised,  the  abdomen  and  thoracic  cavity  of  the  animal  was 
opened.    A  22-gauge  blunted  needle,  attached  to  a  peristaltic  pump  (Harvard 
Apparatus, Massachusetts, USA) was inserted via the left ventricle into the aorta and 
clamped  in  place.    The  right  auricle  was  cut  to  allow  the  outflow  of  blood  and 
perfusate.  Thirty ml of ice cold heparinised saline (0.9% NaCl containing heparin 2 
I.U/ml  [Jurox,  Rutherford,  Australia])  was  perfused  through  the  animal  (6ml  per 
minute), followed by 180ml of ice-cold 4% formalin diluted in 0.9% saline at the 
same rate.  The spinal cord (for IML experiments) and brain [for rostral ventrolateral 
medulla (RVLM) and paraventricular hypothalamus (PVN) experiments] were then 
removed and post fixed in 4 % formalin for 4 h at 4°C.  Brainstem and spinal cord 
blocks was washed in 0.1M phosphate buffer (PB; pH 7.4, 3 x 10 min), then stored in 
0.1M phosphate buffered saline containing 10 mM Tris base (TPBS; pH 7.4), plus 
0.3% Triton X 100 (Tx), and either 0.1% Sodium Azide (NaN3; Sigma, Castle Hill, 
Newcastle,  Australia)  for  fluorescence  microscopy  studies,  or  0.05%  Thimerosal 
(Sigma) for light microscopy studies.  Hypothalamic blocks (see section 2.5.1) were 
cryoprotected by being placed in 30% sucrose solution for 3 days and then frozen 
down and stored at -80°C.       61 
2.5.  Immunohistochemistry 
2.5.1.  Sectioning 
Spinal Cord 
The fixed cord was washed for 30 minutes (min) in 0.1M PB.  The pia was 
removed and the cord mounted ventral surface down on a cutting block with super 
glue (Selleys, NSW, Australia).  Additional support was provided with 2% w/v Agar 
(Sigma).    Horizontal  sections  (50mm)  were  cut  using  a  vibrating  microtome 
(Vibratome, St Louis, MO, USA) and placed in 0.1M PB.  Sections were mounted 
temporarily  on  glass  slides  and  viewed  under  UV  fluorescence  light  using  an 
Olympus BX 51 microscope (Olympus, Mt Waverly, VIC, Australia).  The presence 
of Fluorogold
® labelled cells within the IML region, as well as within the central 
autonomic area (CAA) confirmed the identification of slices containing retrogradely 
labelled  SPN.    Sections  then  underwent  fluorescent  or  peroxidase 
immunohistochemistry as required.   
RVLM  
Hindbrains were dissected from the spinal cord at the level of the obex, and 
the forebrain at the junction between cerebrum and cerebellum.  Any remaining pia 
mater was removed  and the hindbrain was washed once for 30 min in 0.1M PB.  
Coronal sections (50 mm) sections were cut using a Vibratome and placed in 0.1 M 
PB.  A stereomicroscope (Wild M7 S, Wild Heerbrugg, Switzerland) was used to 
determine anatomical landmarks.  Sections containing the RVLM region were defined 
as those contained within the region extending caudally 600-800 mm from the caudal 
pole of the facial nucleus.  This corresponds to 12.5mm to 11.7mm caudal to Bregma       62 
(Paxinos  and  Watson,  1998).    The  region  was  bounded  laterally  by  the  spinal 
trigeminal  tract,  medially  by  the  inferior  olive  and  pyramids,  and  dorsally  by  the 
compact formation of the nucleus ambiguus. 
Hypothalamus (PVN) 
Experiments performed on the hypothalamus were carried out at the Genome 
Research Facility, University of Cincinnati 
 
The hypothalamus was dissected from the brainstem, at the junction between 
the cerebrum and cerebellum, and trimmed at the optic chiasm.  Hypothalamic tissue 
was placed into the cryostat (Leica CM 3050S, Wetzlar, Germany) and allowed to 
warm to -20°C.  Hypothalamic sections (25 µm) were cut coronally in a rostro-caudal 
fashion.  Sections were placed in 0.1M PBS.  Anatomical landmarks were confirmed 
using a stereomicroscope (Leica), the rostral portion being identified by flattening and 
broadening of the supra optic nucleus, and the loss of the mamillothalamicus nucleus, 
the  caudal  end  located  by  the  moving  of  the  fornix  below  the  zona  inserta, 
corresponding to 1.3 mm to 2.1 mm caudal to Bregma (Paxinos and Watson, 1998). 
2.5.2.  Immunofluorescence immunohistochemistry 
RVLM and spinal cord 
Following sectioning, sections were incubated in 50 % ethanol for 30 min and 
then washed in TPBS  (2 x 15 min).  Sections were incubated for one hour at room 
temperature  in  blocking  solution  containing  donkey  serum  (10%  Chemicon, 
Temecula, CA, USA), diluted in TPBS with 0.3% Tx and 0.1% NaN3.  Sections were 
then incubated free floating in primary antibody diluted in blocking solution, either 
singly or in combinations as detailed in the respective chapters.  Details regarding all       63 
antibodies  used  are  provided  in  Table  2.1.    Details  of  experiments  confirming 
specificity are provided in the relevant experimental chapter.  Sections were incubated 
for 24 hours at room temperature, then 72-96 hours at 4°C.  Following incubation 
with the primary antibodies, sections were washed in TPBS (3 x 30 min) and then 
incubated  for  either  4  hours  at  room  temperature,  or  overnight  at  4ºC  in  species-
specific secondary antibodies (Table 2.1) diluted in TPBS containing 0.3% Tx, 0.1% 
NaN3, and donkey serum (1%).  Sections were then washed TPBS (3  x 30 min), 
mounted on  glass slides (Starfrost, ProSciTech, Thuringowa, QLD, Australia) and 
coverslipped in Prolong Antifade (Molecular Probes, Mt Waverley, VIC, Australia).   64 
Table 2.1: Antibody Details 
Antigen and Host Species  Source  Catalogue #  Lot # 
Primary Detection Antibodies 
Anti cGMP: Rabbit  Chemicon (Temecula CA)  AB303  24091218 
Anti neuronal NOS: Mouse  Sigma (St Louis, MO)  N2280  022K4838 
Anti Oxytocin: Mouse  Chemicon  AB153  220541143 
Anti Vasopressin: Guinea Pig  Peninsula Laboratories (San Carlos, CA)  T-5048  031088-2 
Anti ChAT: Goat  Chemicon  AB144P  22041143 
Anti FG: Rabbit  Chemicon  AB153  22061290 
Secondary Detection Antibodies 
 
 
 
 
Cy2: Donkey anti goat  Jackson (West Grove, PA)  705-096-147  70600 
Cy3: Donkey anti-rabbit  Jackson  711-166-152  59892 
Cy5: Donkey anti-mouse  Jackson  715-096-151  58916 
FITC: Donkey anti-guinea pig  Jackson  705-096-147  58196 
FITC: Donkey anti mouse  Jackson  715-096-150  76041 
AlexaFluor 568: Donkey anti mouse  Molecular Probes (Mt Waverly, Aus)  A-21203  93D1-1 
Table 2.1.  Source, catalogue and lot number of antibodies use throughout this thesis. Cyclic guanosine monophosphate (cGMP); nitric oxide 
synthase (NOS), choline acetyltransferase (ChAT), fluoroscein isothiocyanate (FITC), Fluorogold (FG), Cyanine 2 (Cy2), Indocarbocyanine 3 
(Cy3) and Indodicarbocyanine (Cy5). 
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Hypothalamus 
Hypothalamic  sections  were  washed  in  0.01M  PBS  (2  x  5  min),  and 
transferred in to a blocking solution containing 0.01M PBS with 0.01% Triton X and 
10% goat serum (Chemicon) and 0.04% NaN3  for one hour at room temperature.  
Sections were washed 3 times for 5 min in 0.01M PBS, prior to incubation with the 
primary antibody/antibodies diluted in the same blocking solution overnight at room 
temperature.  Sections were washed again 3 times for 5 min in 0.1M PBS, before 
being incubated with the secondary antibody diluted in blocking solution as above, for 
4 hours at room temperature in a darkened environment.  Sections were again washed 
(0.1M PBS, 1 x 5min), and then mounted on glass slides (Starfrost) using Vectashield 
(Vector Laboratories, Burlingame, CA, USA).   
For  both  the  fluorescence  immunohistochemistry  and  immunoperoxidase 
immunohistochemistry (below), negative controls were run in parallel by omitting the 
primary antibody and incubating sections in blocking solution only.  
2.5.3.  Immunoperoxidase immunohistochemistry 
Following  sectioning,  tissue  was  washed  in  0.1M  PB  overnight.    Sections 
were incubated in 30% methanol and washed twice in TPBS for 15 min.  Sections 
were then incubated in a blocking solution of TPBS containing 10% goat serum, 0.3% 
Tx,  0.05%  thimerosal  (Sigma)  and  20%  avidin  blocking  solution  (Vector 
Laboratories) for 1 hour and then washed TPBS (2 x 5 min).  Primary antibodies were 
diluted  in  blocking  solution  (TPBS  with  0.3%  Tx,  0.05%  thimerosal,  10%  goat 
serum) and 20% biotin blocking solution (Vector Laboratories) and the tissue was 
incubated free floating for 72 hours at room temperature.  Sections were washed in 
TBPS (3 x 20 min), and incubated overnight at 4°C with a biotinylated anti goat       66 
secondary antibody (Vector Laboratories) diluted to 1:500 in TPBS with 0.3% Tx, 
0.05% thimerosal and 1 % goat serum.  After washing in TPBS (3 x 30 min), sections 
were  incubated  in  a  solution  containing  avidin-biotin  peroxidase  complex  (1:500; 
Vectastain) diluted in TPBS with 0.3 % Tx and 0.05 % Thimerosal overnight at 4°C.  
Sections were washed in TPBS (3 x 5 min) and incubated with diaminobenzidase 
(DAB)  solution,  containing  0.02%  hydrogen  peroxide,  0.02%  buffer  (Vector 
Laboratories)  and  0.04%  DAB  diluted  in  distilled  H20  (dH2O)  for  2  mins.    The 
reaction was terminated by diluting in dH2O. Sections were washed twice in dH20, 
mounted  on  glass  slides  (Starfrost),  and  allowed  to  air-dry.    They  were  then 
dehydrated in ethanol (70 %, 80 %, 90 % and 100 %; 1 x 2 min each) and then xylene  
(2 x 5 min) and cover slipped in Ultra Mount (Lomb Scientific, Taren Point, NSW, 
Australia). 
2.6.  Imaging  
2.6.1.  Confocal microscopy  
A BioRad MRC-1024 confocal laser scanning  microscope  (Carl  Zeiss  Pty. 
Ltd. North Ryde, NSW, Australia) was used to examine fluorescent labelling using 
filter  settings  specific  for  identification  of  the  secondary  antibody  fluorophores 
(fluorescein  isothiocyanate  [FITC],  cyanine  [CY2],  indocarbocyanine  [CY3]  and 
indodicarbocyanine  [CY5]).    Each  fluorochrome  was  viewed  separately  in  single 
channel mode to improve scanning accuracy and no “bleed through” was observed.  
To excite FITC labelled and CY2 secondary antibodies, excitation was set at 488nm, 
while 568nm excitation was used for CY3, and 650 for CY5.  Collection filters for 
FITC/CY2 were set to 510, while CY3 was set at 580 and CY5 670.  Images were 
captured  as  either  single  images  or  by  taking  4  –  6  optical  “slices”  through  the       67 
sections as a “z” series imaging 10 – 30 microns of tissue, and then reconstructed as a 
single two-dimensional image using Confocal Assistant Software (BioRad, Hercules, 
California, USA).  Figures were assembled and labelled using Photo Shop software 
(version  7,  Adobe  Systems,  Mountain  View,  CA).    Overall  colour  balance  and 
contrast were adjusted, but no other modifications were made. 
2.6.2.  Light microscopy  
NADPH and DAB immunohistochemistry  
Sections  processed  using  DAB  immunohistochemistry  and  NADPH 
diaphorase  histochemistry  (Chapters  3  and  4)  were  examined  using  an  Olympus 
BX51 light microscope (Olympus) under bright field microscopy. Images were taken 
using DP-Controller Software (Olympus, version 3.1).  Figures were assembled and 
labelled using Photo Shop software (Adobe Systems), and labelled using Microsoft 
PowerPoint  (version  11.2,  Microsoft  PowerPoint  for  Mac,  Microsoft  Corporation, 
WA, USA) 
2.7.  Analysis 
The specific statistical tests and software utilised are described within each 
chapter.         68 
3. Distinct subpopulations of cyclic guanosine 
monophosphate (cGMP) and neuronal nitric oxide 
synthase (nNOS) containing sympathetic preganglionic 
neurons in Spontaneously Hypertensive and Wistar-
Kyoto rats 
3.1.  Introduction   
Despite  having  different  initiating  mechanisms,  many  forms  of  chronic 
hypertension  demonstrate  increased  activity  of  the  sympathetic  nervous  system 
(Campese  and  Krol,  2002;  Esler  and  Kaye,  1998;  Rahn  et  al.,  1999)  and  the 
therapeutic value of down-regulating sympathetic activity in these conditions is now 
evident (Esler and Kaye, 1998).  In experimental models of hypertension induced by 
long-term inhibition of nitric oxide (NO) sympathetic activity is increased (Souza et 
al.,  2001).    While  much  research  has  been  directed  towards  the  deficiency  of 
endothelial  NO  in  hypertension,  it  is  becoming  increasingly  evident  that  central 
neuronal NO influences cardiovascular homeostasis, and that impaired NO production 
may contribute to autonomic dysfunction observed in both essential and secondary 
hypertension (Chowdhary and Townend, 2001; Patel et al., 2001).  Nitric oxide may 
influence excitatory neuronal responses by chemical modification (s-nitrosylation) of 
the NMDA receptor, thereby reducing co-incident excitatory responses to glutamate 
(Ahern  et  al.,  2002).    Alternatively,  NO  can  stimulate  soluble  guanylate  cyclase 
(sGC),  and  activate  intracellular  target  proteins  via  the  production  of  cyclic       69 
guanosine-3',5'-monophosphate (cGMP).  Target proteins include protein kinase G, 
cGMP gated ion channels and/or cGMP-stimulated or inhibited phosphodiesterases 
(Lucas et al., 2000). 
Sympathetic  preganglionic  neurons  (SPNs)  receive  extensive  monosynaptic 
inputs from the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), 
medullary raphe and A5 area, all of which are critical to the maintenance of vascular 
tone (Sved et al., 2001).  In the rat, SPN are situated in the thoraco-lumbar spinal 
cord, with approximately 85% located in the intermediolateral cell column (IML) and 
the rest distributed in the central autonomic area (CAA) and intercalated nuclei and 
the dorsolateral funiculus (Strack et al., 1988).  It has been shown previously that 
under basal conditions, the SPN of the spontaneously  hypertensive rat  (SHR) has 
increased c-fos expression compared to its normotensive control, the Wistar Kyoto 
(Minson et al., 1996), suggesting that these neurons are likely to contribute to the 
elevated blood pressure in this model of hypertension.  
There is considerable evidence that neuronal NO is a critical neurotransmitter 
regulating the activity of the SPN.  In the Sprague-Dawley rat, up to 70% of the SPN 
contain neuronal NO synthase (nNOS) (Anderson, 1992) and while a pressor role for 
NO in the spinal cord has been demonstrated (Hakim et al., 1995; Lee et al., 1996), 
the majority of studies support a depressor role for NO in the spinal cord (Chen and 
Shyr, 2005; del Carmen Garcia et al., 1997; Iida, 1999; Koga et al., 1999).  A role for 
spinal NO as a functional inhibitory regulator of blood pressure has been shown in a 
previous study demonstrating that endogenous NO acts to limit pressor responses to 
intrathecal injection of NMDA (Arnolda et al., 2000) and work by Lu et al., (Lu et al., 
1999),  who  determined  that  intrathecal  NOS  inhibitors  attenuate  the  decreases  in 
blood pressure induced by haemorrhage.  While no studies up to now have directly       70 
examined altered NO signalling in the spinal cord associated with hypertension, there 
is convincing evidence from the SHR animal model suggesting that the NO signalling 
pathway is impaired in other central autonomic regions in association with essential 
hypertension, (Edwards et al., 2004; Kagiyama et al., 1998; Krukoff, 1998; Patel et 
al., 2001). 
The first aim of this study was examine the hypothesis that the number of 
nNOS containing SPN are lower in the spontaneous hypertensive rat (SHR) compared 
to its normotensive control, the Wistar Kyoto (WKY), thereby extending the previous 
conclusion  that  endogenously  produced  NO  acts  to  inhibit  the  activity  of  SPN 
(Arnolda et al., 2000).  The second aim of this study was to determine the anatomical 
relationship between nNOS and its classical signalling molecule cGMP in the SPN of 
both rat strains.        71 
3.2.  Methods 
3.2.1.  Animals 
All  experiments  were  carried  out  with  the  approval  of  the  Animal  Ethics 
committees of Murdoch University.  Data were obtained from 12 male WKY rats (> 6 
months old, average systolic blood pressure 120 mm/Hg ± 15) and 12 male SHR rats 
(> 6 months old, average systolic blood pressure 200 mm/Hg ± 20).  Systolic arterial 
blood pressure was measured 1 week prior to euthanasia using the tail-cuff method 
(see section 2.2.1). 
3.2.2.  Tissue preparation 
Fourteen  days  prior  to  experimentation,  (to  label  SPNs)  retrograde  tracer 
Fluorogold was injected into the intraperitoneal cavity (see section 2.3.3).  Animals 
were perfused transcardially (see section 2.4.1) and the spinal cord was removed and 
divided into thoracic segments T1-3, T4-5, T6-7, T8-9 and T10-11.  Sections were 
then  cut  (see  section  2.6.1  Spinal  Cord),  and  treated  for  nicotinamide  adenine 
dinucleotide phosphate (NADPH) histochemistry (see below) and Fluorogold
® (FG
®) 
histochemistry (section 2.5.3). 
3.2.3.  NADPH histochemistry 
Detection of NADPH, a co product required in the production of NO, can be 
used as a marker to identify cells capable of NO production (Nakamura, 1997).  
In order to determine which SPN were able to produce NO from SHR and 
WKY animals (n  = 5  each, total n = 10), sections were double labelled for  FG
Ò 
retrograde  labelling  to  identify  SPN  (section  2.3.1)  and  beta  NADPH  (Sigma).        72 
Sections were washed (2 x 30 min; TPBS + 0.3% Triton X (Tx), treated with 2 x 5 
min  0.1M  Tris  Hydrochloride  (Tris  HCl,  pH  7.4)  and  then  incubated  in  dH2O 
containing  0.3%  Tx,  1mM  NADPH  (Sigma)  and  0.2mM  nitroblue  tetrazolium 
(Sigma) for 30 minutes at 37°C.  Sections were then washed for 10 minutes in 0.1M 
Tris  HCl,  before  undergoing  immunohistochemical  processing  for  detection  of 
Fluorogold using DAB (Section 2.5.3) (see Table 3.1 for antibody concentrations). 
3.2.4.  nNOS, cGMP and ChAT fluorescence immunohistochemistry  
To  determine  the  relationship  between  nNOS,  cGMP  and  choline  acetyl 
transferase (ChAT) in SPN, sections from T1-T9 from 7 SHR and 7 WKY animals 
were treated for fluorescence immunohistochemistry as described in section 2.5.2.  
Sections were incubated free floating in primary antibodies directed against nNOS 
and cGMP (n= 4 WKY and 4 SHR) or ChAT and cGMP (n= 3 WKY, 3 SHR, Table 
3.1).  Labelling was detected using species specific secondary antibodies as described 
in Chapter 2 with dilutions as provided in Table 3.1.    73 
Table 3.1: Antibody combinations used for fluorescence immunohistochemistry in Chapter 3 
Animal cohorts  Antibody 
combination  Dilution  Conjugated to  Dilution 
WKY (n = 5) & 
SHR (n = 5) 
6 months 
NADPH 
rabbit a FG 
1:2000  goat a rabbit  1:500 
WKY (n = 4) & 
SHR (n =4 )  
6 months 
mouse a nNOS 
rabbit a cGMP 
1:400 
1:500 
FITC: donkey a mouse 
CY3: donkey a rabbit 
1:500 
1:500 
WKY (n = 3) & 
SHR (n = 3) 
6 months 
goat a ChAT 
rabbit a cGMP 
1:500 
1:500 
FITC: donkey a goat 
CY3: donkey a rabbit 
1:500 
1:500 
Table 3.1.  Table provides the details of the various combinations used in each of the immunohistochemical experiments.  
Fluorescence histochemistry experiments were used to investigate the basal levels of nNOS of ChAT with cGMP expression 
in the IML.  Light histochemistry for Fluorogold was coupled with NADPH histochemistry to determine the number of NO 
expressing SPN in WKY and SHRs.  Source, batch and abbreciations detail can be found in Table 2.1.     74 
3.2.5.  Analysis 
Sections were examined using a light microscope (section 2.6.2) or a confocal 
dual  laser-scanning  microscope  (section  2.6.1),  with  appropriate  excitation  and 
fluorescence  filter  sets  to  discriminate  between  the  fluorophores  (fluorescein 
isothiocyanate [FITC] and indocarbocyanine [CY3]).  
3.2.6.  Control experiments 
For  negative  controls,  tissue  sections  were  treated  as  described  above  but 
sections were incubated with normal  rabbit serum (NRS; 1:100, Sigma, St  Louis, 
Missouri,  USA)  in  place  of  primary  antibody,  or  in  blocking  solution  alone  (no-
antibody controls).  In addition, sections were also treated with anti-cGMP antibody 
(1: 500) that had undergone pre-adsorption (12 hrs at 4ºC) with cGMP (1mM; Sigma, 
St Louis, MO) or acetylated cGMP (0.5mM).  Acetylation of cGMP was achieved by 
1:1 incubation of cGMP with acetylation reagent (33% v/v Triethylamine [Sigma] and 
66% v/v Acetic Anhydride [Sigma]).  The use of acetylated cGMP was performed 
based on the manufacturers recommendation that the antibody recognises both free 
and  acetylated  cGMP.    This  polyclonal  antibody  is  specific  for  cGMP  with  no 
significant cross-reaction to other nucleotides at concentrations to 1mM as tested by 
radioimmunoassay, and was raised against 2’0-succinyl cGMP conjugated to BSA 
(manufacturer’s technical information).  
The  mouse  monoclonal  nNOS  antibody  (Sigma)  was  raised  against  a 
recombinant  nNOS  fragment  (amino  acids  1-181)  and  on  western  blots  reacts 
specifically with brain NOS and does not react with NOS derived from macrophages 
(iNOS)  or  endothelial  cells  (eNOS)  (manufacturer’s  technical  information).    The 
antiserum stains a single band at 150kDa on Western blot staining and controls have       75 
been  performed  using  preabsorption  studies  with  excess  nNOS  fusion  protein 
(Dinerman et al., 1994).  The goat polyclonal ChAT antibody (Chemicon) was raised 
against  human  placental  ChAT  (manufacturer’s  technical  information).    Control 
studies  by  (Kha  et  al.,  2000)  showed  that  all  ChAT  staining  was  abolished  by 
preabsorption with the human placental ChAT antigen.  The rabbit anti-FG
® antibody 
(Chemicon)  was  prepared  against  the  whole  molecule  FG
®  (hydroxystilbamidine; 
manufacturers technical information).  Staining of sections of spinal cord produced a 
pattern  of  FG-immunoreactivity  identical  to  that  seen  when  sections  were  viewed 
under  ultraviolet  light  (direct  visualisation  of  FG
®  molecule),  and  was  the  same 
pattern  of  staining  as  described  previously  with  IP  FG
®  as  a  retrograde  label  to 
identify SPN (Anderson and Edwards, 1994).  Histochemical controls omitting the 
substrate NADPH  were performed to test for non-specific deposition of formazan 
(Rothe et al., 1998). 
3.2.7.  Quantification of labelled neurons within the IML region and 
statistical analysis 
Cells with a nucleus were counted if they were FG
® immunoreactive and were 
located in the IML bordering the white and grey matter, or associated with that cell 
group but lying in the lateral funiculus.  Thus cells from both the intermediolateralis 
pars funicularis and intermediolateralis pars principalis were included.  The presence 
or absence of NADPH-diaphorase staining was then noted.  On average, 5 sagittal 
sections from each of the spinal segmental regions contained SPN.  The total number 
of labelled cells from each spinal cord region for each animal were then tallied to give 
a  total  cell  count  breakdown  per  animal,  testing  the  hypothesis  that  there  were 
reduced numbers of NADPH reactive SPN in the thoracic spinal cord of the SHR, 
compared  to  the  WKY.    Individual  regions  of  the  thoracic  spinal  cord  were  not       76 
assessed separately in order to limit inflated risk of type 1 error, when testing multiple 
null hypotheses from a single experiment (Ludbrook, 1998).  No correction factor was 
applied to cell counts.  The number of FG
®/NADPH labelled cells were calculated as 
a percentage of the total number of FG
® positive cells in each rat strain. Statistical 
comparison of the total number of FG
® labelled SPN and percentage of FG
®/NADPH 
between the two strains was calculated using a single factor ANOVA using Microsoft 
Excel (2004).  Significance was set at p < 0.05.  All figures were assembled and 
labelled using Photo Shop software (version 7, Adobe Systems, Mountain View, CA).  
Overall image levels and contrast were adjusted equally for all images, but no other 
modifications were made.       77 
3.3.  Results 
3.3.1.  General observations  
Within each spinal cord segment, the general anatomical arrangement of SPN 
in the IML of the WKY and SHR animals were distinctly different.  Classically, the 
distribution of SPN is known for its’ clustered appearance, which resembles a ladder 
like  pattern  (Henry  and  Calaresu,  1972).    The  WKY  showed  this  characteristic 
distribution, with clusters of SPN easily recognised when stained for FG
® (Fig. 3.1A), 
ChAT, nNOS or cGMP.  On the other hand, the SHR demonstrated a more continuous 
distribution (Fig. 3.1B) with the distribution of SPN neurons evenly spread along the 
rostro-caudal axis of the IML.  The dendritic pattern of SPN in the SHR also appeared 
to be altered in comparison to the WKY, with marked reduction in the number of 
mediolateral projections relative to those in the rostro-caudal dimension.       78 
 
Figure 3.1: Differences in neuroanatomical arrangement of SPN between 
SHRs and WKY 
Fluorescent  images  illustrating  neuroanatomical 
arrangement  of  SPN  labelled  for  Fluorogold
® 
(FG
®)  in  WKY  (A)  and  SHR  (B).  (A)  WKY 
animal  demonstrating  clusters  of  SPN  with 
prominent mediolateral dendritic projections. (B) 
SHR  animal  demonstrating  a  more  continuous 
distribution of SPN with less obvious mediolateral 
dendritic  projections.  Small  numbers  of  neurons 
immunoreactive for FG
® can also be seen around 
the central canal in panel B.  Scale bar in B depicts 
500 mm in both panels       79 
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3.3.2.  Number of SPN and the relationship with NADPH-diaphorase 
Combined NADPH-diaphorase histochemistry and immunohistochemistry for 
the retrograde tracer FG
® was used to determine (1) whether there was any difference 
in the total number of SPN between the WKY (n = 5) and SHR (n = 5) in the IML 
region of the thoracic spinal cord (T1-T11), and (2) if there was any variation in the 
proportion  of  SPN  containing  NOS,  as  determined  by  NADPH-diaphorase 
histochemistry.  The total number of FG
® labelled SPN in the thoracic IML region of 
WKY (T1-T11) was 6542 ± 828 cells, and in the SHR was 6091 ± 820 and these were 
not significantly different (Table 3.2).  All NADPH-diaphorase positive cells in the 
IML  region  were  labelled  with  FG
®,  but  not  all  FG
®  immunoreactive  cells  were 
positive  for  NADPH-diaphorase  (Fig  3.2A-B,  Table  3.2).    The  double-labelled 
NADPH/FG
®  were  usually  located  more  laterally  in  the  IML  than  the  FG
®-only 
labelled cells. There were significantly less NADPH-diaphorase positive SPN in the 
SHR animals when compared to WKY (Table 3.2) and as a proportion of the total 
number of FG
® labelled cells, this was equivalent to 64.4 ± 5.1% NADPH reactive 
FG
® cells in the WKY vs. 55.6 ± 2.1% in the SHR (n = 10, p ≤ 0.05).  Cells reactive 
for NADPH-diaphorase only were noted in the region of the central canal (Fig 3.2C).       81 
Figure 3.2: Retrograde labelling of SPN, with NADPH histochemistry of SHRs and 
WKY 
Light  microscopy  images  depicting  Fluorogold® 
(FG®) retrograde labelling of SPN detected with 
immunohistochemistry  combined  with  NADPH-
diaphorase  histochemistry  for  NOS  in  T1-3  in 
WKY  (A)  and  SHR  (B,  C).    In  A  and  B,  the 
central  canal  is  to  the  right  of  the  image,  white 
matter to the left. In C, the region of the central 
canal  is  in  the  middle  of  the  image.    Double-
labelled  cells  appear  black  while  single  labelled 
cells  (FG®-only)  are  brown  (arrows)  and  are 
located predominantly in the medial region of the 
IML. Cells labelled for NADPH-diaphorase only 
appear blue and are illustrated in panel C. Note the 
dense  rostro-caudal  dendritic  tree  reactive  for 
NADPH only (arrow heads B) in the SHR.  Scale 
bar in C depicts 100mM for all panels.       82 
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Table 3.2: SPN cell counts in thoracic IML region of WKY and SHR 
Animal  FG only  FG and 
NADPH  
Total FG  
 
% NADPH  
re total FG  
WKY1  2047  3667  5726  64.04% 
WKY2  2041  4558  6599  69.07% 
WKY3  1782  3970  5754  69.00% 
WKY4  3029  3935  6956  56.57% 
WKY5  2786  4883  7675  63.62% 
Mean + SD WKY  2337 + 538.6  4202.6 + 500.5  6542 + 828.4  64.4 + 5.1% 
SHR1  2333  2764  5099  54.21% 
 
SHR2  2527  3098  5661  54.73% 
 
SHR3  3039  3563  6588  54.08% 
 
SHR4  2424  3501  5905  59.29% 
 
SHR5  3179  4019  7203  55.80% 
 
Mean + SD SHR  2700.4 + 382.5  3389 + 478.3  6091.2 + 819.6  55.6 + 2.1% 
Table 3.2.  Uncorrected bilateral counts for FG-labelled neurons and FG/NADPH diaphorase 
double-labelled neurons in the thoracic IML spinal cord region (T1 – T11) for each WKY and 
SHR animal examined.       84 
 
Cells  immunoreactive  for  nNOS  showed  strong  cytoplasmic  staining  that 
extended  into  the  proximal  dendrites  in  both  WKY  and  SHR  (Figs  3.3A,  C).  A 
consistent  and  unexpected  finding  was  the  co-localisation  of  cGMP  in  all  nNOS 
immunoreactive neurons in the IML (Figs 3.3B, D) in both the SHR (n = 4) and WKY 
(n = 4) animals.  In contrast, nNOS immunoreactive cells positioned near the central 
canal were never co-localised with cGMP (data not shown).  Further, we identified a 
subpopulation of IML neurons that were immunoreactive only for cGMP and these 
were found predominantly in the medial part of the IML.  In contrast the double-
labelled cGMP/nNOS neurons were located mainly in the lateral regions of the IML 
(Fig 3.3).  This distribution was similar to that described above for NAPDH/FG® 
double labelled vs. FG® only labelled SPN.  These cGMP only neurons were found 
in both the WKY and SHR in all thoracic segments of the spinal cord examined.  
Immunoreactivity for cGMP was cytoplasmic and had distinct punctate or granular 
appearance that extended into associated process. Blood vessels in the region also 
showed cGMP immunoreactivity (Fig 3.3B).        85 
Figure 3.3: Relationship of nNOS and cGMP in SPN in WKY and SHRs 
Confocal  images  illustrating  co-localisation  of 
nNOS (A, C) with cGMP (B, D) in cells from the 
IML of the thoracic spinal cord (T4-T6) in WKY 
(A, B) and SHR (C, D).  Central canal is to the left 
of the image, white matter to the right.  All nNOS 
positive  neurons  contain  cGMP,  but  there  is  a 
subpopulation  of  cells,  located  predominantly  in 
the  medial  region  of  the  IML  that  are 
immunoreactive for cGMP-only (asterix). Arrows 
indicate blood vessels labelled with cGMP.  Scale 
bar in D depicts 20mm in all panels.       86 
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3.3.3.  Cyclic GMP and ChAT immunoreactivity  
To determine if the cGMP-immunoreactive neurons in the IML region were 
SPN, double labelling of sections for ChAT and cGMP was performed (n = 3 WKY, 
n = 3 SHR).  Incompatibility of primary antibodies prevented the use of FG
® in these 
experiments.  No difference was found between SHR and WKY and so results have 
been combined.  Overall, 98% of ChAT immunoreactive neurons in the IML region 
were double labelled for cGMP-immunoreactivity (97.94 % ± 2.06%; n = 3 WKY 
animals, 3 SHR animals; 650 cells counted in total across T1-T9, Fig 3.4A, B).  In 
conjunction with the total cell count and nNOS/cGMP double labelling experiments, 
these  results  confirm  that  all  the  cGMP  (i.e.  both  the  nNOS-positive  and  nNOS-
negative populations) labelled cells within the IML are SPN.  Further, they indicate 
that there is no difference in the total number of cGMP immunoreactive SPN between 
the two rat strains. 
3.3.4.  Control experiments.   
Sections  processed  in  the  absence  of  primary  antibody  did  not  show  any 
staining.    Pre-absorption  of  the  anti-cGMP  antibody  with  free  cGMP  caused  a 
significant reduction of cGMP immunoreactivity in spinal cord segments from both 
SHR and WKY, and pre-absorption of the anti-cGMP antibody with acetylated cGMP 
abolished cGMP immunoreactivity (Fig 3.4C).  These results are similar to a study by 
de Vente (De Vente et al., 1998) using a different anti cGMP antibody.  Negative 
controls using NRS did not show any preferential staining of neuronal cells, instead 
demonstrating  weak,  non-specific  staining  of  all  cells.    Histochemical  controls 
omitting the substrate NADPH showed no staining.       88 
Figure 3.4: Relationship of ChAT and cGMP in SPN 
Confocal  images  illustrating  double  labelling  of 
horizontal  cord  section  (T4-T6)  with  ChAT  (A) 
and  cGMP  (B)  in  the  IML  of  a  WKY  animal.  
Central  canal  is  to  the  left  of  the  image,  white 
matter  to  the  right.  Images  demonstrate  double 
labelling of ChAT with cGMP in all SPN shown.  
Panel  C  is  a  control  image  depicting  lack  of 
staining  after  the  cGMP  antibody  had  been  pre-
incubated  in  acetylated  cGMP  prior  to  use  for 
fluorescence immunohistochemistry.  Scale bar in 
C depicts 20mm in both panels       89 
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3.4.  Discussion 
This  is  the  first  detailed  neuroanatomical  analysis  of  cGMP  and  nNOS 
expression in the SPN population within the IML of the thoracic spinal cord.  These 
novel results have determined that two subpopulations of cGMP immunoreactive SPN 
exist (1) those SPN that contain both cGMP and nNOS, and (2) a population of cGMP 
only SPN.  These subpopulations were identified in both SHR and WKY.  Further, we 
have comprehensively demonstrated that in the SHR, there is a significant reduction 
in  the  number  of  SPN  expressing  NOS  when  compared  to  the  WKY,  despite  a 
comparable number of SPN in each strain.  
3.4.1.  Co-localisation of nNOS and cGMP in SPN 
In  the  present  study,  there  was  a  consistent  and  strong  co-localisation  of 
cGMP and nNOS within SPN in the IML region of thoracic spinal cord.  This is in 
contrast to a number of studies, most notably work of (Wu et al., 1997) and (Vles et 
al., 2000), who assessed nNOS and cGMP immunoreactivity in the spinal cord of 
Sprague-Dawley and Lewis rats, but did not report cGMP in cell bodies in the IML 
region,  only  in  nerve  fibres.    Other  detailed  analyses  of  cGMP  and  nNOS 
neuroanatomy in the brain and cervical spinal cord (De Vente et al., 1998; Vles et al., 
2000), describe co-localisation of nNOS and cGMP as the exception rather than the 
rule.  The only other neuronal populations in which a consistent co-expression of 
nNOS  and  cGMP  has  previously  been  described  are  cerebellar  granule  cells  (De 
Vente et al., 1998) and within the supraoptic nucleus (Stern and Zhang, 2005).  Our 
control experiments suggest the cGMP immunoreactivity is specific and additionally, 
the punctate cytoplasmic staining pattern for cGMP in this study is similar to that 
shown in cervical spinal cord laminae (Vles et al., 2000) and the supraoptic nucleus       91 
(Stern and  Zhang, 2005).  A number of studies utilising immunocytochemistry to 
determine  cGMP  expression  pre-treat  with  the  phosphodiesterase  inhibitor 
isobutylmethylxanthine (IBMX) to enhance detection (Allaerts et al., 1998; De Vente 
et al., 1998; Vles et al., 2000).  However, in our preliminary studies, we compared 
results using pre-perfusate saline solution with and without IBMX (1mM) prior to 
fixation, and found that cGMP expressing cells in the IML could be readily detected 
in  the  absence  of  IBMX.    By  omitting  IBMX,  we  believe  our  results  are 
representative of basal cGMP levels in the regions examined.  
Levels  of  cGMP  are  directly  regulated  by  guanylyl  cyclases,  and  NO  is  a 
potent activator of sGC.  It has been argued that the concentrations of Ca
2+ required 
for the activation of nNOS inhibits sGC, such that NO should not be able to induce 
the up-regulation of cGMP in the same cell (Knowles et al., 1989; Parkinson et al., 
1999).  However, through its linkage to the NMDA receptor via postsynaptic density 
protein PSD95 (Christopherson et al., 1999), nNOS is effectively compartmentalised 
to subcellular regions that are exposed to relatively high Ca
2+ levels (Kiedrowski et 
al., 1992).  This would provide a mechanism by which nNOS and sGC are exposed to 
different Ca
2+ concentrations.  Given that we find co-localisation of NO and cGMP in 
SPN, we hypothesise that such partitioning of nNOS and cGMP within the confines 
of the soma would permit autocrine signalling in these neurons. 
Cyclic GMP levels can also be regulated by membrane bound, or particulate 
guanylyl  cyclases, including the  receptors for the atrial natriuretic peptide (ANP), 
brain (BNP) and C-type NP.  While the natriuretic peptides are expressed in the spinal 
cord (Cameron et al., 1996), and increased CNP expression has been documented in 
the SHR (Kuchel et al., 1988), their ability to elicit cGMP synthesis in SPN has not 
been elucidated and would warrant further investigation.       92 
3.4.2.  Chemical phenotype and strain dependent organisation of 
thoracic SPN 
A subpopulation of cGMP-only immunoreactive neurons were also identified 
in the IML region.  Their identity as SPN was confirmed by the presence of ChAT.  
The description of this new sub-population supports the theory of chemical coding 
within the SPN, where neurons can be linked to functional roles by the presence of 
discrete  combinations  of  neurochemical  markers  as  has  been  described  previously 
(Afework  and  Burnstock,  1995;  Cao  and  Morrison,  2001;  Holgert  et  al.,  1995; 
Morrison and Cao, 2000; Murphy et al., 2003).  Interestingly, in both the WKY and 
SHR,  double  labelled  cGMP/nNOS  and  FG
®/NADPH  SPN  were  predominantly 
located laterally within the IML.  We have recently described a similar pattern of 
location for tonically activated subpopulations of SPN, including those  within the 
functionally  defined  adrenal  SPN  subpopulation  (via  immunoreactivity  to 
phosphorylated extracellular signal regulated kinase 1/2 (p-ERK1/2) (Springell et al., 
2005).  A mediolateral topographic organisation of functionally distinct populations 
of SPN is present within the IML, with lateral SPN having a vasomotor function and 
the more medial SPN having a motility regulating function (Janig and McLachlan, 
1986; Pyner and Coote, 1994).  
Our study also indicated an unusual dendritic tree for the SPN in the SHR 
when compared to the WKY and previous reported studies in Sprague-Dawley rats, 
the cat and hamster (Pyner and Coote, 1995; Reuss and Reuss, 2001; Tang et al., 
1995b).  Tang et al (Tang et al., 1995b) propose that the different receptive field may 
restrict inputs to SPN in the SHR.       93 
3.4.3.  Reduced expression of NOS in SPN of the upper thoracic spinal 
cord of the SHR 
The other primary finding in this study was the reduced number of SPN that 
express NOS in the SHR when compared to the WKY, despite comparable numbers 
of  SPN  in  the  two  rat  strains.    Given  that  all  NOS  isoforms  exhibit  NADPH-
diaphorase activity the application of NADPH-diaphorase histochemistry to identify 
nNOS  neurons  deserves  comment.    While  in  some  regions,  including  the  lateral 
collateral pathway of the sacral spinal cord (Doone et al., 1999), NADPH-diaphorase 
does not match nNOS-immunoreactivity, it has been shown previously in the IML 
that  there  is  consistent  double  labelling  of  the  two  markers  (Doone  et  al.,  1999; 
Okamura et al., 1995). 
Our finding of a decreased number of NOS containing SPN in the thoracic 
spinal cord significantly advances the work of Tang et al (Tang et al., 1995a) who 
demonstrated a decreased proportion of NOS containing SPN, but only in those SPN 
that project to the superior cervical ganglion and only in the intermediolateralis pars 
funicularis.    Our  finding  are  based  on  total  thoracic  IML  SPN  cell  numbers  and 
indicate this phenomena is not limited to one subpopulation of SPN but is consistent 
across the thoracic spinal cord region, and will therefore potentially affect multiple 
sympathetic outflow pathways (Strack et al., 1988).  Decreased numbers of nNOS 
neurons has also been described in other sites in SHR including the PVN (DiCarlo et 
al., 2002).  In addition to studies supporting a depressor role for endogenous NO in 
the spinal cord (Chen and Shyr, 2005; del Carmen Garcia et al., 1997), work from our 
laboratory  has  previously  demonstrated  that  endogenous  NO  attenuates  pressor 
responses induced by NMDA (Arnolda et al., 2000), suggesting that NO acts as an 
inhibitory modulator of descending excitatory cardiovascular signals.  While it is not       94 
possible to argue causation on the basis of our neuroanatomical data, a reduction in 
NO in the IML of SHR could be associated with a corresponding decrease in cGMP 
expression, and may contribute to the increase in sympathetic activity associated with 
hypertension.  The next chapter in this thesis explores these possibilities, examining 
the downstream expression of cGMP and its functional activity in SPN of WKY and 
SHR. 
3.4.4.  Conclusion 
We have demonstrated for the first time that cGMP and nNOS are co-localised 
in a subpopulation of SPN, and that cGMP can now be used to discriminate SPN 
according  to  a  unique  profile  of  neurochemicals.    Further,  we  have  convincingly 
demonstrated  that  the  number  of  SPN  in  the  thoracic  IML  expressing  NOS  is 
significantly  less  in  the  SHR  than  in  the  WKY,  despite  each  species  having 
comparable numbers of total SPN in this region.  
It has recently been demonstrated that physiologically relevant inputs to SPN 
arise from intraspinal sources (Llewellyn-Smith et al., 2005).  This, combined with 
our findings, raises the possibility of functional autocrine and paracrine NO signalling 
in the IML, and provides an anatomical substrate for altered SPN activity arising from 
differential supraspinal, intraspinal and local inputs in the SHR.       95 
4. Cyclic GMP demonstrates differential expression levels 
and functional pressor activity in the spinal cord of 
Spontaneously Hypertensive and Wistar Kyoto rats   
4.1.  Introduction  
One of the most widely studied and best-understood signalling pathways for 
nitric oxide (NO) is the activation of the primary neuronal receptor for NO, soluble 
guanylate cyclase (sGC), and the subsequent generation of intracellular 3’, 5’-cyclic 
guanosine monophosphate (cGMP; (Ahern et al., 2002; Knowles et al., 1989).  In 
Chapter 3, we determined that all sympathetic preganglionic neurons (SPN) within 
the thoracic intermediolateral (IML) cell column of the spinal cord express cGMP and 
that  the  SPN  can  be  further  coded  by  the  presence  or  absence  of  neuronal  NO 
synthase (nNOS).  Further, we demonstrated that there are significantly fewer NOS-
containing  SPN  in  the  spontaneously  hypertensive  rat  (SHR),  compared  to  its 
normotensive  control,  the  Wistar  Kyoto  (WKY).    In  this  chapter  we  look  to  see 
whether  this  has  had  a  translational  effect  upon  cGMP  expression  and  functional 
activity within SPN.   
Given the direct relationship between NO activity and the formation of cGMP, 
it would be reasonable to hypothesise that a reduced capacity by SPN to produce NO 
in the SHR animals would translate into lower cGMP levels.  This is supported by 
previous  work  in  other  systems.    For  example,  reduced  production  and/or 
bioavailability of NO has been associated with reduced activity of the sGC/cGMP       96 
system  in  the  vasculature  of  hypertensive  rats  (Kojda  et  al.,  1998;  Ruetten  et  al., 
1999) and experiments utilising NO donors and inhibitors show parallel increases and 
decreases in cGMP levels, respectively.  The NO donor sodium nitroprusside (SNP) 
increases the level of cGMP content in the subfornical organ (Rauch et al., 1997) and 
in the cerebellum, blockade of NMDA receptors reduces not only NO production but 
also reduces basal cerebellar cGMP levels (Yamada et al., 1996).  Finally, in olfactory 
neurons,  a  progressive  reduction  in  nNOS  expression  induced  by  targeted  gene 
deletion is followed by decreased cGMP production (Chen et al., 2004a).  
Cyclic GMP production may also be stimulated when the natriuretic peptides - 
atrial natriuretic peptide (ANP), brain (BNP) and C-type NP (CNP) bind their cognate 
receptors, membrane bound guanylyl cyclases (Lucas et al., 2000).  In the rat, the 
major subtype of natriuretic peptide receptor in the central nervous system (CNS) is 
the ANP-B receptor and the ligand for the ANP-B receptor is CNP.  Thus the ligand 
CNP/ANP-B  receptor  system  may  be  the  most  important  in  the  rat  (Imura  et  al., 
1992).  To date, while it has been shown that natriuretic peptides are expressed in the 
spinal cord (Cameron et al., 1996), their ability to elicit cGMP synthesis in SPN has 
not been elucidated. 
In the thoracic region of the spinal cord, SPN play a key role in the control of 
arterial pressure and heart rate.  The effects of intrathecal injections of NO donors and 
NOS inhibitors are conflicting, with inconsistent pressor (Hakim et al., 1995; Lee et 
al.,  1996)  and  depressor  responses  described  (Chen  and  Shyr,  2005;  del  Carmen 
Garcia  et  al.,  1997;  Iida,  1999;  Koga  et  al.,  1999).    To  date,  only  one  study  has 
directly examined the role of spinal cGMP in modulating cardiovascular parameters.  
Work by members of our group (Malik et al., 2007) has recently demonstrated that 
intrathecally delivered cGMP not only raises mean arterial pressure (MAP) in a dose       97 
dependent  fashion,  but  also  supports  MAP  during  haemorrhage.    This  effect  is 
mimicked by the intrathecal administration of L-arginine, and blocked by intrathecal 
delivery of the selective sGC inhibitor 1H-[1,2,4] oxadiazole [4,3-a] quinoxaline-1-
one  (ODQ),  suggesting  that  within  the  spinal  cord,  sympathoexcitatory  effects  of 
spinal NO are mediated by a cGMP-dependent mechanism.  
The aim of this study therefore was to determine if (i) reduced nNOS levels 
correlate with reduced detectable cGMP in the SPN of SHR vs. WKY animals and (ii) 
if intrathecal administration of cGMP analogue 8-bromo-cGMP would elicit different 
functional pressor effects in the two strains.        98 
4.2.  Materials and methods 
4.2.1.  General methods 
 The experiment was divided into two parts.  The first part was designed to 
compare the amount of cGMP detected in thoracic SPN of SHR and WKY rats using 
immunohistochemical methods.  The second part compared the effects of intrathecal 
administration of the membrane permeable analogue of cGMP, 8-Bromo-cGMP (8-
Br-cGMP), in the spinal cord of WKY and SHR rats on MAP.  
All  surgical  and  recording  procedures  were  performed  in  the  Medical 
Research  Facility,  Royal  Perth  Hospital,  Western  Australia,  and  the 
immunohistochemistry was performed at Murdoch University, Western Australia, in 
accordance  with  the  National  Health  and  Medical  Research  Council  of  Australia 
guidelines on the use of animals for scientific purposes.  Experiments were approved 
by the Animal Ethics Committee of Royal Perth Hospital and Murdoch University.  
Animals  used  for  immunohistochemical  experiments  were  deeply 
anaesthetised  with  an  intraperitoneal  (IP)  injection  of  sodium  pentobarbitone 
(100mg/kg).  The depth of the anaesthesia was monitored using the corneal or the paw 
and tail pinch reflex.  Animals used for surgical experiments were anaesthetised with 
urethane  (ethyl  carbamate,  Sigma,  St  Louis,  MO,  USA)  injected  intraperitoneally 
(1.2g/kg body weight).         99 
4.2.2.  Immunohistochemistry 
Processing 
Details for the immunohistochemical techniques used in this project have been 
provided in Chapter 2, General Materials and Methods.  Briefly, 50 mm horizontal 
thoracic spinal cord sections (T2 – 9) from WKY (n = 4, 6 month old, males) and 
SHR (n = 4, 6 month old, males) rats were cut on a vibrating microtome (see section 
2.5.1) and immunoperoxidase immunohistochemistry (section 2.5.3) was performed 
using  a  rabbit  anti-cGMP  antibody  (1:2000;  Chemicon,  Temecula,  CA,  USA).  
Control sections were processed in parallel without the addition of primary antibody.  
Immunohistochemistry analysis: 
Preparations  were  examined  using  an  Olympus  BX51  light  microscope 
(Olympus, Waverly, Australia) under bright field microscopy.  Images of SPN within 
the IML region were acquired and densitometry used to undertake relative assessment 
of  the  level  of  immunoreactivity  using  Image  J  (Rasband,  W.S.,  ImageJ,  U.  S. 
National  Institutes  of  Health,  Bethesda,  Maryland,  USA,  http://rsb.info.nih.gov/ij/, 
1997-2007).    Only  neurons  that  had  their  full  profile  visible  were  selected  for 
analysis.    Arbitrary  units  (limited  to  the  grey  scale  range  of  0  –  255)  were  then 
expressed as a reciprocal of luminance, giving a direct measure of immunoreactive 
staining intensity.  Raw density measurements  were then  adjusted for  background 
staining, which allowed comparison of data between different animals (Fuller et al., 
2006).  For each animal, 20 SPN cellular intensity values were determined and the 
averages calculated.  Average values from each animal were then used for statistical 
analysis, by using a paired two-tailed Student’s t-test (Microsoft Excel, 2004), with 
the assumption of equal variance and significance set at p < 0.05.         100 
4.2.3.  Surgical preparation   
The surgical procedures were performed by Dr D.J McKitrick and Dr V.V 
Holobotovskyy  at  the  Medical  Research  Facility,  Royal  Perth  Hospital,  Perth, 
Western Australia. 
WKY (n = 12; 8 – 10 weeks, male) and SHR (n = 12; 8 – 10 weeks, male) rats 
were used for the study.  Six rats of each strain were assigned to each of 2 groups, 8-
Bromo-cGMP-treated and phosphate buffered saline (PBS)-treated (8-Bromo-cGMP 
vehicle) groups.   
Placement of femoral artery catheter for blood pressure recordings 
Animals were anaesthetised with urethane diluted in 0.9% saline administered 
ip.  Once anaesthetised, animals were positioned supine and the left leg was shaved 
and cleaned with 70% ethanol.  The femoral vein and artery were exposed and the 
artery dissected from the vein.  The artery was tied distally with a silk ligature (4-0 
silk Ethicon; Johnson and Johnson, Australia) and occluded proximally in a similar 
fashion, but not tied off.  The artery was elevated and a small incision made on the 
surface  to  allow  insertion  of  a  bevelled  polyethylene  catheter  (Dural  Plastic 
Engineering, NSW, Australia; internal diameter 0.8mm, outer diameter 1.0mm), filled 
with sterile heparinised saline (0.9 % NaCl with 2 I.U/ml heparin (Jurox, Rutherford, 
Australia), into the artery (~5 cm).  This was secured with the proximal silk tie.  The 
catheter was then anchored with the distal ligature.  The catheter was connected to a 
pressure transducer (Bell and Howell, California, USA),  
Upon completion of the study, animals were killed with pentobarbital sodium 
(100mg/kg
; Lethabarb, Virbac, Australia) administered via the arterial catheter.       101 
Intrathecal injection 
Animals  were  secured  in  a  stereotaxic  frame  (David  Kopf,  Tujunga,  CA, 
USA) and the cervical spinal region was exposed to the atlanto-occipital membrane.  
The atlanto-occipital membrane and dura mater were pierced with a 25-gauge needle.  
A cannula (polyethylene, internal diameter 0.28mm, outer diameter; 0.61mm, Dural 
Plastic Engineering) was inserted into the subarachnoid space and the tip progressed 
caudally (7.0 cm) to lie above the dorsal surface of the spinal cord, at the level of the 
T12  vertebra.    Placement  of  the  catheter  was  confirmed  with  an  injection  of 
methylene blue (10ml) upon completion of the experiment.  Catheters were filled with 
cGMP analogue, 8-Bromo-cGMP (Sigma Aldrich) or control solution PBS (0.1M pH 
7.4).   
Experimental procedures   
Doses  of  1,  30  and  100  µM  8-bromo-cGMP  dissolved  in  PBS  were  used.  
Prior to the intrathecal injection, MAP values were monitored for two minutes.  At 
two minutes 10ml of 8-Br cGMP [1, 30 and 100  M (assigned in random order)] was 
injected into the subarachnoid space and the haemodynamic effects monitored for a 
further 10 minutes.  Control animals received only PBS (10mL).  At 10 minutes (or 
longer until MAP had returned to preinjection values) a subsequent doses of 8-Br-
cGMP  (or  repeated  10  mL  PBS  in  the  control  groups)  was  given  until  each 
experimental rat had received 3 intrathecal injections. 
Recording procedures and analysis 
The  pressure  transducer  was  connected  to  an  IBM  compatible  computer 
equipped with Power Lab (AD Instruments, Version 5.5.4, 2007, NSW, Australia) 
hardware and Chart software (AD Instruments).  The digitised output was presented       102 
as  pulsatile  pressure  sampled  at  0.01s  intervals.    Pulsatile  AP  information  was 
mathematically converted to MAP and the results recorded and displayed in mmHg. 
Baseline values are presented as the average MAP ± standard error of the mean (SEM).  
Mean arterial pressure values before and after drug administration were compared for 
strain/dose  interactions  using  two-way  ANOVA.    Changes  in  MAP  values  were 
compared by one-way ANOVA, followed by Tukey's Multiple Comparison post-hoc 
test (Graphpad Prism version 3.02, Graphpad Software, San Diego USA).  Results are 
presented as the average change in MAP ± SEM for each strain and dose, and a p value 
of ≤ 0.05 was taken to indicate significant differences for all tests.        103 
4.3.  Results 
4.3.1.  Immunohistochemistry 
As described in the previous chapter, the general anatomical arrangement of 
the  SPN  of  the  IML  was  different  between  the  two  strains.    Figure  4.1  provides 
representative  images  of  cGMP  staining  in  WKY  and  SHR.    Analysis  of  cGMP 
immunoreactivity of SPN within the IML of SHR and WKY rats is summarised in Fig 
4.2A.  WKY rats had an average intensity score that was 3-fold greater than that of 
the SHR (Fig 4.2B). 
4.3.2.  Effects of intrathecal 8-Br-cGMP on MAP 
Prior  to  intrathecal  injections,  the  baseline  MAP  was  recorded  in  all 
experimental  and  control  groups.    The  baseline  recordings  for  the  WKY  groups, 
experimental and control were 97.0 + 3.0 mmHg (n = 6), and 91.17 + 3.6 mmHg (n = 
6) respectively and were not significantly different (overall average MAP 94.085 + 
2.3 n = 12).  The baseline MAP recordings for the SHR groups, experimental and 
control were 134.7 + 0.5 mmHg (n = 6), and 130.8 + 3.3 mmHg respectively and 
were not significantly different (overall average 136.75 + 1.4 n = 12). 
Changes in MAP in response to intrathecal administration of 8-Br-cGMP are 
illustrated  in  Figure  4.3.    One-way  ANOVA  indicated  a  significant  difference 
between all groups (p ≤ 0.0001).  Post hoc analysis indicated that in the SHR, each 
dose significantly increased MAP (p ≤ 0.01) compared to PBS, and that the response 
seen with 100 mM 8-Br-cGMP was significantly greater than that seen with 1 mM and 
30 mM 8-Br-cGMP (p ≤ 0.05, respectively).  In contrast, intrathecal 8-Br-cGMP did 
not cause a significant change in MAP in WKY animals.  A 2-way ANOVA (strain       104 
vs. dose of 8-Br-cGMP) indicated significant strain affect  (p ≤ 0.0001).  The WKY 
data therefore reanalysed independently of the SHR.  One-way ANOVA indicated a 
significant  difference  between  groups  (p  =  0.0036)  and  post-hoc  analysis  showed   
that the 100 µM intrathecal dose of 8-Br-cGMP in the WKY caused a change in MAP 
that was significantly different to both the PBS and 1 and 30 µM injections (p ≤ 0.01).        105 
Figure 4.1: Relative expression levels of cGMP in SPN in SHRs and WKY 
Light  microscopy  images  depicting  Cyclic  GMP 
labeling of SPN detected with diaminobenzidase 
(DAB) immunohistochemistry in WKY (male,  6 
months) (A, C) and SHR (male, 6 months)  (B, D). 
In all images the central canal is to the right of the 
image, white matter to the left.  Images A and B 
demonstrate  distinct  differences  in  SPN 
arrangement  between  the  WKY  (A)  and  SHR. 
Images C and D demonstrate individual SPN (*) 
which  were  further  assessed  for  cGMP 
immunoreactivity  intensity,  corrected  for 
background  staining.    It  is  apparent  from  these 
images  by  visual  assessment  that  there  is  a 
difference  in  the  level  of  intensity  of  staining.  
Scale bar equals 50mm (A, B), and 100 mm in (C, 
D). 
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Figure 4.2: Arbitrary readings for cGMP expression in SHRs and WKY 
Panel  A  provides  the  uncorrected  arbitrary 
intensity  readings  for  cGMP  immunoreactivity 
(cGMP-IR)  straining  for  individual  WKY  and 
SHR  adult  animals  (n  =  4,  each).  Figure  4.2B 
graphically  represents  the  differences  in  cGMP 
expression between the SHR and WKY.  The Y-
axis indicates the difference of cGMP-IR intensity 
between  cell  and  background  (arbitrary  units, 
scale  0  –  255).    Results  show  that  WKY  have 
relative intensity reading that is 3 fold greater that 
that  seen  in  the  SHR  when  corrected  for 
background staining  (p ≤ 0.05).       108 
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Figure 4.3: Change in MAP for SHRs and WKYs in response to intrathecal 8-br-
cGMP 
Changes in mean arterial pressure (MAP) in WKY 
and SHR in response to intrathecal administration 
of the cGMP [8-bromo-cGMP: 8-Br-cGMP, 1, 30 
and  100  µM  dissolved  in  phosphate  buffered 
saline (PBS; 0.1M, pH 7.4)]. Results are presented 
as  the  average  change  in  MAP  ±  sem.  for  each 
animal strain and dose used.  *Response to 100 
µM  8-Br-cGMP  in  the  WKY  were  significantly 
different  to  PBS,  1  and  30  µM  (p  ≤  0.01).    ** 
Response to 100 µM 8-Br-cGMP in the SHR is 
significantly different to that PBS, 1 and 30 µM of 
8-Br-cGMP  (p  ≤  0.05).    All  dosages  of  8-Br-
cGMP significantly increased MAP compared to 
PBS.       110 
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4.4.  Discussion 
The major findings of this study are (i) that the basal detection of cGMP levels 
within the SPN, as shown using immunohistochemistry, is significantly less in SHR 
compared to WKY rats, correlating with our finding of a reduced number of nNOS 
producing SPN (Chapter 3) and (ii), that intrathecal administration of exogenous 8-
Br-cGMP induces a marked increased in MAP in the SHR, while in the WKY, only a 
small increase in MAP could be elicited at the highest dose used.  These results agree 
with recent work by our group looking at intrathecal pressor response to cGMP in 
Sprague Dawley rats (Malik et al 2007), but highlight significant strain variation that 
may be linked to the degree of autonomic tone.  Overall, these results suggest that 
while there is less endogenous cGMP in SPN of the SHR under basal conditions, the 
functional response to exogenous cGMP is not diminished and indeed is enhanced. 
4.4.1.  Methodological issues 
Catheter placement is a key issue with regard to the outcome of the intrathecal 
injection experiments.  In 1976, Yaksh and Rudy (Yaksh and Rudy, 1976) examined 
intrathecal spread of drug in the spinal cord and demonstrated that drugs injected at 
the  level  of  T12  (tip  of  the  cannula)  flow  further  rostral  than  they  do  caudal.  
Furthermore,  the  spread  of  a  10mL  injection  from  T12  is  restricted  to  the  upper 
thoracic region of the spinal cord, where the majority of the SPN that provide cardiac 
and vascular sympathetic innervation are located (Malik et al., 2007).  Our placement 
of the catheter tip at T12 was therefore appropriate and would have further served to 
prevent distribution of the drug to brainstem cardiovascular centres.   
Given that intrathecal injection will affect all parts of the spinal cord to which 
the drugs spreads, it could be argued that the changes in MAP recorded were not       112 
solely due to changes in the activity of SPN.  However, based on our work (Chapter 
3) and that of others (Anderson, 1992 (Chapter 3); Tang et al., 1995b), the localisation 
of cGMP, and NOS within the upper thoracic spinal cord is limited to SPN and the 
dorsal horn, where presumably, NO serves to modulate pain pathways (Dun et al., 
1992; Reuss and Reuss, 2001).  We  can therefore speculate that the responses to 
intrathecal  8-Br-cGMP  injection  were  modulated  by  the  SPN  in  the  IML  regions 
targeted. 
4.4.2.   Reduced cGMP expression within SPN 
The reduced expression of cGMP in the SPN of SHRs relative to WKY was 
predicted in accord with the results of Chapter 3.  Our demonstration of cGMP in all 
SPN indicate it is a key signalling molecule in this cell population, and our finding of 
both a reduced number of NOS neurons (Chapter 3) and reduced basal level of cGMP 
suggests that NO-cGMP signalling is altered in SHR, and may therefore be associated 
with the hypertension seen in these animals.  Such a phenomena is described in the 
RVLM  of  SHR,  where  decreased  activity  of  the  L-arginine-NO  pathway  is  also 
thought to contribute to hypertension in this model (Kagiyama et al., 1998). 
As described in Chapter 1, cGMP is formed within neurons when NO binds to 
sGC.  For activity, both a and b isoforms of the sGC are required in 1:1 stoichiometry 
(Cabilla et al., 2006) and the balance of these subunits is critical to cGMP production.  
It  is  possible  that  in  the  SHR,  decreased  expression  or  malfunctioning  of  sGC 
receptors in the SPN could inhibit or reduce their capacity to produce cGMP.  For 
example, it has been shown in pituitary tissue that the application of estradiol causes 
both the mRNA and protein levels of the a1 subunit to increase, and b1 to decrease 
(Cabilla  et  al.,  2006).    This  imbalance  results  in  unstable  sGC  subunits  and       113 
consequently a reduction in cGMP (Cabilla et al., 2006).  Further support for this 
hypothesis arises from studies using ANP.  Stimulation of primary brainstem cultures 
with ANP show that there is significantly less cGMP produced in SHRs comparative 
to  WKYs  (Tang  et  al.,  1993)  and  this  down  regulation  has  been  attributed  to  a 
reduction  of  guanylate  cyclase-coupled  ANP  receptors.    Future  studies  aimed  at 
elucidating the level of expression of the a and b isoforms of sGC in SPN, and the 
capacity  for  natriuretic  peptide  to  regulate  cGMP  synthesis  in  SPN  would  be 
warranted.  
4.4.3.  Intrathecal administration of exogenous cGMP 
While our initial work (Chapter 3) led us to consider that reduced NO, and 
therefore cGMP levels in the SPN of SHR was a “causal” mechanism that drove 
increased sympathetic drive at the level of the spinal cord, this hypothesis required 
revisiting based on recent studies from our group examining the effect of intrathecal 
delivery of (the membrane permeable analogue of cGMP) 8-Br-cGMP (Malik et al., 
2007).  In that study it was shown MAP in Sprague-Dawley rats increased in response 
to exogenous cGMP in a dose dependent manner.  We therefore predicted that the 
intrathecal injection of 8-Br-cGMP would result in an increase in blood pressure in 
both strains.  This is indeed what we were able to demonstrate, however, the results 
also show a significant strain-dependent effect, with the SHR demonstrating much 
greater pressor responses at all doses tested.  Like the Sprague-Dawley (Malik et al., 
2007), both strains showed the greatest response to 8-Br-cGMP at the highest 100mM 
dosage, but again this was significantly more pronounced in the SHR.  It is possible 
therefore that in the SHR, the SPN have a heightened responsiveness to the NO-sGC-
cGMP  cascade,  and  that  it  has  functional  consequences.    Such  a  differential       114 
responsiveness has been documented in WKY and SHR previously.  In the aorta of 
the SHR, despite a reduced basal level of cGMP, stimulation with the excitatory drug 
YC-1  produces  a  significantly  greater  increase  in  cGMP  compared  to  the  WKY 
(Ruetten et al., 1999), and the use of the adenoviral vector, Ad.PRS-nNOS, which 
drives nNOS, reverses the attenuated production of cGMP (Li et al., 2007).  These 
results suggest a compensatory increased sensitivity or effectiveness of the NO-sGC-
cGMP pathway in the SHR (Ruetten et al., 1999). 
Alternatively,  the  increase  in  blood  pressure  seen  in  response  to  8-bromo-
cGMP administration may be due to a decreased capacity to breakdown cGMP in the 
SHR.  An approach to address this would be to radio isotope tag 8-Br-cGMP, and 
then measure the break down rate using radioimmunoassay on slices of spinal cord 
taken at various time points.  This approach has been used by (Rengasamy et al., 
1997), to demonstrate the effect of inhaled anaesthetics on NO and cGMP production.   
Another possibility is that the increased responsiveness to intrathecal 8-Br-
cGMP in the SHR is due to heightened downstream effects.  A number of secondary 
pathways, including the protein kinase G (PKG) and cGMP modulated ion channels 
may be modified in these animals.  It has already been shown that the stimulation of 
protein kinase C in aortic tissue of SHRs results in heightened sensitivity compared to 
the  WKY,  as  the  aorta  of  these  rats  display  increased  contractility  and  decreased 
ability to relax (Bruschi et al., 1988). 
An interesting study by Schmid and Pehl (Schmid and Pehl, 1996) examined 
the  electrophysiological  effect  of  NO  donors  and  cGMP  donor  on  neurons  in  the 
spinal  cord.  Lumbar  spinal  cord  slices  were  superfused  with  NO  donor  sodium 
nitroprusside (SNP) and then 8-Br-cGMP.  In the lamina I and II neurons, 32% of 
neurons were excited by both SNP or 8-Br-cGMP, 46% were inhibited by both SNP       115 
or 8-Br-cGMP and 22% had no response to either compound.  If there are similar 
excitatory and inhibitory NO-cGMP dependent responses in SPN, is it possible that 
the proportions change in the SHR relative to the WKY.  In Chapter 3, we illustrated 
neurochemical and anatomical differences in the SPN of the SHR, which may perhaps 
also reflect altered inhibitory/excitatory neuron distribution.  
4.4.4.  Conclusion 
The work by Malik et al. (Malik et al., 2007) determined that not only does 
intrathecal  8-Br-cGMP  and  L-arginine  increase  blood  pressure,  but  in  the  case  of 
haemorrhage, preadministration of 8-Br-cGMP attenuates the fall in MAP while ODQ 
augments it.  Interestingly, intrathecal ODQ did not alter basal MAP, suggesting that 
the endogenous formation of cGMP is not a key factor driving resting MAP, but that 
it assumes greater importance under relevant physiological stimuli.  As the NO-cGMP 
pathway in the SHR appears to be sensitised, it would therefore fit that only small 
changes  in  cGMP  levels,  as  through  exogenous  administration,  would  elicit  a 
pronounced response.   
Given  our  combined  neuroanatomical  and  functional  findings,  it  is  now 
possible to speculate that reduced levels of cGMP expression in the SHR are not 
necessarily contributing to the hypertension, but that they are instead a consequence.  
Down  regulation  of  the  levels  of  cGMP,  mediated  by  reduced  endogenous  NO 
production, are a reflex response mediating the pressor effects of cGMP.         116 
5. Differential expression of neuronal nitric oxide synthase 
and inducible nitric oxide synthase in the rostral 
ventrolateral medulla of the  
Spontaneously Hypertensive rat 
5.1.    Introduction 
Brain  pathways  controlling  arterial  pressure  are  distributed  throughout  the 
neuraxis  in  discrete  topographically  arranged  networks.    Within  the  rostral 
ventrolateral  medulla  (RVLM)  sympathoexcitatory  neurons  directly  innervate 
sympathetic preganglionic neurons (SPN) in the spinal cord and are critical to the 
tonic and reflex regulation of sympathetic tone and therefore of arterial blood pressure 
(Lipski et al., 1997).  The activity of these RVLM neurons is regulated not only by 
baroreceptor  input  via  the  nucleus  tractus  solitarii  (NTS)  and  caudal  ventrolateral 
medulla (CVLM) (Loewy, 1991), but also by synaptic inputs from many other areas 
of the central nervous system.  An increase in sympathoexcitatory output from the 
RVLM  has  been  reported  in  different  forms  of  hypertension,  despite  different 
initiating mechanisms (Campese, 2000; Colombari et al., 2001; Rahn et al., 1999).  
Recently, evidence for interactions between nitric oxide (NO) and sympathetic 
output via the RVLM has been presented (Chan et al., 2003a; Chan et al., 2001b).  
However, the role of this molecule is controversial, for although inhibitory effects 
evoked by NO within the RVLM have been described (Maeda et al., 1999), excitatory 
effects have also been reported (Hirooka et al., 1996; Martins-Pinge et al., 1999).  It       117 
has  been  proposed  that  NO  produced  from  different  sources  [i.e.  neuronal  NO 
synthase  (nNOS)  vs.  inducible  NO  synthase  (iNOS)]  mediate  differing  effects  on 
sympathetic output and blood pressure.  In a study by Chan (2003), application of 
nNOS or iNOS blockers in anaesthetised rats resulted in a respective reduction or 
increase  in  mean  arterial  pressure  (MAP)  (Chan  et  al.,  2001c).    Furthermore, 
investigations in conscious rats have indicated that microinjection of nNOS inhibitors 
appears to decrease MAP, while iNOS inhibitors increases MAP (Martins-Pinge et 
al., 2007).  These studies indicate nNOS having an excitatory action, while iNOS is 
inhibitory.  Furthermore, co-injecting iNOS inhibitors with glutamate, which has an 
excitatory action on bulbospinal RVLM neurons, appears to accentuate the action of 
glutamate, while the opposite happens when nNOS is applied, further adding support 
to iNOS and nNOS having differential effects (Martins-Pinge et al., 2007).   
Given  the  discrepancies  in  the  literature  and  the  indication  that  different 
isoforms of NOS within the RVLM affect blood pressure differentially, the present 
study was designed to investigate if differences in the expression of NOS isoforms 
exist  between  the  normotensive  Wistar  Kyoto  (WKY)  rat  and  the  Spontaneously 
Hypertensive Rat (SHR).  As nNOS appears to enhance MAP, we predicted that the 
relative expression of nNOS would be greater in the SHR, compared to the WKY.  
Reverse  transcription  polymerase  chain  reaction  (RT-PCR)  experiments  were 
designed to assess differential expression of iNOS and nNOS mRNA followed by 
assessment of protein levels using immunohistochemistry.        118 
5.2.  Materials and methods 
5.2.1.  Animals  
All  experiments  were  carried  out  with  the  approval  of  the  Animal  Ethics 
Committee of Murdoch University, Western Australia.  Gene expression data was 
obtained from mature male WKY and SHR rats (n = 9 each strain, 16-23 weeks old).  
Systolic arterial blood pressure was measured 1-2 weeks prior to tissue collection for 
mRNA analysis using the tail-cuff method. Blood pressure values for WKY and SHR 
were, respectively, 127.6 ± 16.7 mm Hg (n = 9) and 198.4 ± 18.8 mm Hg (n = 9).  
Prior  to  decapitation  for  tissue  removal,  animals  were  anaesthetised  with  carbon 
dioxide (CO2).  A further 3 SHR and 4 WKY male animals (12-14 weeks old) were 
used for immunohistochemical testing of nNOS protein  expression in the RVLM.  
These animals were lightly anaesthetised with CO2, and then deeply anaesthetised 
with sodium pentobarbitone by intraperitoneal (IP) injection (Nembutal; Nembutal 
Sodium Solution; Abbott Laboratories, Co. Ltd., Chicago, IL, USA; 100mg/kg) prior 
to perfusion with fixative through the ascending aorta. 
5.2.2.  Reverse transcription-polymerase chain reaction (RT-PCR) 
Polymerase  chain  reaction  experiments  were  performed  by  Mrs  Rhonda 
Loxley and Mr Mark Edwards at Murdoch University, South St, Murdoch. 
Tissue preparation and RNA extraction 
The brainstem was removed and frozen with dry ice in sterile 0.1M phosphate 
buffer  (PB).    Sections  (200  mm)  were  cut  on  a  freezing  cryostat,  and  the  RVLM 
region of the ventrolateral medulla identified under a light microscope (Wild M7 S, 
Wild Heerbrugg, Switzerland).   Bilateral tissue  punches were taken  from sections       119 
containing the RVLM (6-8 punches in total from 3-4 slices from each animal) with a 
sharpened needle (external and internal diameters, 1.2 and 1.0 mm respectively).  The 
RVLM was identified as that region extending caudally 600-800 mm from the caudal 
pole of the facial nucleus.  This corresponds to -12.5 mm to -11.7 mm caudal to 
Bregma (Paxinos and Watson, 1998).  The region was bounded laterally by the spinal 
trigeminal  tract,  medially  by  the  inferior  olive  and  pyramids,  and  dorsally  by  the 
compact formation of the nucleus ambiguus, as described by us previously (Fig. 5.1) 
(Phillips et al., 2001).  The punches were transferred into isolation reagent (Promega 
Total RNA Isolation System; Promega, WI, USA) and total RNA extracted according 
to  the  manufacturer’s  instructions.    Contaminating  genomic  DNA  was  destroyed 
using RQ1 DNAse 1 (1U, Promega) in 1X buffer at 37
o C for 20 min, containing 40U 
of  RNAsin  (Promega).    RNA  was  re-extracted  with  phenol/chloroform/isoamyl 
alcohol and Phase Lock Gel Tubes (Eppendorf; Brinkman Instruments, NY, USA) 
and precipitated in 100% ethanol with 20 U glycogen (Roche) and 0.3 M sodium 
acetate (pH 4.0).         120 
Figure 5.1: Location of the RVLM 
Photograph  illustrating  the  location  of  the  tissue 
punch site, RVLM, NTS, inferior olive, pyramidal 
tracts  and  the  compact  formation  of  the  nucleus 
ambiguus.       121 
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Reverse transcription – polymerase chain reaction 
The RNA was reverse transcribed in a 20 ml final volume using Superscript II 
(100U, Invitrogen, CA, USA) in 1X RT buffer, with 2.5 ng/ml random primers, 1 mM 
each deoxynucleoside-triphosphate (dNTPs), 5 mM dithiotreitol and 20 U RNAsin at 
42
oC for 45 min and then 50
oC for 30 min.  The RT enzyme was heat inactivated 
(90
oC for 5 min).  
Only  samples  that  tested  positive  for  the  catecholaminergic  marker 
phenylethanolamine N-methyltransferase (PNMT) were used for subsequent analysis. 
This  gene  was  used  as  a  control  for  regional  location,  given  the  position  of  the 
catecholaminergic C1 cell group in the RVLM (Paxinos and Watson, 1999).  Primers 
for PNMT were as described by Andreassi et al. (Andreassi et al., 1998).  Not all 
genes could be tested in all samples due to the small amounts of RNA extracted from 
each region and therefore results were pooled. Each result represents data obtained 
from a minimum of three separate animals. 
Quantitative Real-Time PCR  
Real time PCR was performed using an ABI Prism 7700 Sequence Detection 
System  (Applied  Biosystems).    The  reactions  were  performed  in  the  presence  of 
conventional forward and reverse primers and an MGB Taqman probe labelled with a 
fluorescent reporter dye (FAM or VIC©).  Primers and probes for nNOS and iNOS 
were designed using Primer Express (Applied Biosystems) software (see Table 5.1 for 
primer and probe details).  Expression of nNOS and iNOS were normalised to an 
endogenous control gene (neuronal specific enolase; NSE) to give a DCt value (see 
Real-time data analysis).  This allowed us to account for variability in the initial       123 
starting  amount  of  cDNA.    Multiplexed  reactions  (where  target  and  control  gene 
primers  and  probes  were  amplified  in  the  same  tube)  were  compared  with  non-
multiplexed reactions to check that one primer pair was not limiting the performance 
of the other.  For the iNOS primers, the Ct values from the reactions could not be 
matched, and subsequent reactions were therefore performed in separate tubes. Linear 
range analysis (diluting template cDNA 10 - 1000 fold; n = 3) was used to assess 
amplification efficiency.  For both sets of primers, the DCt value between target and 
NSE remained constant.   124 
Table 5.1: Primer and Probe Sequences and Conditions used for Real-Time PCR 
Primer/ 
Probe  Sequence  Product  
Size
 (bp) 
Sequence 
GenBank ID 
Conc. 
(nM) 
(a) 
PNMT 
Forward primer 
Reverse primer 
Taqman probe 
 
5¢-CAACAACTACGCGCCTCCTC-3¢ 
5¢-TGAGGCCAGACATGCTGGCTAT-3¢ 
288     
200 
200 
NSE 
Forward primer 
Reverse primer 
Taqman probe 
 
5¢-GGGCACTCTACCAGGACTTTGTC-3¢ 
5¢-TGGACCAAGCTGCCCAGT-3¢ 
5¢-FAM-CATGGAAAAACACAATTAC-3¢ 
89  M11931  120 
120 
250 
nNOS 
Forward primer 
Reverse primer 
Taqman probe 
 
5¢-ATCGGCGTCCGTGACTACTG-3¢ 
5¢-TCCTCATGTCCAAATCCATCTTCT-3¢   
5¢-FAM-CCTGGAGGAAGTAGCCA-3¢   
84 
 
X59949 
 
 
300 
300 
250 
iNOS 
Forward primer 
Reverse primer 
Taqman probe 
 
5¢-TGGCCTCCCTCTGGAAAGA-3¢ 
5¢-GGTGGTCCATGATGGTCACAT-3¢  5¢- 
FAM-CTGCTTCTGAAAACTAT-3¢   
95 
 
 
U03699 
 
 
 
900 
900 
250 
 Table  5.1.  Table  depicts  the  primer  and  probe  sequences  used  to  identify  the  mRNA  for  nNOS  and  iNOS;  (a) 
concentration of primer or probe used in the real time PCR reaction.     125 
Real-time data analysis 
Results obtained using primers for NSE were used to normalise the data.  To 
determine  relative  concentrations  of  DNA  during  the  exponential  phase  of  the 
reactions, level of fluorescence is plotted against cycle number on a logarithmic scale, 
so  an  exponentially  increasing  quantity  will  give  a  straight  line.    A  threshold  for 
detection of fluorescence above background is determined.  The cycle at which the 
fluorescence  from  a  sample  crosses  the  detection  threshold  is  called  the  cycle 
threshold (Ct).  The NSE Ct values were subtracted from the Ct value for each gene 
(to give DCt values).  These values were used to carry out statistical comparisons 
between genes and within strains.  For graphical representation, the fold variation was 
then determined using the 2
-(DDCt) method according to published protocols (Livak and 
Schmittgen,  2001)  and  the  manufacturer’s  recommendations.    Fold-variation  was 
calculated by determining the difference in DCt values between a chosen reference 
and test sample (DDCt value), and applying the 2
-(DDCt) formula.  The range values 
were then determined using the formula 2
-(DDCt ± SD DCt) (Livak and Schmittgen, 2001).  
When comparing individual genes between rat strains, the reference was expression 
levels of each gene in the WKY animal.  For determination of relative expression of 
the NOS isoform expression, nNOS was used as the reference gene.  
Statistical analysis  
Values  are  reported  as  mean  ±  standard  deviation  (sd)  of  the  DCt  values. 
Reported n values indicate actual PCR reaction numbers.  Duplicate or triplicates 
reactions  from  a  minimum  of  three  animals  were  pooled.  Statistical  analysis  was 
performed using the SPSS Statistical Package (SPSS Inc., IL, USA).  A two-tailed       126 
Students  t-test  was  used  for  analysis  with  the  assumption  of  equal  variance  to 
compare individual genes in SHR vs. WKY and iNOS vs. nNOS. 
5.2.3.  Immunohistochemistry 
Processing 
Animals were perfused with ice-cold solutions of 0.9% saline with heparin 
(1000 IU/ml), followed by a 4% solution of formaldehyde in 0.1M phosphate buffer 
(PB; pH 7.4).  The brainstem was then removed and post fixed for 2 – 4 hours at 4°C.  
Horizontal sections of brain stem (50 mm thick) were cut on a vibrating microtome 
(section  2.5.1)  and  alternate  sections  were  collected  in  series  for  subsequent 
examination.  Sections were treated for immunofluorescence immunohistochemistry 
as per section 2.5.2.  Table 5.2 lists the nNOS antibody and dilution used for this 
experiment. Control experiments were processed in parallel without the addition of 
primary antibody.   127 
Table 5.2: Antibody combination used for fluorescence immunohistochemistry in Chapter 5 
Animal  Combination  Dilution  Conjugated to  Dilution 
WKY (n = 3) & 
SHR (n = 3) 
10 - 12 weeks 
mouse a nNOS  1:400  FITC: donkey a mouse  1:500 
WKY (n = 3) & 
SHR (n = 3) 
10 - 12 weeks 
sheep a PNMT  1:500  CY2: donkey a sheep  1:500 
Table  5.2.    Table  details  the  various  antibody  combinations  used  in  each  of  the  immunohistochemical  experiments 
investigating the basal levels of nNOS or PNMT expression in the RVLM in WKYs and SHRs.  Alternating sections were 
taken from each animal, one series being processed for nNOS, the other series being processed for PNMT.  Source, batch and 
abbreviations detail can be found in Table 2.1.     128 
Imaging and quantitation 
Sections were imaged as detailed in section 2.6.1.  To count cell numbers, 
composite figures of the RVLM region    were assembled using PhotoShop software 
(Version  7,  Adobe  Systems,  Mountain  View,  CA).    Overall  colour  balance  and 
contrast  were  adjusted;  however  no  other  changes  were  made.  Only  nNOS 
immunoreactive  cell  profiles  that  included  a  nucleus  or  PNMT  neurons  with  a 
complete  profile  were  counted.    A  total  of  8  sections  were  examined  from  each 
animal, extending 800 mm from the facial nucleus as described for the tissue punch 
RNA extraction (Section 5.2.2).  Rostrocaudal distribution patterns represent bilateral 
cell counts made every 100 mm. The mean ± sd was calculated from a minimum of 
three animals.  Statistical difference was calculated using a two tailed Students t-test 
assuming equal variance.        129 
5.3.  Results 
5.3.1.  Quantitative analysis of NOS isoform expression in the RVLM 
Table 5.3 presents the NOS isoform mean DCt scores ± sd. and results of 
analysis for significant difference between variables.  Data was then transformed to 
show fold variation and range. 
Comparative analysis of expression levels of each gene between rat strains, 
utilising the WKY as the reference, indicated that nNOS expression in the SHR was 
1.76 times higher than the WKY (Fig. 5.2, p ≤ 0.05 determined using the DCt values; 
Table  5.3).    Although  there  was  a  trend  towards  higher  levels  of  iNOS  mRNA 
expression in the SHR, there was no significant difference in the levels between the 
two  strains.    Comparison  of  the  isoform  data  indicated  that  iNOS  mRNA  was 
expressed  at  significantly  lower  levels  than  nNOS  within  the  RVLM  of  both  rat 
strains (p ≤ 0.05) being 0.03 (± 0.01) that of nNOS in both the SHR and WKY. 
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Figure 5.2: Relative mRNA expression within the RVLM of NOS isoforms in WKY 
and SHRs 
Relative  expression  of  NOS  isoforms  in  RVLM 
punches  taken  from  SHR  and  WKY.  Data 
presented  as  fold  difference  ±  range  values, 
determined using the 2−(
  Ct) and 2−(
  Ct±S.D.  Ct) 
formulas,  respectively,  relative  to  the  expression 
level  in  WKY  animals  (=  1).  Significant 
differences  were  seen  in  the  levels  of  nNOS 
(higher  level  in  the  SHR)  (**p  ≤  0.05).    Data 
represent sample results pooled from a minimum 
of three animals each. 
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Table 5.3: Means and standard deviation of D D D DCt values for 
NOS isoform genes from each rat strain 
   nNOS  iNOS 
SHR 
94.58+0.38a,b 
79.84+0.94a 
WKY 
85.41+0.27b,c 
710.56+0.47c 
Table 5.3.  Italic superscript indicates value of n for each sample.  Means 
labelled with the same alphabetical subscript are statistically different (p 
<0.05), as determined by Student’s t-test for paired comparisons (nNOS 
vs. iNOS and SHR vs. WKY).  Note lower DCt values indicate higher 
relative levels of mRNA expression.   133 
5.3.2.  nNOS immunoreactivity in the RVLM 
In order to confirm the finding of increased nNOS expression in the RVLM of 
SHR animals, fluorescence immunohistochemistry was performed using an antibody 
directed  against  nNOS.    Confocal  imaging  demonstrated  a  cluster  of  nNOS 
immunoreactive  neurons  located  predominantly  in  the  region  of  the  lateral 
paragigantocellular  nucleus  (Fig.  5.3.).  The  rostrocaudal  distribution  of  nNOS 
immunoreactive cells was assessed along the axis of the RVLM.  There was some 
variability between individual animals, but the majority of nNOS cells were located 
caudal to the facial nucleus.  When comparing the SHR and WKY animals, the total 
number of cells counted in the RVLM region was not significantly different (SHR = 
573 ± 164.9 n=3 vs. WKY = 357.5 ± 122 n=4) but when individual rostrocaudal 
levels were compared using a students’ t-test, significantly greater numbers were seen 
at the rostral end of the RVLM in the SHR (p ≤ 0.05).  Control experiments that did 
not contain any primary antibody did not show any labelled cells.       134 
Figure 5.3: Neuronal NOS immunoreactivity in RVLM  
(A)  Confocal  image  illustrating  nNOS 
immunoreactivity  in  the  RVLM  of  an  SHR. 
Midline  is  located  to  the  left  and  ventrolateral 
edge  by  the  dotted  line.  The  nNOS-
immunoreactive cells were predominantly located 
adjacent to the inferior olive (io). Scale bar equals 
100  m. (B) Rostrocaudal distribution pattern of 
nNOS immunoreactivity in neurons of the RVLM 
of SHR and WKY animals. Figure shows mean ± 
sd of cells counted bilaterally in RVLM region in 
sections taken every 100  m. Results illustrate that 
the majority of the nNOS immunoreactive neurons 
are  located  in  the  region  caudal  to  the  facial 
nucleus (7th) and that there are significantly more 
cells staining for nNOS in this area in the SHR as 
compared to the WKY (**p ≤ 0.05, n=7). 
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5.4.  Discussion 
This study has demonstrated differential expression of nNOS in the RVLM of 
SHR as compared to the WKY rat strain.  Quantitative analysis showed nNOS mRNA 
levels  were  greater  in  SHR  animals  than  WKY  and  that  iNOS  levels  were  at 
significantly  lower  levels  than  nNOS  for  both  strains.    The  nNOS  finding  was 
confirmed  using  immunohistochemistry  to  assess  nNOS  protein  expression 
throughout the RVLM region.  
5.4.1.  Methodological considerations 
Quantitative real-time PCR was used for this study as it is an accepted highly 
sensitive methodology that allowed us to compare a large number of genes from a 
very small amount of starting material.  Neuron specific enolase, which was used to 
normalise gene expression levels, is a glycolytic enzyme responsible for converting 2-
phospho-D-glycerate to phosphoenolpyruvate (Marangos et al., 1978).  To confirm 
the  suitability  of  NSE  as  an  endogenous  housekeeping  gene,  work  from  our 
colleagues has shown previously that the levels of this gene do not vary in central 
sites between rat strains (Reja et al., 2002c).  Further evidence for NSE as a sound 
endogenous control are studies that show constant mRNA levels of this gene despite 
various neuronal states, including status epilepticus and traumatic brain injury (Iino et 
al., 2003; Schreiber et al., 1999).   
Our results show some differences from the quantitative mRNA data reported 
previously  regarding  the  level  of  expression  of  NOS  isoforms  within  the  RVLM 
(Chan et al., 2001a; Chan et al., 2003b; Plochocka-Zulinska and Krukoff, 1997).  A 
number  of  factors  may  have  contributed  to  these  differences.    First,  our  study       137 
analysed gene expression levels in older animals (≥ 16 weeks), while the study by 
Chan et al., 2001 (Chan et al., 2001a) used 8-10 week old animals.  Second, both the 
type  and  time  of  anaesthesia  prior  to  euthanasia  may  be  a  contributing  factor, 
resulting in a change in transcription.  For example, in the work by Chan et al., 2001, 
2003  (Chan  et  al.,  2001a;  Chan  et  al.,  2003b)  both  sodium  pentobarbitone  and 
propofol were used, and then the animals were paralysed with pancuronium which 
would have resulted in a much longer time frame between anaesthetic induction and 
death/tissue  removal  compared  to  our  study  that  involved  the  use  of  CO2  and 
decapitation.    This  may  have  caused  different  gene  expression  levels  and  such  a 
possibility is supported by work conducted in other brain areas.  For example, NR2C 
message  in  the  hippocampus  and  cortex  is  up-regulated  in  the  long-term,  but  not 
immediately following a hypoxic episode (Perez-Velazquez and Zhang, 1994).  We 
suggest that our study,  which used a very  short time frame between induction of 
anaesthesia and death, more closely represents basal expression levels of the NOS 
isoforms.  However, the possibility of post transcriptional and translational regulation 
applies limitations to any inferences drawn from mRNA analysis.  
5.4.2.  Neuronal nitric oxide synthase expression 
Our  study  demonstrated  a  significant  increase  in  the  mRNA  and  protein 
expression  of  nNOS  in  the  RVLM  of  the  SHR.  Both  the  mRNA  and 
immunohistochemical data from tissue punches and the rostral portion of the RVLM, 
respectively, showed close to twice as much nNOS in the SHR as compared to WKY.  
While the population of nNOS neurons in the RVLM has been described previously 
(Chang et al., 2003; Iadecola et al., 1993; Paxinos and Watson, 1999), this is the first 
study to show increased expression of nNOS at both the protein and mRNA levels in       138 
a hypertensive rat strain.  These nNOS containing cells do not project to the spinal 
cord  (Iadecola  et  al.,  1993),  but  they  have  been  implicated  in  central  autonomic 
control by their proximity to the RVLM and it is possible they form part of a network 
of modulatory interneurons in the region (Zanzinger, 1999). 
Microinjection  studies  indicate  that  the  neurons  within  the  RVLM  are 
susceptible to modulation by NO, with both inhibitory and excitatory effects over 
sympathetic  output  from  the  region  being  described  (Maeda  et  al.,  1999).    An 
alteration in the balance between nNOS and iNOS activity may underlie the genesis 
of augmented sympathetic vasomotor tone during hypertension.  This was elegantly 
demonstrated by Chan et al., 2001 (Chan et al., 2001c), who using selective blockade 
of nNOS and iNOS in the RVLM, elicited a reduction or enhancement of sympathetic 
vasomotor  outflow,  respectively.    More  recent  work  by  this  group  (Chan  et  al., 
2003b)  showed  that  NO  derived  from  nNOS  in  the  RVLM  induces 
sympathoexcitation via activation of both NMDA and non-NMDA receptors, and 
sympathoinhibition  elicited  by  NO  generated  by  iNOS  is  mediated  by  GABAA 
receptors.  Our  finding  that nNOS  has  a  comparatively  greater  expression than 
iNOS in both strains suggests that the proposed sympathoexcitatory effects of NO 
production may generally predominate in the RVLM.  While not examined in our 
study,  higher  levels  of  nNOS  expression  could  therefore  be  considered  as  a 
potential  factor  contributing  to  increased  sympathetic  tone  from  the  region.  
Alternatively, it is possible that increased expression of nNOS in the RVLM of SHR 
is  a  compensatory  response  to  elevated  blood  pressure.    A  study  by  Plochocka-
Zulinska  and  Krukoff  (Plochocka-Zulinska  and  Krukoff,  1997),  demonstrated 
increased nNOS expression in the hypothalamus, dorsal medulla and CVLM of adult 
SHR, but not in young pre-hypertensive rats or WKY and Sprague Dawley rats.  The       139 
inference drawn from these studies was that NO production is up-regulated in specific 
brain regions in response to increased sympathetic activity in order to re-establish 
homeostatic  balance.    Obviously  further  studies  will  be  required  to  address  these 
issues. 
5.4.3.  No difference in iNOS expression between the two strains 
This study also demonstrated that there appeared to be no difference in the 
level of iNOS mRNA expression between the two strains.  As no differences were 
found  at  the  mRNA  level,  subsequent  analysis  of  protein  expression  was  not 
performed. 
This is an interesting result as previous work has indicated that not only are 
there dose dependent changes in MAP in response to microinjection or blockade of 
iNOS  (Chan  et  al.,  2003b;  Chan  et  al.,  2001c),  there  have  been  previous  studies 
detailing lower  expression of iNOS in SHR rats compared to WKY (Chan et al., 
2003a; Chan et al., 2001a).  However, these studies were done in rats younger than 
the ones we tested, suggesting that the relative levels of iNOS in the SHR increases 
with age.  Apart from the activation of sGC, NO can readily react with superoxide to 
form peroxynitrite (Ohkuma and Katsura, 2001), which can stimulate the release of 
GABA,  providing  NO  with  an  alternative  way  of  influencing  neurotransmission 
(Mayorov, 2005).  Increasing levels of iNOS through the use of an adenovirus in the 
RVLM causes a pressor response in awake normotensive rats, a result that is said to 
be  in  response  to  an  increase  in  oxidative  stress  (Kimura  et  al.,  2005).    This  is 
consistent with recent work has shown an increase in superoxide in the brain playing 
a  key  role  in  sympathoexcitation  after  myocardial  infarction  (Gao  et  al.,  2004; 
Lindley et al., 2004).  Finally, studies show that superoxide is involved in the tonic 
regulation  of  sympathetic  outflow  in  the  RVLM  of  WKY  and  SHRs,  as       140 
microinjection  of  superoxide  dismutase,  the  enzyme  that  converts  superoxide  into 
oxygen and hydrogen peroxidase, reduces HR and MAP (Tai et al., 2005).  The Chan 
study (Chan et al., 2001a) indicated that though both WKYs and SHRs respond to 
microinjections of iNOS with increases in MAP, the onset latency in SHRs was much 
faster, indicating increased relative sensitivity to NO production in the SHR.   
5.4.4.  Conclusions 
This study has demonstrated that nNOS expression is significantly greater in 
SHR rats, while iNOS mRNA levels do not appear to be different.  While this study 
has not addressed issues of cause versus effect, it has highlighted key differences that 
may underlie some of the functional diversity that has been described in the literature. 
Determining physiological relevance will be a key focus for future studies.        141 
6. Immunohistochemical detection of soluble guanylate 
cyclase (sGC) and cyclic guanosine monophosphate 
(cGMP) within the rostral ventrolateral medulla 
6.1.   Introduction 
The rostral ventrolateral medulla (RVLM) contributes significant excitatory 
drive  to  sympathetic  preganglionic  neurons  (Lipski  et  al.,  1995)  via  two  well 
characterised phenotypic populations of neurons, the C1 (adrenergic) and non-C1 cell 
groups,  which  project  monosynaptically  to  the  spinal  cord  (Phillips  et  al.,  2001; 
Stornetta  et  al.,  2002).    While  glutamate  is  the  major  neurotransmitter  driving 
sympathetic activity within the RVLM nitric oxide (Gordon and Sved, 2002) (NO) is 
thought to play a key role in regulating glutamate induced pressor responses, and 
therefore modulating the activity of RVLM neurons and in turn homeostatic blood 
pressure mechanisms (Chen et al., 2001; Huang et al., 2003; Wu et al., 2001).  In the 
previous  chapter  (Chapter  5)  we  demonstrated  an  increase  in  NO  expression  in 
spontaneously hypertensive rats (SHR), and altered NO signalling in the RVLM is 
associated  with  increased  sympathetic  outflow  in  a  number  of  animal  models  of 
hypertension (Krukoff, 1998), however the mechanism of action is unclear, with a 
range  of  effects  attributed  to  NO  being  reported  including  NO-mediated  pressor, 
depressor or neutral responses (Hirooka et al., 1996; Martins-Pinge et al., 1997; Tseng 
et al., 1996).       142 
As described in Chapter 1, one of the most widely studied and best-understood 
NO second messenger systems is the activation of NO-receptor, soluble guanylate 
cyclase (sGC) and the subsequent generation of intracellular 3’,5’-cyclic guanosine 
monophosphate (cGMP) (Ahern et al., 2002; Lucas et al., 2000).  Soluble GC is a 
heme-containing  heterodimer  of  a  and  b  subunits,  with  the  b1  subunit  being  the 
major subunit, as there is no catalytic activity in its' absence (Friebe et al., 2007; 
Mergia et al., 2003).  Activation of NMDA receptors can drive this pathway, with 
increased  intracellular  Ca  stimulating  the  Ca
2+/calmodulin  NO  system,  promoting 
conversion of L-Arginine to NO.  Intracellular cGMP levels can also be regulated by 
membrane  bound,  or  particulate  guanylyl  cyclases,  incorporating  the  receptors  for 
atrial (ANP), brain (BNP) and C-type (CNP) natriuretic peptides (Lucas et al., 2000).  
As a second messenger, cGMP can target various protein kinases and ion channels, 
and its activity is limited through degradation by phosphodiesterases (PDE) (Lucas et 
al., 2000). 
Nitric oxide has alternative neuromodulatory mechanisms.  This includes the 
s-nitrosylation of proteins and in particular that of NMDA receptors (Ahern et al., 
2002), and interactions with superoxide, with the resultant peroxynitrite having potent 
oxidising properties that convey a variety of physiological and pathophysiological 
effects (Ohkuma and Katsura, 2001).  
While all three NO synthase (NOS) isoforms are present in the RVLM, as 
described in chapter 5, work by Chan et al. (Chan et al., 2003b) suggests that the 
relative balance of functional nNOS vs. inducible (i)NOS activity determines RVLM 
output, and further, that the different NOS isoforms activate different downstream 
signals, with nNOS driving sGC/cGMP-dependent sympathoexcitatory responses, and 
NO  produced  by  iNOS  driving  peroxynitrite  formation  and  sympathoinhibitory       143 
responses (Chan et al., 2005).  Glutamate-induced pressor responses in the RVLM are 
in general proposed to be modulated by NO-sGC/cGMP (Chen et al., 2001; Morimoto 
et al., 2000; Wu et al., 2001) and this is supported by electrophysiological studies 
showing  cGMP-dependent  potentiation  of  glutamate  currents  in  RVLM  slice 
preparations (Huang et al., 2003).  
To date, no studies have described the immunohistochemical localisation of 
neurons capable of expressing cGMP within the C1 region (De Vente et al., 1998).  
Given the strong evidence that NO signalling plays a functional role in the RVLM we 
sought to identify the cellular targets for NO in the RVLM, visualising cGMP and its 
neuroanatomical relationship with the C1 cell group, as identified by the presence of 
phenylethanolamine  N-methyltransferase  (PNMT)  and  the  more  medially  located 
nNOS expressing cell population (previous chapter; (Iadecola et al., 1993).  Given the 
results presented in Chapter 5 showing significantly higher expression of nNOS in 
SHR  compared  to  the  Wistar  Kyoto  (WKY),  and  studies  that  show  augmented 
responses to microinjection of glutamate in the RVLM in the SHR (Tsuchihashi et al., 
2000;  Tsuchihashi  et  al.,  1998),  we  considered  the  hypothesis  that  downstream 
signalling pathways (i.e. the NO/sCG/cGMP pathway) may be altered.  Our initial 
aim  therefore  was  to  determine  if  altered  cGMP  expression,  as  determined  using 
immunohistochemistry, could be demonstrated in the RVLM of the SHR.  Additional 
studies  sought  to  increase  synthesis  of  cGMP  in  fresh  RVLM  brain  slices  and 
examine sGC immunoreactivity (IR) throughout the region also.       144 
6.2.  Materials and methods 
6.2.1.  Animals 
Male rats were used in all experiments. WKY (n = 22 in total) and SHR (n = 3 
total) were used in the different age groups as detailed in each experimental protocol 
(Table 6.1 and 6.2). 
6.2.2.  Animal tissue preparation for immunohistochemistry 
Rats  were  anaesthetised  with  sodium  pentobarbitone  (Thiobarb,  Jurox, 
Rutherford,  Australia;  100mg/kg)  administered  intraperitoneally.    A  pre-fixation 
solution  of  ice-cold  heparinised  saline  was  perfused  via  the  ascending  aorta  as 
detailed in section 2.4.  In one set of experiments, the phosphodiesterase inhibitor 
isobutylmethylxanthine (IBMX; 0.5mM Sigma, St Louis, MO, USA) was added to 
the pre-fixation saline solution.  Brains were removed and sectioned on a vibrating 
microtome, as per section 2.5.1.  Sections were split into two alternate series, with 
each  section  therefore  100  um  apart.    Sections  were  then  treated  for  the 
immunohistochemistry  in  the  combinations  detailed  as  in  Table  6.1,  using  the 
protocol  described  in  section  2.5.2.    Previous  studies  and  manufacturers  product 
information  have  documented  the  specificity  of  antibody  reactions  for  cGMP 
(Chapter 3), nNOS (Dinerman et al., 1994), sGC (Gutierrez-Mecinas et al., 2005) and 
PNMT (Rinaman, 2001).  Negative controls sections were processed in parallel with 
primary antibody experiments.  
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Table 6.1: Antibody combinations used for fluorescence immunohistochemistry in Chapter 6 
Animal  Exp.  Condition  Combination  Dilution  Conjugated to  Dilution 
 
WKY (n = 3) & 
SHR (n = 3)  
Aged animals  
(6 months) 
mouse a nNOS 
rabbit a cGMP 
1:400 
1:500 
FITC: donkey a mouse 
CY3: donkey a rabbit 
1:500 
1:500 
WKY (n = 3) & 
SHR (n = 3) 
Aged animals  
(6 months) 
sheep a PNMT 
rabbit a cGMP 
1:500 
1:500 
CY2: donkey a sheep 
CY3: donkey a rabbit 
1:500 
1:500 
WKY  
+ IBMX (n = 3) 
- IBMX (n = 3) 
Young animals 
(10 weeks) 
mouse a nNOS 
rabbit a cGMP 
1:400 
1:500 
FITC: donkey a mouse 
CY3: donkey a rabbit 
1:500 
1:500 
WKY  
+ IBMX (n = 3) 
- IBMX (n = 3) 
Young animals 
(10 weeks) 
sheep a PNMT 
rabbit a cGMP 
1:500 
1:500 
CY2: donkey a sheep 
CY3: donkey a rabbit 
1:500 
1:500 
WKY (n = 3) 
 
Young animals 
(10 weeks) 
mouse a nNOS 
rabbit a sGC 
1:400 
1:500 
FITC: donkey a mouse 
CY3: donkey a rabbit 
1:500 
1:500 
WKY (n = 3) 
 
Young animals 
(10 weeks) 
sheep a PNMT 
rabbit a sGC 
1:500 
1:500 
CY2: donkey a sheep 
CY3: donkey a rabbit 
1:500 
1:500 
Table 6.1.  Table details the various combinations used in each of the immunohistochemical experiments investigating the basal levels of 
cGMP of presence of sGC expression in the RVLM in WKYs (n = 12, total) and SHR (n = 3, total).  Alternating sections were taken from 
each animal, and therefore more than one antibody combination could be used for each animal.  Source, batch and abbreviations detail can 
be found in Table 2.1.     146 
Table 6.2: Antibody combinations used for fluorescence immunohistochemistry after slice incubation in Chapter 6 
Animal 
 
Exp.  Condition 
 
Combination 
 
Dilution 
 
Conjugated to 
 
Dilution 
 
WKY (n=3) 
DETA-NO 
(100mM)  
mouse a nNOS 
rabbit a cGMP 
1:400 
1:500 
FITC: donkey a mouse 
CY3: donkey a rabbit 
1:500 
1:500 
WKY (n=3) 
DETA-NO 
(100mM) 
sheep a PNMT 
rabbit a cGMP 
 
1:500 
1:500 
 
CY2: donkey a sheep 
CY3: donkey a rabbit 
 
1:500 
1:500 
WKY (n=3) 
NMDA 
(100mM) 
mouse a nNOS 
rabbit a cGMP 
1:400 
1:500 
FITC: donkey a mouse 
CY3: donkey a rabbit 
1:500 
1:500 
WKY (n=3) 
NMDA 
(100mM) 
sheep a PNMT 
rabbit a cGMP 
1:500 
1:500 
CY2: donkey a sheep 
CY3: donkey a rabbit 
1:500 
1:500 
WKY (n=3) 
  Control 
mouse a nNOS 
rabbit a cGMP 
 
1:400 
1:500 
 
FITC: donkey a mouse 
CY3: donkey a rabbit 
 
1:500 
1:500 
WKY (n=3)  Control  sheep a PNMT 
rabbit a cGMP 
1:500 
1:500 
CY2: donkey a sheep 
CY3: donkey a rabbit 
1:500 
1:500 
Table 6.2.  Table details the various combinations used for each of the immunohistochemical experiments investigating levels of cGMP in 
the RVLM of WKYs (n = 9), after slice incubation.  Alternating sections were taken from each animal, and therefore more than one antibody 
combination could be used for animal.  Source, back and abbreviation detail can be found in Table 2.1.     147 
6.2.3.  Animal tissue preparation for brainstem slice in-vitro incubation 
The following experiments were done with the assistance of Anna Barron, at 
the School of Veterinary and Biomedical Sciences, Murdoch University, Australia. 
Animals  were  anaesthetised  and  perfused  as  for  the  immunohistochemical 
experiments using a perfusate that consisted of ice-cold sucrose based cutting solution 
(2 mM KCl, 2 mM MgSO4, 1.25 mM NaH2PO4, 1 mM MgCl2, 26 mM NaHCO3, 0.1 
mM CaCl2, 10 mM D-glucose, 248 mM sucrose, 95% O2/ 5% CO2, pH 7.4 (Moyer 
and Brown, 1998) containing IBMX (0.5 mM) and heparin 1000 IU/mL (Jurox).  The 
brains were removed immediately and coronal RVLM sections (400  m) were cut on 
a vibrating microtome while immersed in the same ice-cold sucrose cutting solution. 
After cutting, brain slices were warmed to 37 °C over 20 min in an artificial 
cerebrospinal fluid (aCSF) solution (124 mM NaCl, 2 mM KCl, 2 mM MgSO4.7H2O, 
1.25  mM  NaH2PO4,  26  mM  NaHCO3,  2  mM CaCl2,  10  mM  D-glucose,  0.5  mM 
IBMX, 95%O2 5% CO2, pH 7.4) (Moyer and Brown, 1998).  Once at 37 °C, slices 
were incubated for a further 30 min, prior to incubation in either 100 mM NMDA 
(Sigma, Castle Hill, Newcastle, Australia) plus 10uM glycine for 1 x 5 min (Lerma et 
al.,  1989)  or  100  mM  DETA-NO  (Sigma)  for  1  x  15  min  (Sandirasegarane  and 
Diamond, 1999) in aCSF solution.  Twenty minutes prior to use, DETA-NO was 
prepared in aCSF buffer and warmed to 37 °C to stabilise NO release.  The reaction 
was terminated by submerging the slices in ice-cold 3.7% formalin.  Control slices 
were  incubated  in  aCSF  solution  only.    Slices  were  post-fixed  for  2  h  in  3.7  % 
formalin at 4 °C, followed by washing for in 0.1M PBS (1 x 30 min).  Slices were 
then cryoprotected in 30% sucrose in 0.1M PBS and sodium azide (0.1%; overnight) 
prior to cutting 50 mm sections on a cryostat (Leica CM1510; Leica Microsystems 
GmbH,  Wetzlar,  Germany)  at  -17°C  for  subsequent  immunohistochemistry  using       148 
alternate sections as described above.  Antibody combinations for each experimental 
condition are as detailed in Table 6.2. 
6.2.4.  Imaging and analysis 
Imaging of sections were performed on a BioRad MRC-1024 confocal laser 
scanning  microscope  as  detailed  in  section  2.6.1.    No  statistical  analysis  was 
performed.       149 
6.3.  Results 
6.3.1.  Detection of cGMP-IR in the RVLM 
Initial experiments were undertaken in mature WKY and SHR animals (> 18 
weeks, n = 3 of each strain).  The distribution of cells expressing PNMT and nNOS 
were  used  as  markers  to  delineate  the  neuronal  populations  of  interest  within  the 
RVLM.  PNMT neurons defined the rostro-caudal axis of the C1 cell group while 
nNOS cell bodies bounded the medial RVLM region (Paxinos and Watson, 1998).  
Very  few  cGMP  immunoreactive  neurons  could  be  detected  in  the  RVLM  in 
association with either the PNMT C1 or the nNOS cells groups in either strain of the 
aged animals (Fig 6.1).  No double labelling was noted for any cells for cGMP and 
PNMT or cGMP and nNOS (Fig 6.1 A-F).  In contrast, there was strong cGMP-IR in 
the NA (Fig 6.1B, 6.1F).  In these cells, staining was punctate in appearance and 
localised to the cytoplasm and extending neurites.  Cyclic GMP-IR was visible in the 
vasculature throughout the sections (Fig 6.1 B, D and F). 
As there was no apparent difference in cGMP expression in the neurons of the 
RVLM between the SHR and WKY, all subsequent experiments were performed in 
WKY animals.  
To control for rapid degradation of cGMP under the experimental conditions, 
additional adult WKY animals were assessed after perfusion with IBMX (0.5mM, n = 
3)  in  the  pre-perfusate  solution.    To  assess  the  influence  of  animal  age, 
immunohistochemistry was also repeated in young male WKY animals (10 weeks; n 
=  3).    Neither  the  presence  of  IBMX  in  the  pre-perfusate  solution  or  the  use  of 
younger animals uncovered cGMP-IR neurons in the RVLM.  The use of IBMX did 
not alter PNMT or nNOS-IR but visibly increased the intensity of staining for cGMP       150 
in cells of the NA, and within blood vessels in the region (Figure 6.2).  
To confirm that the cGMP antibody was detecting both neuronal and vascular 
elements, a cGMP/ mouse anti a smooth muscle actin double label combination was 
used (anti α-SMA, mouse monoclonal, 1:500, A5228 clone 1A4: Sigma).  The a-
SMA labels smooth muscle cells of precapillary arterioles in the brain (Boado and 
Pardridge, 1994), and showed co-localisation with cGMP (Fig. 6.5A).  Furthermore, 
the  overall  pattern  of  vascular/microvascular  cGMP  staining  in  the  brain  is  as 
described by (Tassorelli et al., 2004).  Parallel control experiments lacking primary 
antibody showed no staining.    151 
Figure 6.1: Relationship of cGMP with either nNOS or PNMT 
Confocal  images  depicting  double  labelling  for 
PNMT/ cGMP (A, B) and nNOS/ cGMP (C, D) in 
the  RVLM  of  adult  WKY  in  the  absence  of 
IBMX, and PNMT/ cGMP (E, F) in the RVLM of 
an adult SHR in the absence of IBMX.  PNMT-
immunoreactivity (A, E) indicates the location of 
the C1 adrenergic cell group.  Panel C illustrates 
nNOS  immunoreactive  cells,  located  adjacent  to 
the inferior olive (IO) in the ventromedial region 
of  the  RVLM.    cGMP-IR  in  the  neurons  of  the 
nucleus  ambiguus  (NA)  and  in  blood  vessels 
(arrows) is evident (panels B, D, F) however there 
is no double labelling of neurons with cGMP in 
association  with  either  the  PNMT  or  nNOS  cell 
groups.    A  single  cGMP-IR  neuron  is  visible 
(arrow head, panel F) in the C1 region of the SHR 
animal.  Scale bar in Panel B = 200um for panels 
(A-B). Scales bars in panels D and F equal 100mm 
for panels (C-D) and (E-F), respectively.       152 
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Figure 6.2: Cyclic GMP expression in sections preincubated with IBMX 
Confocal  images  illustrating  cGMP  in  RVLM 
sections taken from adult WKY (A) and SHR (B) 
animals  treated  with  IBMX  in  the  pre-perfusate 
solution.  Midline is located to the left and ventral 
surface of the medulla towards the base.  Figures 
show the marked increase in detection of cGMP in 
the vasculature (arrows) and cells of the nucleus 
ambiguus  (NA)  when  compared  to  Figure  6.1, 
however very few neurons expressing cGMP were 
detected in the RVLM region.  Individual neurons 
showing cGMP-IR above the level of background 
staining are shown (arrow heads).  Scale bar in A 
equals  200mm,  scale  bar  in  panel  B  equals  100 
mm.       154 
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6.3.2.  Detection of cGMP–IR in brainstem slices after incubation in-
vitro 
Given the lack of detection of cGMP in the RVLM, cGMP-IR in the RVLM 
was  re-examined  in  brainstem  slices  that  were  treated  in-vitro  using  experimental 
paradigms designed to increase cGMP synthesis.  Due to the extended time frame of 
the experimental protocol, all experiments were performed in the presence of IBMX 
(0.5mM).  Sections were examined after incubation of brainstem slices in-vitro in 
aCSF (control), with 100uM NMDA or the NO donor DETA-NO (100uM; n = 3 for 
each  experiment,  total  n  =  9  WKY  10  week  old  animals).    In  the  aCSF  control 
experiments, the location of neuronal cGMP staining was comparable with that from 
the fixation perfused experiments (Figure 6.3A/B).   However, tissue integrity  and 
overall fluorescence was reduced in this series of experiments due to the incubation 
protocol  and  the  requirement  for  cryoprotection  prior  to  sectioning.    In  those 
brainstem slice preparations incubated with NMDA or DETA-NO, cGMP staining in 
the  vasculature  and  NA  was  notably  brighter  when  compared  to  control  (aCSF) 
preparations, but no additional neuronal staining in RVLM neurons was uncovered 
(Figs 6.3C - F). 
6.3.3.  Detection of sGC-IR in the RVLM 
Given that there was no cGMP immunofluorescence, immunohistochemistry 
was performed for the presence of the NO receptor sGC.  Sections from 3 male WKY 
animals (10 weeks) were examined for sGC/NOS and sGC/PNMT-IR.  Within the 
RVLM  region,  sGC-IR  was  widely  distributed  and  unlike  the  PNMT  and  nNOS 
immunoreactive neuronal populations, sGC cells could not be defined as belonging to 
a distinct group or nuclei.  While cells immunoreactive for sGC were often in close       156 
proximity to nNOS or PNMT immunoreactive cells there was no co-localisation (Fig 
6.4A and B).  Control experiments for sGC in the cerebellum showed the typical 
sGC-IR staining in cerebellar Purkinje (Fig. 6.5B) as previously described by Ding et 
al (Ding et al., 2004).    157 
Figure 6.3: Cyclic GMP expression in RVLM sections incubated with NO donors 
Confocal images depicting cGMP (B, D, E) and 
either PNMT (A, C) or nNOS-IR (E) in RVLM 
sections from WKY rats after treatment in-vitro to 
increase cGMP synthesis.  Panels A/B show the 
PNMT/cGMP  IR,  respectively  under  control 
incubation  conditions.    Panels  C/D  illustrate 
PNMT/cGMP-IR  respectively  after  in-vitro 
incubation in NMDA (100 mm 2 min).  Panels E/F 
show  nNOS/cGMP-IR,  respectively  after 
incubation in DETA-NO (100 mm 15 min).  Insets 
B’,  D’&  F’  illustrate  cGMP  expression  in  the 
nucleus  ambiguus  (NA)  under  control,  NMDA 
and  DETA-NO  experimental  conditions, 
respectively.  All experiments were performed in 
the presence of 0.5mM IBMX.  Despite cGMP-IR 
in blood vessels (arrows) and NA being enhanced 
by the in-vitro treatments, they failed to reveal the 
presence  of  additional  cGMP-IR  neurons  in  the 
RVLM  regions  in  association  with  either  the 
PNMT or nNOS cell groups.  Scale bar in F equals 
100mm for panels (A-F).  Scale bar in F’ equals 
100mm for panels (B’, D’ and F’). 
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Figure 6.4: Relationship of PNMT or nNOS with sGC 
Confocal images illustrating double labelling for 
PNMT/sGC in RVLM from WKY animals (male, 
10 weeks old).  Panels A/B/C show PNMT and 
sGC  as  individual  images  and  then  overlain  in 
colour,  respectively,  and  illustrate  cells 
immunoreactive  for  PNMT  (#;  red)  and  sGC 
(arrows; green) but lack of co localisation.  Scale 
bar in C equal 100mm for panels (A-C). 
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Figure 6.5: Control sections depicting specificity of cGMP and sGC 
Control  experimental  results.    Panel  A  shows 
control  experiments  assessing  the  vascular 
expression  of  cGMP.    Sections  were  double 
labelled  for  a-smooth  muscle  actin  (a-SMA; 
green – FITC secondary antibody) and cGMP (red 
–  CY3  antibody).    All  a-SMA-IR  structures 
showed  clear  co-localisation  with  cGMP  as 
illustrated.  The cGMP expression can be seen to 
extend  from  the  larger  precapillary  arteriole 
(arrows)  to  the  microvasculature,  where  it  is 
expressed in pericytes (the contractile elements of 
the brain microvasculature), that do not label for 
a-SMA {Poeggel, 1992 #865; Ehler, 1995 #899}.  
Panel  B  shows  intense  labelling  for  sGC  (red  – 
CY3 secondary antibody) in the cerebellum.  Scale 
bar  in  A  equals  20um and  scale  bar  in  panel  B 
equals 50mm.       162 
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6.4.  Discussion 
It is well documented that the premotor sympathetic neurons in the RVLM are 
critical to the maintenance and control of blood pressure (Dampney, 1994) and that 
endogenous NO is an important mediator in this regulatory process (Hirooka et al., 
1996; Martins-Pinge et al., 1997; Morimoto et al., 2000).  Functional studies provide 
strong  evidence  that  NO  acts  through  the  sGC-cGMP  signalling  pathway  in  the 
RVLM to drive sympathoexcitatory responses (Chan et al., 2005; Martins-Pinge et 
al., 1999; Mayorov, 2005; Wu et al., 2001), however, we were unable to detect cGMP 
in neurons of the C1 region of either the SHR or WKY rat strains.  This was despite 
the use of PDE inhibitors of the use of specific stimulators of cGMP synthesis in slice 
preparations.  We were able to demonstrate abundant sGC-IR in neurones throughout 
the RVLM region.  
6.4.1.  Cyclic GMP in the RVLM 
The detection of cGMP expression in the adjacent brainstem regions of the 
NA,  as  well  as  expression  in  the  blood  vessels  within  the  RVLM  lessens 
methodological  concerns  regarding  the  adequacy  of  antigen  recognition  and/or 
antibody penetration. The lack of detectable cGMP expression is in accord with a 
detailed study by De Vente et al. (De Vente et al., 1998), who similarly observed 
cGMP expression in the NA and nucleus tractus solitarii in the brain stem region, but 
do not comment on its expression in the RVLM, despite the use of in-vitro stimulation 
paradigms as applied in this study.  In the work by De Vente et al., the importance of 
IBMX to reveal otherwise non-detectable cGMP populations was stressed (De Vente 
et al., 1990; De Vente et al., 1998) and this has also been noted by other authors 
(Allaerts et al., 1998).  For this reason, IBMX was used in a subset of studies in       164 
perfusion  fixed  rats  and  for  the  brainstem  slice  in-vitro  incubation  experiments.  
However, while we found that IBMX did increase the levels of cGMP in already 
visible cell populations and in blood vessels in the brainstem, it did not uncover new 
cGMP-IR neurons in the RVLM, suggesting IBMX-sensitive PDE activity did not 
limit detection.  This concurs with data presented in Chapter 3 where we were able to 
show  that  cGMP  expressing  sympathetic  preganglionic  neurons  could  be  readily 
detected in the absence of IBMX.  
The effects of anaesthetic on cGMP levels also require consideration. For this 
project, anaesthetic was an ethical requirement.  Results from studies investigating the 
effect of anaesthetic on cGMP in the central nervous system are conflicting, with 
some reports describing the effects of anaesthetics as inhibitory, while others suggest 
no effect or indeed an increase in cGMP levels (Galley, 2000).  Thiopentone was 
chosen for this study on the rationale that intravenous agents are less likely to depress 
cGMP levels than inhalation anaesthetics (Tobin et al., 1994), and that pentobarbital 
drugs specifically do not depress cGMP levels in the brainstem (Galley et al., 2001).  
Given  that  our  brainstem  slice  in-vitro  incubation  experiments  failed  to  uncover 
cGMP-IR in the RVLM, despite the demonstration of an increase of detectable cGMP 
in surrounding tissues, and the time available for anaesthetic wash-out, it is likely the 
effects of anaesthetic were minimal in this study. 
The use of NMDA and NO donors to increase detectable cGMP in brain slice 
in-vitro preparations has been demonstrated previously in various tissues including 
the paraventricular nucleus (Vacher et al., 2003) cerebellum (De Vente et al., 1990; 
De Vente et al., 1998) and hippocampus and thalamus (van Staveren et al., 2005).  
The choice of DETA-NO as a donor was based on its ability to spontaneously liberate 
NO in aqueous solutions in a stable, time-controlled fashion (Keefer, 2005).  It has       165 
been proposed that the type of NO donor can make a significant difference to the way 
in which cGMP is stimulated (Butt et al., 1995), however a recent study comparing 
the  effects  of  NONOates  to  the  classical  NO  donor  sodium  nitroprusside  found 
limited  difference  in  their  ability  to  stimulate  sGC  or  influence  cGMP  staining 
patterns in brain slice preparations (van Staveren et al., 2005).  Similar to our study, 
nitroglycerin,  another  NO  donor,  has  been  shown  to  increase  cGMP-IR  in  both 
neuronal and vascular elements of the brain but did not uncover any additional or 
previously undetected cGMP immunoreactive neuronal cell groups (Tassorelli et al., 
2004). 
6.4.2.  Soluble guanylate cyclase expression within the RVLM 
The widespread detection of sGC within neurones of the RVLM is in accord 
with previous studies that have demonstrated both mRNA and protein for sGC within 
the medulla (Campese et al., 2007; Krukoff et al., 1995).  It is likely to be a functional 
form of sGC, as the antibody we used was specific for the b1 subunit, which is the 
obligatory subunit for functional sGC (Friebe et al., 2007), and has been shown to co-
localise extensively with the  a subunit throughout the CNS of the adult rat brain 
(Ding et al., 2004).  
While  we  did  not  demonstrate  co-localisation  of  sGC  with  the  nNOS  cell 
population,  they  were  often  in  close  association.    This  pattern  of  expression  is 
consistent  with  other  brain  regions,  where  NO  responsive  and  NO  producing 
structures are not necessarily found within the same neuronal profile (De Vente et al., 
1998; Ding et al., 2004; Schmidt et al., 1992).  An exception is the NTS, where nNOS 
and sGC have been shown to co-localise (Lin and Talman, 2005).  Similarly, we saw 
sGC in close association but not co-localised with the C1 cell group.  Additional       166 
studies aimed at determining the cell population which expresses sGC should include 
retrograde  labelling  as  a  means  of  identification  of  the  non-C1  bulbospinal  group 
(Phillips et al., 2001), and double labelling for markers such as neuropeptide Y to 
identify  neurons  which  project  to  the  hypothalamus  (Verberne  et  al.,  1999),  or 
markers to enable identification of glutamatergic and GABAergic neurons (Stornetta 
et al., 2002).  This would then allow potential functional relevance to be attributed to 
sGC expression in the region.  Interestingly, in an in-vivo study of the cat, nNOS-sGC 
co-localisation  was  present  in  the  RVLM  only  after  activation  by  bradykinin  (as 
identified  by  the  presence  of  c-fos)  (Guo  and  Longhurst,  2006).    This  raises  the 
hypothesis that functional network inputs, such as the sympathetic baroreflex pathway 
(Mayorov, 2005) are required to drive a sGC/cGMP cascade in the RVLM. 
6.4.3.  Conclusion 
Despite our lack of detection of cGMP in the neurons of the C1 region, a 
number of physiological studies indicate that NO can modulate pressor responses in 
this  region  via  a  sGC/cGMP  dependent  mechanism  (Huang  et  al.,  2003;  Martins-
Pinge et al., 1999; Wu et al., 2001), including facilitation of sympathetic baroreflex 
transmission (Mayorov,  2005).  Given the properties of  NO as a  freely  diffusible 
molecule, and its tight coupling to both the NMDA receptor and sGC, the dynamics 
of NO signalling can be very confined, short lived and discrete (Garthwaite, 2005).  
The kinetics of the cGMP signalling in the RVLM may therefore be finely tuned to 
respond to very low NO concentrations.  A recent study has shown that in similar 
conditions to ours, the use of a NO donor in the presence of IBMX was not sufficient 
to maximise cGMP detection in the hippocampus, but instead required the further 
addition of YC-1 or BAY 41-2272, NO-independent activators of sGC (van Staveren 
et al., 2005).       167 
The  expression  of  an  IBMX-insensitive  cGMP-specific  phosphodiesterase 
(PDE9) in the RVLM may be another important factor limiting detection of cGMP 
accumulation (Soderling et al., 1998; van Staveren et al., 2005).  As basal cGMP 
levels in neurons have been shown to result from a dynamic equilibrium between 
synthesis by sGC tonically stimulated by endogenous NO, and degradation by PDEs, 
including PDE9 (Hepp et al., 2007), we can speculate that these mechanisms may 
participate  in  maintaining  cGMP  levels  in  the  RVLM  at  undetectable  low  levels.  
Examination  of  the  role  of  NO-independent  activation  of  sGC  and  specific 
phosphodiesterases is therefore required before the role of cGMP as a contributor to 
altered sympathetic tone in the SHR can be ascertained. 
In conclusion, if present in the RVLM, cGMP does not exist in detectable 
quantities in the resting state and cannot be elicited by NMDA receptor stimulation, 
NO donor or by PDE inhibition.  This finding raises questions now as to whether 
endogenous NO in the RVLM is truly working through this pathway. 
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7. Heterogeneous distribution of basal cyclic guanosine 
monophosphate within distinct neuronal populations in 
the hypothalamic paraventricular nucleus 
7.1.  Introduction 
The sympathetic nervous system is critical to the regulation of physiological 
homeostasis  under  basal  conditions  (Kenney  et  al.,  2003;  Patel  et  al.,  2001).  
Substantial data indicates that forebrain, brainstem and spinal networks are involved 
in  this  process  (Dampney,  1994).    Located  either  side  of  the  third  ventricle,  the 
paraventricular  hypothalamus  (PVN)  is  a  convergence  point  for  many  regions 
involved  in  the  maintenance  of  homeostasis,  including  roles  in  fluid  regulation, 
metabolism,  immunological  responses  and  thermoregulation  (Benarroch,  2005),  as 
well as being pivotal in the maintenance of cardiovascular function (Coote, 2005; 
Guyenet, 2006). 
The PVN is a complex nucleus made up of three functionally distinct subsets 
of  neurons:  magnocellular  neurosecretory  neurons,  parvocellular  neuroendocrine 
neurons (Swanson and Sawchenko, 1983) and parvocellular preautonomic neurons 
(Swanson and Sawchenko, 1983).  The magnocellular neurons produce oxytocin (OT) 
and arginine vasopressin (AVP) peptides, and innervate the posterior pituitary gland. 
The  parvocellular  neuroendocrine  neurons  project  to  the  median  eminence,  and 
regulate  the  release  of  hormones  from  the  anterior  pituitary  gland.    Parvocellular 
preautonomic neurons send descending projections to brainstem regions including the       169 
nucleus  tractus  solitarii  (NTS),  rostral  ventrolateral  medulla  (RVLM),  and 
sympathetic  preganglionic  neurons  (SPNs)  located  the  intermediolateral  (IML) 
column of the spinal cord (Armstrong et al., 1980; Dampney, 1994; Portillo et al., 
1998; Pyner and Coote, 1999; Ranson et al., 1998; Shafton et al., 1998; Stern, 2001; 
Swanson and Sawchenko, 1980). 
Significant evidence supports a major role for preautonomic PVN neurons in 
the  control  of  tonic  and  reflex  autonomic  function,  including  modulation  of  renal 
sympathetic nerve activity (Chen and Toney, 2001; Kannan et al., 1987; Malpas and 
Coote, 1994; Zhang et al., 1997) as well as the baroreceptor reflex (Patel and Schmid, 
1988; Zhang and Ciriello, 1985a) and volume expansion reflex (Haselton et al., 1994; 
Pyner and Coote, 2000).  Autonomic outflow from the PVN is regulated by the action 
of numerous neurotransmitters, including glutamate, GABA and angiotensin II (Chen 
et al., 2003; Li et al., 2001; Tagawa and Dampney, 1999; Zhang and Patel, 1998).  Of 
particular interest is nitric oxide (NO), a ubiquitous modulatory molecule that acts as 
a  non-conventional  neurotransmitter  in  the  central  nervous  system  (Schuman  and 
Madison, 1994).  In general, NO is believed to act as an inhibitory molecule within 
central  regions  involved  in  autonomic  and  neuroendocrine  control  (see  (Krukoff, 
1999) and (Kadekaro, 2004) for review).  For example, incremental increases in NO 
levels  within  the  PVN  result  in  diminished  neurohumoral  secretion,  decreased 
sympathetic nerve activity, and concomitant decreases in blood pressure and heart 
rate (Hashiguchi et al., 1997; Li et al., 2001; Zhang et al., 1997).  Importantly, NO is 
constitutively produced within the PVN and supraoptic nucleus (SON) (Stern, 2004), 
and  basal  NO  levels  restrain  neurohumoral  output  from  these  regions.    This  is 
supported by recent studies indicating that inhibitors of NO synthase (NOS) activity 
within the PVN result in sympathoexcitation and increased blood pressure (Zhang and       170 
Patel, 1998).  Further, diminished basal NO availability within the PVN has been 
shown to contribute to elevated neurohumoral drive in pathological conditions such as 
hypertension, heart failure and diabetes (DiCarlo et al., 2002; Zhang et al., 2001; 
Zheng et al., 2007).   
Accumulating  evidence  indicates  that  NO  effects  on  neuroendocrine  and 
autonomic outputs from the SON and PVN are mediated by inhibition of the electrical 
activity of both magnocellular (Bains and Ferguson, 1997; Liu et al., 1997; Stern, 
2001; Stern and Zhang, 2005) and preautonomic neurons (Li et al., 2002; Li et al., 
2003b), and that these actions are mediated through an enhancement of GABAergic 
transmission  (Li  et  al.,  2003a;  Li  et  al.,  2003b;  Yang  et  al.,  2007).    One  of  the 
classical  mechanisms  underlying  NO  signalling  in  neurons  involves  activation  of 
soluble guanylyl cyclase (sGC) (Knowles et al., 1989).  Recent studies indicate that 
NO facilitation of GABAergic function and inhibitory effects in PVN preautonomic 
neurons involves activation of a cGMP-dependent pathway (Li et al., 2003a; Yang et 
al.,  2007).    Altogether,  this  supports  the  NO-cGMP  signalling  cascade  as  a  key 
mechanism controlling ongoing neuronal activity and neurohumoral output from the 
PVN. 
In the present chapter, we aim to expand on this knowledge by performing a 
detailed anatomical characterization of constitutive NO-receptive, cGMP producing 
neuronal populations within the PVN.  Retrograde labelling techniques have been 
combined  with  immunohistochemistry  to  visualise  cGMP  within  functionally, 
neurochemically and topographically discrete PVN neuronal populations.        171 
7.2.  Materials and methods 
7.2.1.  Animals 
All  experiments  were  carried  out  with  the  approval  of  the  Animal  Ethics 
committees  of  Murdoch  University  and  the  University  of  Cincinnati.    Data  were 
obtained from 12 male Wistar rats (aged 7 – 8 weeks old, 250g).  Animals were 
housed and treated as per methods section 2.1. 
7.2.2.  Microinjection of retrograde tracer Fluorobeads 
Individual animals had retrograde tracer injected in one site only, being either 
the RVLM (n = 4), NTS (n = 4) or IML (n = 4).  
The candidate conducted IML injections with the assistance of Mr Courtney 
Reddrop, at the School of Veterinary and Biomedical Sciences, Murdoch University, 
Australia. RVLM and NTS microinjections were undertaken by Dr Vinicia Biancardi, 
and Associate Professor Javier Stern, at the University of Cincinnati, OH, USA. 
Fluorobeads (Lumafluor, Naple, Fl, USA) are latex microspheres labelled 
with a fluorescent marker, (either fluorescein or rhodamine) and utilise the retrograde 
axonal system to be transported from motor end plate to soma (Katz et al., 1984).  
Fluorobeads were used in this study to identify hypothalamic neurons with projections 
to the IML, RVLM and NTS regions.  
Retrograde label from sympathetic preganglionic neurons 
Anaesthesia  was  induced  with  an  intramuscular  (IM)  injection  of 
ketamine/xylazine combination (40 mg/kg:
 5 mg/kg; Ketamil 100mg/ml: Xylazil 20 
mg/ml, both Ilium Troy Laboratories, NSW Australia), and subsequently maintained       172 
using  isofluorane  by  mask  administration  (Isorane,  Veterinary  Companies  of 
Australia, NSW, Australia; 2 – 5%; 1 L/min).  
Animals  were  placed  in  the  prone  position  and  a  midline  incision  made 
between T1 and T4.  After dissection through the muscle layers, the dorsal surface of 
T2 and T3 was removed with rongeurs.  A bent 25-gauge needle was used to pierce 
the pia mater, which was then cleared from the dorsal surface of the spinal cord.  
Once  exposure  of  the  spinal  cord  was  completed  the  animal  was  placed  into  a 
stereotaxic frame.  A glass micropipette (Socorex, Ecublens, Switzerland; tip diameter 
50 – 70 mm) was filled with Fluorobeads (Green) and inserted 0.6mm lateral to the 
midline, to a depth of 0.7 mm below the dorsal surface (Kantzides and Badoer, 2003).  
Two bilateral injections (200 nl each) were undertaken in separate sites 200 mm apart, 
running in a rostral to caudal fashion (total of 4 injections) (Cham et al., 2006).  To 
minimise leakage of tracer from the injection site, administration was undertaken over 
a 5-minute period (Cham et al., 2006; Kantzides and Badoer, 2003).  The location of 
the  IML  injections  were  examined  and  verified  histologically  at  the  end  of  the 
experiment, and only animals (n = 4) in which the injected tracer covered the IML 
were utilised.  As per the Cham study (Cham et al., 2006) the tracer also spread to 
parts of the tractus rubrospinalis, tractus corticothalamicus lateralis  and the tractus 
corticothalmucus lateralis. 
Upon completion the overlying muscles were sutured with silk (4-0; Ethicon; 
Johnson  and  Johnson,  Australia)  and  the  skin  incision  closed  with  Vicryl  (4-0; 
Ethicon).  Preoperatively, animals received penicillin (100mg/kg IM Norcillin L.A. 
1000 units/ml, Norbrook Laboratories, Northern Ireland) and the non-steroidal anti-
inflammatory drug Carprofen (4 mg/kg; Rimadyl 50mg/ml, Pfizer, NSW, Australia).        173 
Additional analgesia (Carprofen 4 mg/kg) was administered 24 and 48 hours post 
surgery.  Animals were monitored daily for a week post surgery. 
Retrograde labelling from NTS and RVLM 
Rats were anaesthetised by injection of ketamine/xylazine mixture (90 mg/kg:
 
5 mg/kg
 respectively) administered IP.  Animals were placed in a stereotaxic frame, 
and ear and nose bars were fixed so that the head was horizontal.  For injections in the 
NTS, the dorsal medulla was exposed after retraction of the overlying muscles and 
occipital membranes.  A small part of the occipital bone was removed to increase the 
exposure of the medulla.  Rhodamine-labelled microspheres (Lumafluor, Naples, FL, 
USA) were pressure-injected unilaterally (200 nl) into the NTS at the level of the 
obex.  The injection site was 12mm caudal to Bregma, 1 mm lateral to the midline 
and 0.8 mm below the dorsal surface.  To minimise the leakage of the tracer from the 
injection administration was undertaken over a 5-minute period.  Following injection 
the muscles were sutured together and the incision closed as described above.  
For injections in the RVLM, a 4-mm burr hole was made in the skull and the 
same tracer was injected at the co-ordinates 12.0 mm caudal to Bregma, 2 mm lateral 
to the midline and 8 mm below the dorsal surface.  Injections and aftercare were made 
as per the NTS injections.  The location of the tracer was verified histologically, as 
previously reported (Stern, 2001; Stern et al., 2003). 
7.2.3.  Tissue removal and immunohistochemistry 
Seven days post surgery for retrograde labelling, animals were anaesthetised 
(Section  2.4),  and  tissue  was  removed  after  transcardial  perfusion  with  ice-cold 
heparinised saline, followed by 4% formalin (as per section 2.4.1).  To determine the 
relationship between cGMP and either OT or AVP in cell populations differentially       174 
identified  by  retrograde  labelling,  sections  were  prepared  for  fluorescence 
immunohistochemistry  (section  2.5)  and  treated  with  the  combinations  of  primary 
antibody as outlined in Table 7.1.  When double labelling for OT and cGMP, primary 
antibodies were incubated consecutively, each for 24 hours.  Negative controls were 
processed  in  parallel  in  the  absence  of  primary  antibody.    Previous  studies  and 
manufacturers  product  information  have  documented  the  specificity  of  antibody 
reactions for the cGMP (Chapter 3) OT (Wainwright et al., 2004) and AVP (Nylen et 
al., 2001b) antibodies.   175 
Table 7.1 Antibody combinations used for fluorescence immunohistochemistry in Chapter 7 
Animal number 
(Wistar) 
Origin of  
retrograde label 
Combination 
 
Dilution 
 
Conjugated to 
 
Dilution 
 
n = 4 
n = 4 
n = 4 
IML 
RVLM 
NTS 
mouse a OT 
rabbit a cGMP 
 
1:20000 
1:500 
 
CY5: donkey a mouse 
CY3: donkey a rabbit 
 
1:500 
1:500 
 
n = 4 
n = 4 
n = 4 
 
IML 
RVLM 
NTS 
 
guinea pig a AVP 
rabbit a cGMP 
 
1:50000 
1:500 
 
CY5: donkey a sheep 
CY3: donkey a rabbit 
 
1:500 
1:500 
 
Table 7.1.  Table details the various combinations of antibodies used in this chapter, to explore the relationship between cGMP and the 
subpopulations of neurons found in the PVN, based on peptide expression or the identification of retrograde label.  Source, batch and 
abbreviations detail can be found in Table 2.1.     176 
7.2.4.  Quantification and analysis 
Sections  were  examined  using  a  confocal  microscope  under  fluorescence 
microscopy and images acquired of the PVN regions ranging from Bregma -1.40 mm 
through Bregma -2.10 mm.  Cells were included in the analysis if they contained 
single, double or triple staining and if the nucleus was clearly visible.  Analysis was 
undertaken using Image Pro Plus software (Media Cybernetics, Silver Spring, MD, 
USA).  Images were opened as a stack and the following regions of the PVN were 
examined for labelling: lateral magnocellular (LM), dorsal cap (DC), ventromedial 
parvocellular  (VM)  and  posterior  parvocellular  (PaPo)  subnucleus.    OT/AVP 
immunoreactive and/or retrogradely labelled positive cells were traced using a free 
hand  tool  within  the  Image  Pro  Plus  programme.    To  detect  and  quantify  cGMP 
immunoreactivity (IR), the mean intensity of cGMP signal within traced neurons was 
calculated  and  expressed  as  fluorescence  arbitrary  units,  ranging  from  0  (absolute 
black) to 255 (absolute green).  Background fluorescence was subtracted from all 
images.    Neurons  were  arbitrarily  considered  to  be  cGMP  positive  when  the 
fluorescence intensity within the neurons was 30% greater than background (see also 
(Stern  and  Zhang,  2005).    The  percentage  of  total  magnocellular  neurosecretory 
neurons  (determined  by  their  location  and  OT/AVP  IR)  or  preautonomic  neurons 
(determined by presence of retrograde label) containing cGMP was determined and 
statistically compared.  
7.2.5.  Statistical analysis 
To determine differences in the incidence of cGMP  IR  among the various 
neuronal populations sampled, a Chi Square test was used.  Values were compared to       177 
a c
2 
crit values table, obtained from Pagano (Pagano, 1994), with level of significance 
set to p ≤ 0.01.         178 
7.3.  Results 
7.3.1.  General cGMP immunoreactivity within the PVN 
The majority of retrograde labelling from the three different regions (IML, 
RVLM and NTS) was concentrated in mid to caudal regions of the PVN (Bregma -1.3 
mm  through  -2.1  mm).    Neurons  were  clustered  within  the  DC,  VM  and  PaPo 
parvocellular  PVN  subnuclei.    Conversely,  OT  and  AVP  magnocellular 
neurosecretory neurons were concentrated in the LM and in the medial magnocellular 
(MM) region (see Fig 7.1).  In general, cGMP IR was diffusely observed throughout 
the PVN.  Within neuronal profiles, a characteristic clustered pattern of cGMP was 
observed, whereas a more diffuse pattern was observed within PVN capillaries and 
arterioles.    Representative  examples  of  cGMP  IR  at  different  rostro-caudal  PVN 
levels are shown in Fig. 7.1 A2-C2.  As has been recently reported in the supraoptic 
nucleus (Stern and Zhang, 2005) control experiments that involved preincubation of 
hypothalamic slices containing the PVN in the presence of the NOS antagonists (1 
mM L-NAME) or the NO scavenger c-PTIO (500 µM) almost completely abolished 
cGMP IR  (not shown), indicating that most basal cGMP levels within the PVN is 
NO-driven.       179 
Figure 7.1: Photomicrographs depicting retrogradely labelled 
Confocal  photomicrographs  at  three  different 
rostro-caudal levels of the PVN (A: Bregma -1.40; 
B:  Bregma  -1.80;  C:  Bregma  -2.0)  depicting 
retrogradely-labeled PVN-IML projecting (green) 
and  OT  immunoreactive  neurons  (red)  (A1-C1), 
and  corresponding  cGMP  immunoreactivity  (IR) 
(A2-C2).  Arrows  point  to  examples  of  cGMP 
immunoreactive  capillaries  (B2)  and  arterioles 
(C2).    3V,  third  ventricle.  DC:  dorsal  cap;  LM: 
lateral magnocellular; MM: medial magnocellular; 
PaPo:  posterior  parvocellular;  VM:  ventromedial 
parvocellular.    Figure  serves  to  demonstrate  the 
cGMP IR of the region from which neurons were 
counted.       180 
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7.3.2.  Heterogeneous distribution of cGMP expression within 
neurosecretory and preautonomic PVN neuronal populations 
Double labelling fluorescent immunohistochemistry combined with retrograde 
tracing  was  performed  to  determine  co-localisation  of  cGMP  within  identified 
magnocellular  neurosecretory  or  preautonomic  PVN  neurons.    Representative 
examples  are  shown  in  Fig.  7.2.    A  total  of  173  and  860  magnocellular  and 
preautonomic  neurones,  respectively,  were  sampled  for  this  study.  Of  the 
magnocellular neurons, 119 were shown to contain cGMP (68.8%).  In contrast, only 
80  preautonomic  neurons  expressed  cGMP  (9.3%),  a  proportion  significantly  less 
than that observed in magnocellular cells (p < 0.01) (Fig 7.3). 
7.3.3.  Oxytocin   and   vasopressin   magnocellular   neurons   express   
similar   basal   cGMP   levels.                                     
Analysis was undertaken to determine if there was any difference in cGMP IR  
between magnocellular neurons that expressed OT and those that expressed AVP.  Of 
the  173  cells  counted,  90  and  83  neurons  were  OT  and  AVP  immunoreactive, 
respectively.    Both  populations  showed  similar  levels  of  colocalisation.    Each 
subgroup  showed  ~69%  of  magnocellular  neurones  were  also  immunoreactive  for 
cGMP (62/90 OT and 57/83 AVP, p > 0.5 Fig. 7.4), indicating that basal cGMP levels 
in magnocellular neurosecretory neurons are not dependent on their neurochemical 
identity.   182 
Figure 7.2: Cyclic GMP reactivity within magnosecretory and presympathetic PVN 
neurons  
Basal  cGMP  immunoreactivity  in  representative 
magnocellular neurosecretory and presympathetic 
PVN  neurons.    A;  Confocal  images  depicting 
cGMP  immunostaining  (A1)  and  OT 
immunoreactive  neurons  (A2).    In  A3,  both 
images  are  superimposed  to  illustrate 
colocalisation.    Arrows  point  to  examples  of 
double-labeled  neurons.    Asterisks  point  to 
examples of cGMP immunoreactive neurons that 
are  OT  immunonegative.    B;  Confocal  images 
depicting  cGMP  immunostaining  (B1)  and 
retrogradely-labeled PVN-IML projecting neurons 
(B2, green) and OT immunoreactive neurons (B2, 
blue,  respectively).    In  B3,  both  images  are 
superimposed  to  illustrate  colocalisation.  An 
arrow points to an example of PVN-IML, cGMP 
double-labeled  neuron.    Arrowheads  point  to 
examples  of  PVN-IML  neurons  lacking  cGMP 
immunoreactivity.  Asterisks point to examples of 
cGMP  immunoreactive  neurons  that  are  OT 
immunonegative  and  do  not  contain  retrograde 
label.  Scale bar: 20  m.       183 
 
       184 
Figure 7.3: Relationship of magnocellular and preautonomic neurons with cGMP 
Summary  data  showing  percentage  of 
magnocellular  and  preautonomic  neurons  that 
colocalised  with  cGMP.    Magnocellular  neurons 
were identified through the presence of either OT 
or AVP immunoreactivity.  Preautonomic neurons 
were identified by retrograde labelling from either 
the  IML,  RVLM  or  NTS.    The  incidence  of 
double-labeled  cells  was  significantly  higher  in 
magnocellular  neurosecretory  as  compared  to 
preautonomic  neurons  (*  p<0.01;  n  =  173 
magnocellular total, 119 cGMP positive, and 860 
preautonomic neurones total, 80 cGMP positive). 
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Figure 7.4: Relationship of OT and AVP magnocellular neurons and cGMP 
Summary  data  showing  percentage  of  oxytocin 
and  vasopressin  magnocellular  neurosecretory 
cells that express cGMP.  Magnocellular oxytocin 
and  vasopressin  cells  were  identified  through 
immunoreactivity  to  OT  and  AVP  respectively. 
Both  populations  showed  similar  levels  of 
colocalisation (p>0.01; n = 173 cells total). 
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7.3.4.  Comparison of cGMP immunoreactivity among preautonomic 
neurons according to their subnuclei distribution. 
Previous data from the laboratory of Stern et al (Stern, 2001) supports the 
presence of subnuclei-dependent differences in functional and structural properties of 
preautonomic PVN neurons.  Thus, we aimed to determine whether basal cGMP IR  
in  preautonomic  PVN  neurons  was  dependent  on  their  subnuclei  distribution, 
regardless  of  their  projection  target  (see  below).    Therefore,  we  compared  the 
expression of cGMP among retrogradely labelled neurones located in the VM, DC 
and PaPo subnuclei (Fig 7.5A).  Within the VM, only 6.3% (21/332) of PA neurons 
expressed cGMP, while in the DC and PaPo, 10% (24/240) and 12.15% (35/288) of 
neurons,  respectively,  were  found  to  express  cGMP.    Our  results  indicated  no 
significant  difference  in  the  distribution  of  cGMP  among  these  topographically 
distinct preautonomic neuronal populations (p > 0.1). 
7.3.5.  Comparison of cGMP immunoreactivity among preautonomic 
neurons according to their innervated target 
We next analysed whether cGMP levels in preautonomic PVN neurons varied 
according to their innervated targets (i.e., NTS, RVLM or IML).  Within the NTS-, 
RVLM- and IML-projecting PVN neuronal populations, 7.9% (24/301), 2.4% (3/121) 
and 12.1% (53/438), respectively, were found to be cGMP immunoreactive.  Basal 
cGMP  IR  between  these  target-specific  PVN  populations  was  not  significantly 
different (Fig 7.5B).        189 
7.3.6.  Comparison of cGMP immunoreactivity among preautonomic 
neurons according to their neurochemical phenotype 
Preautonomic PVN neurons are known to be neurochemically heterogeneous 
(Hallbeck  et  al.,  2001).    Similar  to  magnocellular  neurosecretory  neurons,  a 
proportion  of  preautonomic  neurons  express  OT  and  AVP  peptides.    Thus,  we 
performed  triple  fluorescence  labelling  (i.e.,  OT  or  AVP,  retrograde  labelling  and 
cGMP) to determine whether cGMP levels in preautonomic PVN neurons may be 
dependent, at least in part, on their neurochemical identity.  Of the total number of 
preautonomic cells sampled, we were able to identify 253 and 185 as OT and AVP 
immunoreactive, respectively.  Within the OT population, 15.4% (39/253) were found 
to  contain  cGMP.    Within  the  AVP  population,  7.5%  (14/185)  contained  cGMP.  
Although twice as many OT preautonomic neurons were shown to express cGMP, 
this was not statistically significant (Fig 7.5C).  When the incidence of cGMP IR in 
neurochemically  identified  OT  and  AVP  neurons  was  compared  between 
magnocellular  and  preautonomic  PVN  neurons,  significantly  higher  levels  were 
observed in magnocellular neurons [OT: 68.8% versus 16.4% in magnocellular (total 
n = 90, cGMP positive n = 62) and preautonomic (total n = 256, cGMP positive n = 
42), respectively, p < 0.01; AVP: 68.6% versus 8.5% in magnocellular (total n = 83, 
cGMP positive n = 57) and preautonomic (total n = 187, cGMP positive n = 16) 
respectively, p < 0.01].  These results indicate that basal cGMP levels in major PVN 
neuronal  populations  is  largely  dependent  on  their  overall  function  (i.e., 
magnocellular  neurosecretory  versus  preautonomic),  rather  than  on  their 
neurochemical  phenotype,  topographical  distribution  and/or  autonomic-related 
innervated target.        190 
 
Figure 7.5: Basal cGMP expression in identified preautonomic PVN 
subpopulations  
Basal  cGMP  immunoreactivity  in  identified 
preautonomic  PVN  subpopulations.    Summary 
data  showing  the  incidence  of  cGMP 
immunoreactivity  in  PVN  preautonomic  neurons 
according  to  their  subnuclei  location  (A),  their 
innervated  targed  (B)  and  their  neurochemical 
phenotype  (C).    No  significant  differences  were 
observed  in  any  cases  (p  >  0.01).    The  Y-axis 
depicts  the  percentage  of  cells  that  expressed 
cGMP. VM: ventromedial; DC: dorscal cap; PaPo: 
posterior  parvocellular;  NTS:  nucleus  of  the 
solitarii  tract;  RVLM:  rostral-ventrolateral 
medulla; IML: intermediolateral cell column; OT: 
oxytocin; VP: Vasopressin. 
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7.4.  Discussion 
Since it’s discovery, NO has been shown to be a key signalling molecule in a 
number of central and peripheral processes including the regulation of sympathetic 
activity  (Krukoff,  1999).    In  the  PVN,  NO  inhibits  neuronal  activity,  of  both 
presympathetic  (Li  et  al.,  2003b),  and  magnocellular  neurons  (Stern  and  Ludwig, 
2001).  As a membrane permeant neuronal messenger, NO produces its biological 
actions through distinct signal transduction pathways (Ahern et al., 2002; Stamler et 
al., 1997), such as the modification of proteins (S-Nitrosylation) (Jaffrey et al., 2001) 
or the formation of peroxynitrite (Trabace and Kendrick, 2000).  However, the most 
common NO signalling cascade is the activation of sGC, which subsequently elevates 
intracellular  cGMP  (Southam  and  Garthwaite,  1993).    Indeed,  a  cGMP-dependent 
cascade  was  recently  demonstrated  to  mediate  inhibition  of  presympathetic  PVN 
neuronal activity in response to SNAP, an NO donor (Li et al., 2004).  Moreover, it 
has been shown that NO is constitutively produced within the PVN (Stern and Zhang, 
2005), where it restrains ongoing presympathetic neuronal firing activity (Li et al., 
2003b).    Constitutively  produced  NO  has  also  been  shown  to  inhibit  PVN-driven 
renal sympathetic nerve discharge (Zhang and Patel, 1998).  However, whether or not 
cGMP is the actual mediator of constitutively produced NO actions within the PVN is 
unknown,  and  a  detailed  characterisation  of  NO-receptive,  cGMP  producing  PVN 
neuronal populations, and specifically preautonomic ones, is lacking.  In this study, 
we evaluated cGMP expression within various cell populations within the mid rostro-
caudal portion of the PVN, including preautonomic IML, RVLM and NTS- projecting 
neurons,  and  magnocellular  neurosecretory  OT  and  AVP  neurons.    Our  results 
support  a  heterogeneous  distribution  of  basal  cGMP  levels  within  PVN  neuronal       193 
populations,  with  relatively  high  levels  found  in  magnocellular  neurosecretory 
neurons.  Conversely, a relatively small proportion of preautonomic PVN neurons, 
regardless  of  their  innervated  target,  topographical  distribution  or  neurochemical 
identity, were found to be cGMP immunoreactive. 
7.4.1.  Methodological considerations 
To  identify  target-specific  populations  of  preautonomic  PVN  neuronal 
populations, a retrograde tracer was injected  at three different targets,  namely the 
IML, RVLM and NTS.  Based on the nature of the tracer used (highly restricted and 
well-defined injection sites, and lack of labelling of fibres in passage (Katz et al., 
1984), as well as the trajectory and topography of descending axonal projections from 
the PVN (Luiten et al., 1985; Swanson, 1977), it is very unlikely that PVN neurons 
projecting to areas other than the targeted ones were labelled.  Essentially separate 
populations  of  PVN  neurons  have  been  shown  to  project  to  sympathetic  and 
parasympathetic preganglionic neurons (Portillo et al., 1996; 1998) and the distinct 
anatomical  segregation  of  descending  PVN  axonal  projections  at  the  level  of  the 
medulla (Luiten et al., 1985; Swanson, 1977) precluded the simultaneous labelling of 
different  PVN  descending  pathways  (e.g.,  NTS-  and  RVLM-projecting  neurons) 
following  a  single  site  injection.    It  is  worth  noting  however,  that  a  small 
subpopulation of PVN-RVLM neurons (between 5 and 16%) has been shown to send 
axon collaterals to the spinal cord (Pyner and  Coote, 2000; Shafton et al., 1998).  
Thus, our experimental approach based on a single tracer injection at a single target 
site  precluded  us  from  differentiating  this  small  population  of  RLVM-  and  IML-
projecting neurons.  Further, it is well established that virtually no neurons project 
both  to  autonomic-related  medulla  centres  and  the  pituitary  or  median  eminence 
(Swanson  et  al.,  1980),  and  that  magnocellular  and  preautonomic  neuronal       194 
populations are topographically segregated within the PVN (Armstrong et al., 1980; 
Swanson and Sawchenko, 1983).  Thus, we believe that all the above considerations 
support  the  specificity  of  the  different  PVN  neuronal  populations  sampled  in  our 
studies. 
7.4.2.  Cyclic GMP is highly expressed in PVN magnocellular 
neurosecretory neurons 
Consistent with recent studies on supraoptic neurons (Stern and Zhang, 2005), 
we found the majority of PVN magnocellular neurosecretory neurons to contain high 
basal levels of cGMP.  However, whereas significantly higher levels of cGMP (as 
well as endogenous NO levels) were observed in AVP as compared to OT neurons in 
the  SON  (Stern  and  Zhang,  2005),  similar  cGMP  levels  between  these  two 
populations were observed in the present study in the PVN.  Interestingly, results 
from  this  study  and  previous  work  by  Stern  et  al  in  the  SON,  differ  from  those 
previously reported in mice by Vacher and colleagues, who showed cGMP-IR was 
not co-localised with either AVP or OT expressing neurons, and only found cGMP-IR 
in astrocyte-like cells and blood vessels (Vacher et al., 2003).  We currently lack a 
clear explanation for the differences reported in detectable cGMP levels, given that in 
work  not  included  as  part  of  this  thesis,  Stern  et  al  (Stern  et  al,  unpublished 
observations)  have  been  able  to  clearly  demonstrate  cGMP  in  the  cell  bodies  of 
neurons in the PVN of a transgenic mouse that expresses enhanced Green Fluorescent 
Protein (eGFP) driven by the glutamic decarboxylase (GAD67) promoter (Oliva et al., 
2000).  Moreover, cGMP IR was also readily identified within GFP-labelled PVN 
axonal terminals of the transgenic mouse.  However, since cGMP levels in our work 
and  that  of  Vacher  have  been  evaluated  in  the  absence  of  the  phosphodiesterase 
inhibitor IBMX, it is possible that a differential degradation of cGMP by endogenous       195 
phosphodiesterases  exists  under  the  different  experimental  paradigms  between  the 
laboratories and has resulted in different detection sensitivities. 
Magnocellular SON and PVN neurosecretory neurons are known to express 
high levels of nNOS (Arevalo et al., 1992; Hatakeyama et al., 1996; Stern and Zhang, 
2005), expression of which is enhanced in an activity-dependent manner (Kadowaki 
et al., 1994; Srisawat et al., 2000; Ueta et al., 1995).  Moreover, both the a1 and b1 
subunits of sGC are highly expressed in the SON and PVN (Furuyama et al., 1993). 
In addition, Stern et al have recently demonstrated a high degree of colocalisation of 
nNOS,  constitutive  NO levels  (measured  as  NO-induced  fluorescence)  and  cGMP 
within  SON  magnocellular  neurons  (Stern  and  Zhang,  2005).    Altogether,  these 
studies, along with a well established role of the NO-cGMP pathway in the control of 
the magnocellular neurosecretory system (Briski, 1999; Li et al., 2003b; Stern and 
Zhang, 2005; Vacher et al., 2003; Yang and Hatton, 1999; Zhang et al., 2007) (see 
however, (Ozaki et al., 2000; Terrell et al., 2003), support the NO-cGMP cascade as 
an  important  autocrine  pathway  by  which  magnocellular  neurosecretory  neurons 
regulate their own degree of activity. 
Interestingly, in addition to magnocellular neurosecretory neurons (Stern and 
Zhang, 2005), colocalisation of nNOS and cGMP has only been reported previously 
in  cerebellar  granule  cells  (De  Vente  et  al.,  1998)  and  in  our  study  examining 
sympathetic preganglionic neurons in the spinal cord (Chapter 3).  Thus, a NO-sGC-
cGMP autoregulatory dependent pathway seems to be highly restricted to specific 
CNS neuronal populations.  In fact, since the concentration of Ca
2+
 required for the 
activation  of  nNOS  inhibits  sGC,  it  has  been  argued  that  nNOS  expressing  cells 
should not be able to auto-regulate their own activity through changes in cGMP levels 
(Knowles et al., 1989; Parkinson et al., 1999).  However, compartmentalisation of       196 
nNOS to specific subcellular regions, largely through its linkage to NMDA receptors 
through  the  postsynaptic  density  protein  PSD95  (Christopherson  et  al.,  1999), 
provides a mechanism by which nNOS and sGC could be differentially exposed to 
different  Ca
2+  concentrations  within  the  same  cell.  This  mechanism  may  support 
findings  that  show  activation  of  NMDA  receptors  constitutes  a  major  mechanism 
driving constitutive NO production in magnocellular neurosecretory neurons (Bains 
and Ferguson, 1997; Stern and Zhang, 2005). 
7.4.3.  Preautonomic PVN neurons express relatively low levels of basal 
cGMP 
In  contrast  to  magnocellular  neurosecretory  neurons,  our  results  indicate  a 
very low incidence (< than 10%) of preautonomic subject neurons expressing cGMP 
under basal conditions.  This was the case regardless of their innervated target, their 
topographical  distribution  within  the  PVN,  and  whether  or  not  they  were 
immunoreactive for OT or AVP.  Previous functional studies by the Stern group have 
shown that NO has an  inhibitory effect on presympathetic  (Li et al., 2003b), and 
magnocellular neurons (Stern and Ludwig, 2001).  Electrophysiology studies showed 
that  retrodialysis  of  NO  donors  or  precursors  of  NO  on  identified  magnocellular 
neurons (Stern and Ludwig, 2001) inhibits the spontaneous firing rate of neurons, 
while  nNOS  inhibitors  increase  the  firing  rate.    Based  on  our  results  showing  a 
significantly higher basal cGMP level in magnocellular neurosecretory compared to 
preautonomic OT/AVP immunoreactive neurons, it is reasonable to conclude that it is 
not  the  neurochemical  phenotype,  but  rather  the  overall  functional  setting  (i.e., 
neurosecretory  vs.  preautonomic)  that  is  associated  with  the  highly  heterogeneous 
distribution of basal cGMP levels in the PVN.  This is in line with work by Nylen et 
al  (Nylen  et  al.,  2001a),  which  looked  at  the  difference  in  co-localisation  of  NO       197 
within  presympathetic  spinally  projecting  neurons,  OT  magnocellular  or  VP 
magnocellular neurons.  They found that over 80% of neurons expressing NO were 
magnocellular, which lends itself logically to the idea that there would be an increase 
in the downstream cGMP of these neurons. 
Despite  the  absence  and/or  low  levels  of  endogenous  cGMP  found  in 
preautonomic PVN neurons, it is now well established that constitutive NO efficiently 
restrains PVN neuron firing activity, and consequently autonomic outflow from the 
region (Li et al., 2002; Li et al., 2003b; Li et al., 2001; Zhang and Patel, 1998).  Thus, 
NO  actions  on  this  subpopulation  of  PVN  neurons  are  likely  mediated  through  a 
direct, cGMP-dependent mechanism, and/or alternatively, NO effects are indirectly 
mediated.  While cGMP-independent mechanisms cannot be ruled out, such as S-
nitrosylation, several lines of evidence support that GABA, the dominant inhibitory 
neurotransmitter in the PVN (Decavel and Van den Pol, 1990), indirectly mediates 
NO effects on preautonomic PVN neurons.  Firstly, results from the Stern laboratory 
show  that  constitutive  NO  inhibitory  actions  on  PVN-RVLM  and  PVN-NTS 
projecting neurons require intact and functional local GABAergic terminals, and that 
enhanced NO availability increased the frequency of GABAergic inhibitory currents 
(Li et al., 2003b) see also: (Li et al., 2004).  Secondly, work from the Patel laboratory 
shows that when acting in the PVN, NO inhibition of renal sympathetic nerve activity 
also required the presence of functional GABAergic inputs (Zhang and Patel, 1998).  
Finally, recent work indicates that NO-mediated increased GABAergic activity in the 
PVN is mediated through a cGMP signalling cascade (Li et al., 2004; Yang et al., 
2007).  Altogether, these data are consistent with the notion that the PVN GABAergic 
interneuronal  population  is  a  key  NO  receptive,  cGMP-producing  neuronal  group 
within the PVN.        198 
Unlike  magnocellular  neurons,  our  preliminary  studies  (data  not  included) 
show that only a relatively small proportion of preautonomic PVN neurons express 
detectable  levels  of  nNOS,  agreeing  with  the  work  of  a  number  of  other  groups 
(Kantzides and Badoer, 2005; Li et al., 2003b; Weiss et al., 2001).  Thus, it is likely 
that the NO modulating preautonomic PVN neuronal activity likely originates from an 
alternative cellular source with projections to the PVN region. 
7.4.4.  Conclusion 
In summary, results from our study indicate that basal cGMP immunoreactive 
levels are heterogeneously distributed within functionally segregated PVN neuronal 
populations.  The high levels of basal cGMP found in the majority of magnocellular 
neurosecretory  neurons  suggest that constitutive NO, likely  acting in an autocrine 
manner, directly modulates magnocellular neurosecretory activity through a cGMP-
dependent pathway.  Conversely, taking into account the literature and our results 
showing relatively low basal cGMP levels in levels in preautonomic PVN neurons, it 
is likely that that NO from inputs to the PVN acts in a paracrine manner to stimulate 
GABAergic inhibitory activity via a cGMP-dependent pathway, which in turn results 
in inhibition of preautonomic neuronal function.       199 
8. Final discussion 
The neural control of blood pressure involves a vast network of autonomic 
centres  that  must  work  in  close  collaboration,  communicating  via  both  direct  and 
indirect  anatomical  connections  and  numerous  neurotransmitters,  receptors  and 
intracellular signalling pathways.  Since its discovery, NO and the role it plays in 
blood  pressure  control  has  generated  much  interest  and  controversy.    The  initial 
premise of this thesis was that central NO signalling is perturbed in the hypertensive 
state, and that basal levels of NO and its signalling cascade messenger cGMP would 
therefore be different when comparing a hypertensive rat model and its genetically 
related control.  We also aimed to determine the relationship between NO and cGMP 
in  the  key  central  autonomic  control  regions  of  the  spinal  cord,  brainstem  and 
hypothalamus.    Our  research  supports  an  underlying  difference  in  the  level  of 
expression of NO and cGMP between the spontaneously hypertensive rat (SHR) and 
the genetically related normotensive Wistar Kyoto rat (WKY) in the central nervous 
system regions studied, however a number of novel and unanticipated results were 
also found.   
8.1.  Is there a difference in the basal expression of NO?  
The  immunohistochemical  results  from  Chapter  3  examining  nNOS 
expression in SPN, and the studies in Chapter 5 examining both nNOS mRNA and 
protein levels in the RVLM do support the notion that there is a difference in the basal 
or resting levels of potential NO production when comparing the hypertensive and 
normotensive rat strains.  Within the RVLM,  we saw that there was  significantly       200 
higher nNOS mRNA expression in the SHRs, compared to the WKYs, and that there 
was significantly more nNOS mRNA expression in both strains when compared to 
iNOS.  Interestingly, while there was no overall significant difference in the number 
of cells expressing nNOS in the region between the two strains, when the data is was 
analysed along a rostro-caudal gradient, there were significantly more nNOS neurons 
in the rostral portion of the RVLM in the SHR animals, suggesting that there may be a 
NO gradient within the RVLM. This has functional relevance given that projection 
sites differ between rostral and caudal regions of the RVLM, with the rostral RVLM 
containing mainly bulbospinal neurons that project to the spinal cord (Kanjhan et al., 
1995), and the caudal RVLM containing neurons that project to the PVN. (Day et al., 
1980;  Sakumoto  et  al.,  1978;  Sawchenko  and  Swanson,  1982).    Localised 
microinjection studies that clearly distinguish between the rostral and caudal regions 
of the RVLM, and studies aiming to compare responses to NO and/or the blockade of 
endogenous NO production between the two regions of the RVLM, may therefore 
provide an answer to the discrepancies reported in the literature regarding regulation 
and its functional role of NO activity in the RVLM region.  
In the spinal cord however, rather than seeing increased nNOS expression, we 
demonstrated reduced number of SPN expressing nNOS in the SHR, which was in 
turn reflected downstream through reduced cGMP detection.  These results suggest 
that global predictions regarding a change of NO expression levels, and the direction 
of that change in association with hypertension in the SHR cannot be made.  Others 
have  demonstrated  similar  variable  directional  changes  in  the  expression  of  other 
neurotransmitters between the SHR and WKY.  Sweerts and colleagues have shown 
that galanin levels were significantly lower in the SHR in the supraoptic nerve when 
compared to the WKY, but significantly higher in the RVLM (Sweerts et al., 1999).        201 
Furthermore,  Boone  and  McMillen  (Boone  and  McMillen,  1994)  found  that  gene 
expression of proenkephalin in the NTS, CVLM and RVLM was lower in the SHR, 
while in the locus coeruleus, anterior and lateral hypothalamus, it was significantly 
increased. In contrast, work by Reja and colleagues (Reja et al., 2002b) showed that 
within  the  SHR,  there  are  significantly  higher  levels  of  the  alpha  1A  adrenergic 
receptor in the hypothalamus, RVLM, spinal cord, myocardium and adrenal medulla, 
but constantly significantly lower levels of the alpha 2A adrenergic receptor in the 
same region.  In this case, the authors were able to attribute the changes to global 
changes in the SHR. 
8.2.   Functionality  of  the  NO-cGMP signalling  pathway  in 
central autonomic nuclei         
In Chapter 3, we made the novel discovery that all nNOS SPN also contained 
cGMP.  Furthermore, we demonstrated a medially located population of SPN that 
contained cGMP in the absence of nNOS.  In Chapter 4, this finding was extended to 
demonstrate  that  in  parallel  with  decreased  levels  of  nNOS,  there  appeared  to  be 
down regulation of cGMP in individual SPN.  From a neuroanatomical perspective, 
these  results  have  two  implications.    Firstly,  they  support  both  a  paracrine  and 
autocrine role for NO within SPN.  It is predominantly assumed that NO works in a 
paracrine  fashion,  as  the  level  of  calcium  required  to  activate  NOS  inhibits  the 
guanylate cyclases (Thippeswamy and Morris, 2001).  However, studies have shown 
that in specific regions of the brain, nNOS is immunohistochemically co-localised 
with  sGC  (Burette  et  al.,  2001).  Also,  within  the  vasculature,  sGC  has  been  co-
localised with both L-arginine and eNOS (Buchwalow et al., 2004) indicating the 
potential for NO to work in an autocrine manner.  An autocrine action of NO has been       202 
described in baroreceptor neurons of the nodose ganglion (Li et al., 1998), although in 
this  region  NO,  has  been  shown  to  work  through  S-nitrosylation,  rather  than  via 
cGMP-dependent mechanisms.  The issue of excessive calcium inhibiting guanylate 
cyclases and therefore preventing an autocrine action of NO can be countered by 
cellular compartmentalisation, whereby spatial confinement of the various pathways 
allows  NO  signals  to  have  independent,  and  even  opposite  effects  through  the 
recruitment of different downstream pathways.  For example, it has been shown that 
the  endoplasmic  reticulum  comes  into  close  apposition  to  the  plasma  membrane, 
which is believed to limit the spatial spread of Ca
2+ and Na
+ in hair cells (Martin and 
Fuchs, 1992), arterial smooth muscle cells (Arnon et al., 2000) and cardiac myocytes 
(Bridge et al., 1990; Leblanc and Hume, 1990; Lederer et al., 1990).  A structural 
barrier overcomes the limiting factor of calcium inhibiting the guanylate cyclases, 
thereby allowing signalling to occur in different locations within the cell.   
Secondly, the anatomical differences between the cGMP expressing SPN cell 
groups  suggest  that  there  may  be  functional  distinctions  between  the  medial  and 
lateral SPN populations (neurochemically defined as cGMP positive/nNOS negative 
and  cGMP  positive/nNOS  positive,  respectively).    This  is  supported  by  our 
complementary work that describes a comparable distribution of tonically activated 
subpopulations  of  SPNs,  [identified  via  immunoreactivity  to  phosphorylated 
extracellular  signal  regulated  kinase  1/2  (p-ERK1/2)]  including  those  within  the 
functionally defined adrenal SPN subpopulation (Springell et al., 2005).  Further, a 
mediolateral topographic organisation of functionally distinct populations of SPN has 
been proposed within the IML, with lateral SPN having a vasomotor function and the 
more medial SPN having a motility regulating function (Janig and McLachlan, 1986; 
Pyner and Coote, 1994).  Indeed, there is increasing evidence to suggest that SPN are       203 
chemically coded and that each discrete group regulates a single autonomic target 
tissue (Minson et al., 2002), with SPN containing neurokinin-1 receptor (Grkovic and 
Anderson, 1996; Llewellyn-Smith et al., 1997b) or calcium binding proteins (Grkovic 
and Anderson, 1995; 1997) having specific targets.  
Our experiments investigating the presence of cGMP in the RVLM  (Chapter 
6) failed to demonstrate its expression in association with the C1 RVLM cell group or 
nNOS populations. These experiments were initially designed in the light of evidence 
indicating that NO was influencing the area in a cGMP dependent manner (Zanzinger, 
2002).  Similarly, in the PVN, we found that very few preautonomic neurons actually 
co-express cGMP.  The lack of expression of cGMP either in, or nearby our neurons 
of  interest  raises  questions  as  to  how  NO  is  influencing  these  regions  and  more 
specifically, regulating autonomic outflow. 
Our initial foray into the signalling of NO within the RVLM was based on the 
functional  studies  mentioned  in  chapter  5.    In  many  of  these  studies,  NO  was 
exogenously added to the RVLM via a number of different NO donors, or the NO 
pathway  was  excited  using  various  drugs,  such  as  NMDA  and  studying  the 
subsequent change in blood pressure.  The experiments went on to clarify the role of 
cGMP  by  either  blocking  the  NO-cGMP  receptor  sGC,  with  a  specific  guanylate 
cyclase inhibitor, or by studying the downstream cascade of cGMP, PKG.  While 
these  are  valid  approaches  designed  to  test  the  effect  NO  has  on  blood  pressure 
regulation,  the  results  do  not  necessarily  confirm  that  the  NO-cGMP  pathway 
mediates physiological responses in the regions.  It may be that the neurons involved 
contain the necessary components to create cGMP, but stimulation via an exogenous 
NO mechanism is different to that evoked by endogenous NO.  In the RVLM, the lack 
of cGMP in the region suggests that endogenous NO may be working via a non-      204 
cGMP  dependent  pathway.    To  elucidate  this  better,  we  need  to  understand  the 
chemical biology of NO. 
Rather  than  traditional  protein  receptor-ligand  interactions,  the  biological 
effects  of  NO  are  determined  by  chemical  reactions,  such  as  binding  to  sGC  or 
phosphorylating receptors for other transmitters, thereby allowing NO to influence a 
number of different cellular regulatory pathways.  The effects of NO can be divided 
into  two  main  categories;  direct,  which  means  the  reaction  occurs  fast  enough  to 
allow  direct  interaction  with  the  target  molecule;  and  indirect,  which  requires  an 
interaction with oxygen or superoxide to generate free radicals which subsequently 
react with biological targets (Wink et al., 1996).  One significant difference between 
the direct and indirect interactions is the concentration of NO – direct interactions 
require concentrations of NO that are under 1mM, while indirect interactions require 
concentrations of NO of 1mM or higher (Thomas et al., 2008).  Furthermore, it has 
been demonstrated in a study on tumour development that different concentrations of 
NO activate different pathways.  Tumour development engages an intricate set of 
molecular  events,  with  several  key  events  being  critical  to  the  process,  such  as 
phosphorylation  of  extracellular  signal-related  kinase  (ERK)  and  activation  of 
proteins p53 and hypoxic inducible factor 1 alpha (HIF-1a) (Thomas et al., 2004).  
Nitric oxide is known to activate these events during tumourogenesis (Hofseth et al., 
2003a; Hofseth  et al., 2003b; Hussain et al., 2003) (although the process through 
which NO affects these proteins is unclear).  In the study by Thomas (Thomas et al., 
2004),  they  correlated  the  concentrations  of  NO  with  when  each  of  these  events 
occurred.  They found that phosphorylation of ERK occurred when the tumour cells 
were exposed to NO concentrations of >1mM, but that HIF-1a activation and p53 
activation did not occur until there was at least a concentration of 50mM and 100mM,       205 
respectively, as detected by gas probe (Thomas et al., 2004).  Though these proteins 
are  not  pertinent  to  our  study,  what  this  experiment  highlights  is  that  different 
concentrations of NO may induce different pathways.  
Importantly, it has been shown that the NO concentration required to stimulate 
catecholamines,  and  more  specifically  our  C1  cells,  has  been  estimated  at  around 
1mM, which is the breakpoint between direct and indirect signalling by NO (Thomas 
et al., 2008).  It is possible therefore that the functional responses attributed to NO in 
the RVLM is mediated via a non-direct pathway, not through the cGMP cascade.  
Given this information it would be reasonable to study the concentration of NO in our 
areas  of  interest  using  for  example  4,5-diaminofluorescein-2-diacetate  (DAF-2),  a 
NO-sensitive indicator which can visually identify NO production in neurons, with 
confocal microscopy to visualise and quantify the NO expression (Kono et al., 2004), 
as  the  fluorescence  signal  generated  is  proportional  to  the  amount  of  NO  present 
(Kojima et al., 1998).  When using NO donors, it would be prudent to measure the 
NO concentrations generated, given that the levels of NO may differentially drive a 
specific pathway that is not stimulated by endogenous NO. 
However,  it  is  important  to  note  here  that  NO  can  modulate  other 
neurotransmitters to elicit various effects.  For example, microdialysis studies have 
shown  that  within  the  PVN,  both  GABAergic  and  glutamatergic  mechanisms  are 
modulated  by  NO,  as  when  NO  is  introduced  to  the  PVN,  there  is  a  significant 
increase  in  the  level  of  both  GABA  and  glutamate  release  (Horn  et  al.,  1994).  
Further, throughout the brain NO, may be produced both pre and post synaptically 
(Garthwaite, 2008), and could be modulating transmission as well.  Many brain areas 
express  prototypic  coupling  with  post  synaptic  NMDA  receptors,  as  discussed  in 
chapter 1.  Presynaptically, NO could effect transmitter release by regulating changes       206 
in  the  intracellular  Ca
2+,  either  by  modulating  the  external  Ca
2+,  influx,  or  by 
regulating the release from intracellular stores (Zanzinger et al., 1995).  Indeed within 
the hippocampus, it has been shown that presynaptic interneurons express the a1b1 
heterodimer of the sGC receptor, while the a2b1 is predominantly in the postsynaptic 
pyramidal neurons. Studies have shown that the a1b1 isoform is cytosolic, while the 
a2b1 is associated with the PDZ-domain containing PSD-95 Russwurm, 2001 #917}.  
Furthermore, it has been shown that PSD-95 can interact with all components of the 
NO-cGMP cascade (Russwurm and Koesling, 2002).  It has therefore been suggested 
that within hippocampal pyramidal cells, excitatory transmission occurs by PSD-95 
binding  the  a2b1  sGC  receptor  to  nNOS  and  NMDA  receptors  postsynaptically 
(Szabadits et al., 2007).  However, within the presynaptic interneurons, as a1b1 is 
cytosolic, NO can bind to PDZ-domain scaffolding proteins.  (Szabadits et al., 2007).  
It has been postulated that the lack of the a2 subunit means that within interneurons 
sGC is now no longer targeted, therefore altering transmission. 
8.3.  Is NO excitatory or inhibitory and is its increase a causal or 
compensatory response to hypertension? 
While our initial work (Chapter 3) led us to consider that reduced NO, and 
therefore cGMP levels in the SPN of SHR was a “causal” mechanism that drove 
increased sympathetic drive at the level of the spinal cord, this hypothesis required 
revisiting based on work from our group examining the effect of intrathecal delivery 
of 8-Br-cGMP (Malik et al., 2007). In that study it was shown MAP in Sprague-
Dawley rats increased in response to exogenous cGMP in a dose dependent manner.  
We  therefore  predicted  that  the  intrathecal  injection  of  the  membrane  permeable 
analogue of cGMP, 8-Br-cGMP would result in an increase in blood pressure in both       207 
strains. This is indeed what we were able to demonstrate, however the results also 
show a significant strain-dependent effect, with the SHR demonstrating much greater 
pressor responses at all doses tested. Like the Sprague-Dawley, both strains showed 
the greatest response to 8-Br-cGMP at the highest 100mM dosage, but again this was 
significantly more pronounced in the SHR.  It is possible therefore that in the SHR, 
the  SPN  have  a  heightened  responsiveness  to  the  NO-sGC-cGMP  cascade  with 
functional consequences. We can speculate that reduced levels of cGMP expression in 
the SHR are not necessarily contributing to the hypertension, but that they are instead 
a  consequence.    Down  regulation  of  the  levels  of  cGMP,  mediated  by  reduced 
endogenous NO production, are a compensatory response to the hypertensive state.  
This would support the idea that within the baroreceptor reflex pathway, NO is a 
sympathoexcitatory molecule at the level of the SPN.   
However, within the RVLM, it has been demonstrated by Chan et al (2001c), 
that  when  carboxyl-PTIO,  a  scavenger  that  obliterates  the  effects  of  NO  is 
administered  there  is  a  significant  increase  in  the  MAP  (Chan  et  al.,  2001c), 
indicating that NO acts as a sympathoinhibitory molecule in this region.  Furthermore, 
when  selective  iNOS  and  nNOS  blockers  were  applied  together,  their  combined 
effects were similar to carboxyl-PTIO, indicating that both iNOS and nNOS are both 
involved in cardiovascular actions within the RVLM (Chan et al., 2001c).  When the 
selective NOS blockers are administered separately, it was found that blocking nNOS 
caused a reduction in MAP and HR, while blocking iNOS caused an increase in MAP 
and HR.  This indicated that nNOS is acting in a sympathoexcitatory manner, while 
iNOS  acts  in  a  sympathoinhibitory  fashion  in  controlling  cardiovascular  function 
(Chan et al., 2001c).       208 
Our work demonstrated a relatively higher levels of nNOS protein and mRNA 
within the RVLM of the SHR when compared to the WKY.  One way to interpret this 
is that given nNOS appears to be excitatory, the increase in nNOS seen in the SHR is 
driving sympathetic output, the outcome being a pressor response.  However, another 
valid interpretation would be to again look at the chemical biology of NO.  It has been 
shown that iNOS produces large amounts of NO, up to 20 times the amount that 
constitutive NOS produces (Bruckdorfer, 2005).  Given that iNOS appears to have a 
sympathoinhibitory effect on cardiovascular function, it would lead to the suggestion 
that the high concentration of NO have a sympathoinhibitory function.  The increase 
in nNOS seen in the SHR therefore may be a mechanism by which NO concentration 
can be increased, and can therefore be alternatively interpreted as a compensatory 
response  designed  to  counter  the  increased  sympathetic  drive.    The  driver  of  this 
increased  sympathetic  tone  is  still  open  to  speculation  but  may  arise  from  higher 
centres in the CNS. 
8.4.  Conclusion 
The key issue this thesis highlights is that unlike in the periphery, where NO has 
been identified as having a vasodilatory role, in central autonomic control centres, its 
effects can be either excitatory or inhibitory, resulting in both pressor or depressor 
responses.  This means that there is limited value in assessing mechanisms that would 
have a global and therefore non-specific effect on NO production in the CNS, and 
instead  targeted  delivery  of  NO  modifying  agents  to  specific  regions  would  be 
required.        209 
8.5.  So where to from here? 
In conclusion, this thesis has shown that hypertensive and normotensive rats 
do show regional and species differences in components of the NO expression and 
signalling pathways.   Importantly, we have demonstrated that while expression of 
cGMP can be used as a marker of sites of NO activity, it doesn’t necessarily explain 
functional significance.  
Genetic  factors  can  cause  differences  not  only  in  expression  of 
neurotransmitters and receptors, but also changes in the sensitivity of the response.  It 
has been shown that although SHRs and WKY can respond to the same NO-mediated 
stimuli  in  the  same  manner,  e.g.  both  can  respond  to  microinjections  in  specific 
regions with a decrease in blood pressure, the latency period can differ as can the 
degree of change induced (Thomas et al., 2008).  This suggests an inherent change in 
sensitivity  to  NO  signalling.    A  change  in  the  levels  of  expression  in  the  NO 
signalling  pathway  may  therefore  not  necessarily  translate  into  a  corresponding 
functional change.  To fully understand the mechanisms by which NO is acting and its 
contribution  to  hypertension,  I  propose  that  looking  at  changes  in  receptors, 
sensitivity and downstream pathways will be the most informative in defining the true 
nature of NO’s role in hypertension.        210 
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